<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">	<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">		<head>			<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />			<meta http-equiv="X-UA-Compatible" content="IE=edge" />			<link rel="shortcut icon" href="dailymed/images/favicon.ico" />			<meta name="ROBOTS" content="NOFOLLOW" />				<script type="text/javascript" src="/dailymed/scripts/1.10.2/jquery-1.10.2.min.js"></script>	<script type="text/javascript" src="/dailymed/scripts/jquery-ui/jquery-ui.min.js"></script>	<script type="text/javascript">		var jQuery_1_10_2 = $.noConflict();	</script>	<link rel="stylesheet"   href="dailymed/scripts/jquery-ui/smoothness/jquery-ui.min.css" type="text/css" />	<link rel="stylesheet"   href="dailymed/styles/base-.min.css?v=1.3" type="text/css"  />		<script src="/dailymed/scripts/drop_down-.min.js" type="text/javascript"></script>	<script src="/dailymed/scripts/shared-.min.js" type="text/javascript"></script>	<!--[if IE]>	<link rel="stylesheet" type="text/css" href="dailymed/styles/ie-hacks-.min.css" />	<![endif]-->		<script type="text/javascript" src="/dailymed/scripts/1.3.2/jquery-.min.js"></script> 	<script type="text/javascript" src="/dailymed/scripts/autocomplete/jquery.autocomplete.min.js"></script>	<script type="text/javascript">		$(document).ready(function(){						// check to see if autocomplete plugin has been loaded by looking for existance of "autocomplete" function in jQuery object			if( $.fn.autocomplete ) {  				// THE PLUGIN HAS BEEN LOADED!				//alert(" autocomplete is already loaded! great! ");			}			else {				// reinsert the script tag into the head to load the autocomplete plugin								//alert(" we need to load in autocomplete..." );								$("head").append('<script type="text/javascript" src="/dailymed/scripts/autocomplete/jquery.autocomplete.min.js" />');					}						// actually activate autocomplete			$("#startswith").autocomplete("/dailymed/autocomplete.cfm?key=search",{				width: 275,				selectFirst: false,				cacheLength:1,				max:200,				matchSubset:false,				delay:300,				minChars:3			});		});	 	</script>			<link rel="stylesheet"   href="dailymed/scripts/autocomplete/jquery.autocomplete-.min.css" type="text/css" />	  	<noscript>Your browser does not support JavaScript!</noscript>														<title>CAMPTOSAR (IRINOTECAN HYDROCHLORIDE) INJECTION, SOLUTION [PHARMACIA AND UPJOHN COMPANY]</title>			<link rel="alternate" type="application/rss+xml" href="dailymed/labelrss.cfm?setid=e518dfc6-7e93-4fee-a66c-51e1ab71c056"			title="RSS Feed for CAMPTOSAR (IRINOTECAN HYDROCHLORIDE) INJECTION, SOLUTION [PHARMACIA AND UPJOHN COMPANY] Label"/>			<link rel="bookmark" href="lookup.cfm?setid=e518dfc6-7e93-4fee-a66c-51e1ab71c056" title="CAMPTOSAR (IRINOTECAN HYDROCHLORIDE) INJECTION, SOLUTION [PHARMACIA AND UPJOHN COMPANY]" />						<link rel="stylesheet" type="text/css" href="fdastyles/spl-.min.css" />							<link rel="stylesheet" type="text/css" href="styles/layouts/slidingdoors-.min.css" />						<link rel="stylesheet" href="styles/colorbox-.min.css" type="text/css" media="screen" />			<script language="javascript" type="text/javascript" src="scripts/jquery.colorbox-min.js"></script>			<script type="text/javascript" src="scripts/autocomplete/lib/jquery.bgiframe.min.js"></script>			<script type="text/javascript" src="scripts/autocomplete/lib/jquery.dimensions-.min.js"></script>            <script>				$(function() {					jQuery_1_10_2( "#pmi-dialog-confirm" ).dialog({					  resizable: false,					  modal: true,					  autoOpen: false,					  position: {						my: "center",						at: "center",						of: $("body"),						within: $("body")					  }					});									jQuery_1_10_2( "#pmi_link a" ).click( function(event){						event.preventDefault();						var setid = this.toString();						jQuery_1_10_2( "#pmi-dialog-confirm" ).dialog( "option", "buttons", 							[								{									text: "Continue", 									click: function() {										jQuery_1_10_2( this ).dialog( "close" );										window.location.href = setid;									}								},								{									text: "Cancel", 									click: function() {										jQuery_1_10_2( this ).dialog( "close" );									}								}							]						);												jQuery_1_10_2( "#pmi-dialog-confirm" ).dialog( "open" );					});				});			</script>		</head>		<body>							<div id="controls"><ul>    	<li><a class="skipicon1" href="#druglabelcontent" title="Skip to DrugLabel content paragraph">Skip to DrugLabel content</a></li>	<li><a class="skipicon2" href="#dmsections" title="Skip to DrugLabel sections paragraph">Skip to DrugLabel sections</a></li>   </ul></div>  <div id="dailymedbanner">  		<div id="brandimage">        <img src="/dailymed/images/DM_LOGO_HEADER.png" alt="DailyMed Logo Header image" />        </div>        <div id="top">          <h1>Daily            <span>Med</span>          </h1>          <h2>            <span>Current </span>            <span>Medication </span>            <span>Information</span>          </h2>        </div>  </div>						<div id="actions">	<div id="options">		<h2>Options</h2>		<ul id="dmnav">	      		<li>					<a 	title=" Link to DailyMed Home "						href='/dailymed/about.cfm'						id="home">Home</a>				</li>	      		<li>					<a 	title=" Link to E-mail Label Information "						href="dailymed/emailWebLink.cfm"						id="email">E-mail Label Information</a>				</li>				<li><a 	class="rightarrow"						href="#"						title="Links to download options">Downloads</a>					<ul>						<li>							<a	title=" Link opens new window to download all drug labels "								href="dailymed/downloadLabels.cfm">Download All Drug Labels</a>						</li>                        <li>                        	<a	title=" Link opens new window to download all indexing files"                             	href="dailymed/downloadIndexing.cfm">Download All Indexing Files</a>                        </li>                        <li>                        	<a	title=" Link opens new window to download all mapping files"                             	href="dailymed/downloadMappingFiles.cfm">Download All Mapping Files</a>                        </li>                    	<li>                        	<a	title="Link to download FDA SPL Stylesheets"                            	href="http://www.fda.gov/downloads/ForIndustry/DataStandards/StructuredProductLabeling/UCM362812.zip">Download FDA SPL Stylesheets</a>                        </li>												<li>							<a	title=" Link opens new window to download this label (XML) "								href="dailymed/getFile.cfm?setid=e518dfc6-7e93-4fee-a66c-51e1ab71c056&amp;type=zip&amp;name=CAMPTOSAR">Download this Label(XML)</a>						</li>                        <li>						                        					</ul>				</li>								<li><a 	title="SPL History"						href="dailymed/splshistory.cfm?setid=e518dfc6-7e93-4fee-a66c-51e1ab71c056"						id="splhistory">SPL History </a>				</li>				<li><a 	title="Link to Print this Label"						href="dailymed/fda/fdaDrugXsl.cfm?setid=e518dfc6-7e93-4fee-a66c-51e1ab71c056&amp;type=display"						id="printitem"						target="_blank"> Print this Label </a>				</li>                <li>                				                    <a	title="Download PDF of this Label"                             href="dailymed/getFile.cfm?setid=e518dfc6-7e93-4fee-a66c-51e1ab71c056&amp;type=pdf&amp;name=e518dfc6-7e93-4fee-a66c-51e1ab71c056"                            id="downloadpdf"> Download this Label (PDF)</a>                                                               </li>        					      	    <li>						<a	title=" Notify of Updates "						href="dailymed/rsshome.cfm?setid=e518dfc6-7e93-4fee-a66c-51e1ab71c056"						id="rss">Notify of Updates</a>				</li>	      		<li>					<a	title=" Contact Us "						href="dailymed/contactUs.cfm"						id="contact">Contact Us</a>				</li>                <li>					<a	title=" Help "						href="dailymed/help.cfm"						id="help">Help</a>				</li>                <li>					<a	title=" Web Services "						href="dailymed/help.cfm#webservices"						id="help">Web Services <img src="/dailymed/images/new.gif" alt="New Web Services" /></a>				</li>                <li class="new-option">                	<a	title=" Browse Drug Classes "                    	href="dailymed/browseClasses.cfm"                        id="browse">Browse Drug Classes                    </a>                                    </li>				<li><h2>Additional Resources</h2></li>                <li>                	<a 	class="rightarrow"                		href="#"	                    title="Links to DailyMed presentations and related material">DailyMed Presentations and Related Material</a>                	<ul>                    	<li>                        	<a	href="http://videocast.nih.gov/Summary.asp?File=18134"                            	title="SPL/DailyMed Jamboree Workshop Videocast">SPL/DailyMed Jamboree Workshop Videocast</a>                        </li>                        <li>                        	<a	href="http://www.nlm.nih.gov/mesh/spl_workshop.html"                            	title="SPL/DailyMed Jamboree Workshop Slides">SPL/DailyMed Jamboree Workshop Slides</a>                        </li>                   		<li>                   			<a 	href="http://spl-work-group.wikispaces.com/Bibliography+-+Articles+containing+SPL"                            	title="Articles and Papers about SPL and DailyMed">Articles and Papers about SPL and DailyMed</a>                   		</li>                    </ul>                </li>                <li>                    <a	href="http://www.fda.gov/oc/datacouncil/spl.html"                        title="Link opens in a new window for FDA SPL Resources"                        target="FDA">FDA Structured Product Labeling Resources and Stylesheets                    </a>                </li>				<li>					<a	id="splimagesspec"						href="dailymed/splimagesspec.cfm"						target="SPLIMAGESPEC"						title="SPLIMAGE Specifications">SPLIMAGE Specification Version 3.0.2  </a>				</li>				<li>					<a	id="report"						href="http://www.fda.gov/medwatch/how.htm"						target="FDA"						title="FDA Page to Report Adverse Event">Report Adverse Event</a>				</li>																				    <li><a href="http://www.nlm.nih.gov/search/medlineplus?query=IRINOTECAN" title="Link opens new window to MedlinePlus Information" target="medlinePlus">MedlinePlus Information</a></li>			    <li><a href="http://www.clinicaltrials.gov/ct/search?submit=Search&amp;term=IRINOTECAN" title="Link opens new window to Find Clinical Trials" target="clinicalTrials">Find Clinical Trials</a></li>				<li><a href="http://www.drugbank.ca/search?query=APRD00579" title="Link opens new window to University of Alberta DrugBank" target="drugBank">Biochemical Data Summary</a></li>			    <li><a href="#" class="rightarrow" title="Links to Search PubMed Articles">Search PubMed Articles</a>				  <ul>					<li><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=IRINOTECAN[All Fields]" title="Link opens new window for All Citations" target="pubmed">All Citations</a></li>					<li><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=IRINOTECAN/AE" title="Link opens new window for Adverse Effects" target="pubmed">Adverse Effects</a></li>					<li><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=IRINOTECAN/TU"  title="Link opens new window for Therapeutic Use" target="pubmed">Therapeutic Use</a></li>					<li><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=IRINOTECAN/PD" title="Link opens new window for Pharmacology" target="pubmed">Pharmacology</a></li>					<li><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=IRINOTECAN[All Fields] AND Clinical Trial[ptyp]" title="Link opens new window for Clinical Trials" target="pubmed">Clinical Trials</a></li>				  </ul>			    </li>				<li>					<a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+lact:@na+IRINOTECAN" target="toxnet" title="Link opens new window for Presence in Breast Milk">Presence in Breast Milk</a>								</li>                <script> $(function() {			jQuery_1_10_2( "#rximage-dialog-confirm" ).dialog({			  resizable: false,			  modal: true,			  autoOpen: false,			  position: {				my: "center",				at: "center",				of: $("body"),				within: $("body")			  }			});					jQuery_1_10_2( ".rximage-link" ).click( function(event){				event.preventDefault();				jQuery_1_10_2( "#rximage-dialog-confirm" ).dialog( "option", "buttons", 					[						{							text: "Continue", 							click: function() {								jQuery_1_10_2( this ).dialog( "close" );								$( "a.rximage" )[0].click();							}						},						{							text: "Cancel", 							click: function() {								jQuery_1_10_2( this ).dialog( "close" );							}						}					]				);								jQuery_1_10_2( "#rximage-dialog-confirm" ).dialog( "open" );			});						$( ".rximage" ).colorbox({				rel:'rximage',				maxHeight:'100%',				maxWidth:'100%'			});		});</script><div id="rximage-dialog-confirm" title="Disclaimer" style="display:none;">  <p><span class="ui-icon ui-icon-alert" style="float: left;"></span>&nbsp;<strong>Disclaimer:</strong> These images are provided by the National Library of Medicine (NLM) and are not part of the official label.</p> </div>    			            	     </ul>		 		 	<div id="mdswitch">									<a  href="dailymed/drugInfo.cfm?id=95945&amp;dictionary=on"						title="Turn Dictionary Words On">						<img src="/dailymed/images/dictionaryon.jpg" alt="Turn Dictionary Words On"/>					</a>							</div>				</div>							<style type="text/css">		html body {		min-width:1024px;		}        .smallimage {            border: 1px solid ##ACBECE;        }</style>						    	    																																																								    	    	                             		       	                                                               <script>	$(function() {		$( '.splimage' ).colorbox({			rel:'splimage',			maxHeight:'100%',			maxWidth:'100%'		});	});</script>		            </div>			<div id="content">			<div id="searchpane">			<div id="search"><form action="/dailymed/search.cfm" name="searchform"><div class="divtable">    <div class="divtr">            <div class="divtd">Search :</div>            <div class="divtd">            	<label for="startswith" class="invisibletag">Enter a drug Name to search</label>                <input style="width:95%;"                type="text"                 id="startswith"                 name="startswith"                 title="enter a drug name to search"                  onclick="javascript:resetme()" /> &nbsp;                       </div>            <div class="divtd">              	<label for="go" class="invisibletag">Go</label>                <input type="image"                 src="/dailymed/images/goButton.gif"                 alt="Click this button to start your drug name search"                 title="Click this button to start your drug name search"                 id="go"/> &nbsp;            </div>            <div class="divtd80">            	<a href="dailymed/advancedSearch.cfm">Advanced Search</a>            </div>    </div>    <div class="divtr">    		<div class="divtd85">Limits:</div>            <div class="divtd85">                <input  class="searchoptions"  type="radio" name="searchdb" value="drugname" id="name-radio" title="Drug Name" />                <label for="name-radio" class="searchoptions">Drug Name</label>                <input  class="searchoptions"  type="radio" name="searchdb" value="ndc" id="ndc-radio" title="NDC Code" />               	<label for="ndc-radio" class="searchoptions">NDC Code</label>                <input  class="searchoptions"  type="radio" name="searchdb" value="drugclass" id="class-radio" title="Drug Class" />               	<label for="class-radio" class="searchoptions">Drug Class</label>                <input  class="searchoptions"  type="radio" name="searchdb" value="setid" id="setid-radio" title="SETID" />               	<label  for="setid-radio" class="searchoptions">SetId</label>            </div>    </div>    <div class="divtr">            <div class="divtd85">Label Type:</div>            <div class="divtd85" style="float:left;">                <input class="searchoptions" type="radio" name="labeltype" value="human" id="human-radio" title="Human Drugs" />               	<label for="human-radio" class="searchoptions">Human Drugs</label>                <input class="searchoptions" type="radio" name="labeltype" value="animal" id="animal-radio" title="Animal Drugs" />               	<label for="animal-radio" class="searchoptions">Animal Drugs</label>            </div>    </div>          </div></form></div>			</div>					<div id="rxnormlist">		<h3>RxNorm Names</h3>								<ul style="maring:0px; padding:0px;">				<li id="item1" style="padding:1px; margin:1px;">					  						<a 	id="viewrxnorm"							href="rxnormdata.cfm?setid=e518dfc6-7e93-4fee-a66c-51e1ab71c056"							onclick="rxnormpopup(this.href);return false;"							target="rxnorm" title="Link to Review RxNorm Normal Forms" >							<img src="images/closed.gif"								 alt="Icon attached Review or Hide All RxNorm Normal Forms Link"								 id="img_item1"								 border="0"								 style="clear:none;float:left">Review RxNorm Normal Forms</a>					  			  	</li>			 </ul>				</div>				<!DOCTYPE html PUBLIC "-"><p class="DocumentTitle"><strong>CAMPTOSAR			(irinotecan hydrochloride) 		 injection, solution</strong><br> [Pharmacia and Upjohn Company] 	</p><br>			<div class="permalink">				<h3><strong>Permanent Link: </strong></h3><span><a href="lookup.cfm?setid=e518dfc6-7e93-4fee-a66c-51e1ab71c056">http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e518dfc6-7e93-4fee-a66c-51e1ab71c056 </a><span>			</div>									                                    			<div id="nlmdrugstatus">			<table border="4" width="100%" style="border: 1px solid rgb(142, 1, 10); padding: 0pt; float: right; margin-bottom: 0.75em; margin-top: 0.75em; position: relative; right: 0pt;">			<thead align="left" bgcolor="#F6F6F6" style="color:#8e010a; font-size:1.2em">			<tr>			<th scope="col">				<a class="anchor1" href="http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162063.htm" target="fda"			onclick="fdapopup(this.href);return false;" title="Document Type including Content of Labeling Type">			Category</a></th>			<th scope="col">				<a class="anchor1" href="http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/DataStandardsManualmonographs/ucm071816.htm" target="fda" onclick="fdapopup(this.href);return false;" title="SPL DEA Schedule">			DEA Schedule</a></th>			<th scope="col">			<a class="anchor1" href="http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/DataStandardsManualmonographs/ucm071826.htm" target="fda" onclick="fdapopup(this.href);return false;" title="Marketing Category">Marketing Status</a></th>			</tr>			</thead>			<tbody>			<tr>			<td scope="row"><strong>HUMAN PRESCRIPTION DRUG LABEL</strong></td>			<td scope="row"><strong></strong></td>			<td scope="row"><strong>New Drug Application</strong></td>			</tr>			</tbody>			</table>			<div id="disclaimer" >											</div>			</div>			<div id="dmsectionsfieldset"><fieldset><legend>Drug Label Sections</legend><div id="dmsections"><ul><li><a title="Description" href="#nlm34089-3" class="nlmlinktrue">Description</a></li><li><a title="Clinical Pharmacology" href="#nlm34090-1" class="nlmlinktrue">Clinical Pharmacology</a></li><li><a title="Indications &amp; Usage" href="#nlm34067-9" class="nlmlinktrue">Indications &amp; Usage</a></li><li><a title="Contraindications" href="#nlm34070-3" class="nlmlinktrue">Contraindications</a></li><li><a title="Warnings" href="#nlm43685-7" class="nlmlinktrue">Warnings</a></li><li><a title="Precautions" href="#nlm43685-7" class="nlmlinktrue">Precautions</a></li><li><a title="Adverse Reactions" href="#nlm34084-4" class="nlmlinktrue">Adverse Reactions</a></li><li><a title="Overdosage" href="#nlm34088-5" class="nlmlinktrue">Overdosage</a></li><li><a title="Dosage &amp; Administration" href="#nlm34068-7" class="nlmlinktrue">Dosage &amp; Administration</a></li><li><a title="How Supplied" href="#nlm34069-5" class="nlmlinktrue">How Supplied</a></li><li><a title="Patient Counseling Information" href="#nlm34076-0" class="nlmlinktrue">Patient Counseling Information</a></li><li><a title="Supplemental Patient Material" href="#nlm38056-8" class="nlmlinkfalse">Supplemental Patient Material</a></li><li><a title="Boxed Warning" href="#nlm34066-1" class="nlmlinktrue">Boxed Warning</a></li><li><a title="Patient Package Insert" href="#nlm42230-3" class="nlmlinkfalse">Patient Package Insert</a></li><li><a title="Highlights" href="#nlmhighlights" class="nlmlinktrue">Highlights</a></li><li><a title="Full Table of Contents" href="javascript:nlmftoc('nlmftoc');" class="nlmlinktrue">Full Table of Contents</a></li><li><a href="#" class="nlmlinkfalse">Medication Guide</a></li></ul></div></fieldset></div>			<div class="spl">				<a name="druglabelcontent"></a><div id="nlmhighlightsmarker"><div class="Highlights" id="Highlights"><table border="0" style="table-layout:fixed" width="100%" cellpadding="5" cellspacing="5"><tr><td valign="top" align="left" width="50%"><div><a name="nlmhighlights"><h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1></a><div class="HighlightsDisclaimer">These highlights do not include all the information needed to use CAMPTOSAR safely and effectively.  See full prescribing information for CAMPTOSAR.<br>&nbsp;<br>CAMPTOSAR (Irinotecan) Injection, intravenous infusion<br> Initial U.S. Approval: 1996</div><div class="Warning"><div><h1 class="Warning">WARNING: DIARRHEA and MYELOSUPPRESSION</h1><h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1><ul><li><span class="Bold">Early and late forms of diarrhea </span><span class="Bold">can occur. Early diarrhea may be accompanied by cholinergic symptoms </span><span class="Bold">which may be prevented or ameliorated by atropine. Late diarrhea can be life threatening and should be treated promptly with loperamide. </span><span class="Bold">Monitor patients with diarrhea and give fluid and </span><span class="Bold">electrolytes as needed.  Institute antibiotic therapy if </span><span class="Bold">patients develop ileus, fever, or severe neutropenia. </span><span class="Bold"> Interrupt CAMPTOSAR and </span><span class="Bold">reduce subsequent doses if severe diarrhea occurs.</span></li><li><span class="Bold">Severe myelosuppression may occur.</span></li></ul></div></div><div></div><div class="HighlightSection"><h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1><div><p class="Highlighta">CAMPTOSAR is a topoisomerase inhibitor indicated for: </p><ul><li> First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. (<a href="#S1">1</a>)</li><li> Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. (<a href="#S1">1</a>)</li></ul></div></div><div class="HighlightSection"><h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1><div><ul><li> Colorectal cancer combination regimen 1:  CAMPTOSAR 125 mg/m<span class="Sup">2</span> intravenous infusion over 90 minutes on days 1, 8,15, 22 with LV 20 mg/m<span class="Sup">2</span> intravenous bolus infusion on days 1, 8, 15, 22 followed by 5-FU intravenous bolus infusion on days 1, 8, 15, 22 every 6 weeks. (<a href="#S2.1">2.1</a>)</li><li> Colorectal cancer combination regimen 2: CAMPTOSAR 180 mg/m<span class="Sup">2</span> intravenous infusion over 90 minutes on days 1, 15, 29 with LV 200 mg/m<span class="Sup">2</span> intravenous infusion over 2 hours on days 1, 2, 15, 16, 29, 20 followed by 5-FU 400 mg/m<span class="Sup">2</span> intravenous bolus infusion on days 1, 2, 15, 16, 29, 30 and 5-FU 600 mg/m<span class="Sup">2</span> intravenous infusion over 22 hours on days 1, 2, 15, 16, 29, 30. (<a href="#S2.1">2.1</a>)</li><li> Colorectal cancer single agent regimen 1:  CAMPTOSAR 125 mg/m<span class="Sup">2</span> intravenous infusion over 90 minutes on days 1, 8, 15, 22 then 2-week rest. (<a href="#S2.2">2.2</a>)</li><li> Colorectal cancer single agent regimen 2:  CAMPTOSAR 350 mg/m<span class="Sup">2</span> intravenous infusion over 90 minutes on day 1 every 3 weeks. (<a href="#S2.2">2.2</a>)</li></ul></div><div><div></div></div><div><div></div></div><div></div><div></div><div></div><div></div><div></div></div><div class="HighlightSection"><h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1><div><p class="Highlighta">CAMPTOSAR Injection is available in three single-dose sizes:  (<a href="#section-3">3</a>)</p><ul><li> 2 mL-fill vial containing 40 mg irinotecan hydrochloride injection</li><li> 5 mL-fill vial containing 100 mg irinotecan hydrochloride injection</li><li> 15 mL-fill vial containing 300 mg irinotecan hydrochloride injection</li></ul></div></div><div class="HighlightSection"><h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1><div><ul><li>Hypersensitivity to CAMPTOSAR or its excipients (<a href="#S4">4</a>)</li></ul></div></div><div class="HighlightSection"><h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1><div><ul><li><span class="Bold">Diarrhea and cholinergic reactions</span>:  Early diarrhea (occurring during or shortly after infusion of CAMPTOSAR) is usually transient and may be accompanied by cholinergic symptoms.  Consider prophylactic or therapeutic administration of 0.25 mg to 1 mg of intravenous or subcutaneous atropine (unless clinically contraindicated).  Late diarrhea (generally occurring more than 24 hours after administration of CAMPTOSAR) can occur.  Monitor and replace fluid and electrolytes.   Treat with loperamide.  Use antibiotic support for ileus and fever. Interrupt CAMPTOSAR and reduce subsequent doses if severe diarrhea occurs.  (<a href="#S5.1">5.1</a>)</li><li><span class="Bold">Myelosuppression</span>:  Manage promptly with antibiotic support.  Interrupt CAMPTOSAR and reduce subsequent doses if necessary. (<a href="#S5.2">5.2</a>)</li><li><span class="Bold">Patients with Reduced UGT1A1 Activity:</span> Individuals who are homozygous for the UGT1A1*28 allele are at increased risk for neutropenia following initiation of CAMPTOSAR treatment. (<a href="#S5.3">5.3</a>)</li><li><span class="Bold">Hypersensitivity: </span>Hypersensitivity reactions including severe anaphylactic or anaphylactoid reactions have been observed. Discontinue CAMPTOSAR if this occurs. (<a href="#S5.4">5.4</a>)</li><li><span class="Bold">Renal Impairment/Renal Failure: </span>Rare cases of renal impairment and acute renal failure have been identified, usually in patients who became volume depleted from severe vomiting and/or diarrhea. (<a href="#S5.5">5.5</a>)</li><li><span class="Bold">Pulmonary Toxicity: </span>Interstitial Pulmonary Disease (IPD)-like events, including fatalities, have occurred.  Interrupt for new or progressive dysnpnea, cough, and fever pending evaluation.  If IPD diagnosed, discontinue and institute appropriate treatment as needed. (<a href="#S5.6">5.6</a>)</li><li><span class="Bold">Toxicity of the 5 Day Regimen:</span>  CAMPTOSAR should not be used in combination with a regimen of 5-FU/LV administered for 4&ndash;5 consecutive days every 4 weeks outside of a clinical study. (<a href="#S5.7">5.7</a>)</li><li><span class="Bold">Pregnancy: </span>CAMPTOSAR can cause fetal harm when administered to a pregnant woman. (<a href="#S5.9">5.9</a>)</li><li><span class="Bold">Patients with Hepatic Impairment:</span>  In clinical trials, CAMPTOSAR has not been administered to patients with serum bilirubin &gt; 2.0 mg/dL, or transaminases &gt; 3 times ULN if no liver metastases, or transaminases &gt; 5 times ULN if liver metastases.  With the weekly dosage schedule, patients with total bilirubin levels 1.0&ndash;2.0 mg/dL had greater likelihood of grade 3&ndash;4 neutropenia. (<a href="#S5.10">5.10</a>)</li></ul></div><div></div><div></div><div><div></div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div><div class="HighlightSection"><h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1><div><p class="Highlighta">Common adverse reactions (&ge;30%) observed in combination therapy clinical studies are: nausea, vomiting, abdominal pain, diarrhea, constipation, anorexia, mucositis, neutropenia, leukopenia (including lymphocytopenia), anemia, thrombocytopenia, asthenia, pain, fever, infection, abnormal bilirubin, alopecia. (<a href="#S6.1">6.1</a>) </p><p class="Highlighta">Common adverse reactions (&ge;30%) observed in single agent therapy clinical studies are: nausea, vomiting, abdominal pain, diarrhea, constipation, anorexia, neutropenia, leukopenia (including lymphocytopenia), anemia, asthenia, fever, body weight decreasing, alopecia. (<a href="#S6.1">6.1</a>) </p><br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at 1-800-438-1985 or <span class="Italics">www.pfizer.com</span> or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch</span>.</span> </p></div><div><div></div><div></div><div></div><div></div></div><div></div></div><div class="HighlightSection"><h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1><div><ul><li> Strong CYP3A4 Inducers: Do not administer for at least 2 weeks prior to initiation of irinotecan therapy. (<a href="#S7.2">7.2</a>)</li><li> Strong CYP3A4 Inhibitors: Discontinue at least 1 week prior to starting irinotecan therapy and do not use during irinotecan therapy. (<a href="#S7.3">7.3</a>)</li></ul></div><div></div><div><div></div><div></div><div></div></div><div></div><div></div><div></div></div><div class="HighlightSection"><h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1><div><ul><li><span class="Bold">Nursing Mothers:</span> Discontinue nursing when receiving therapy with CAMPTOSAR. (<a href="#S8.3">8.3</a>)</li><li><span class="Bold">Geriatric Use:</span> Closely monitor patients greater than 65 years of age because of a greater risk of early and late diarrhea in this population. (<a href="#S8.5">8.5</a>)</li><li> Patients with Renal Impairment: Use caution and do not use in patients on dialysis. (<a href="#S8.6">8.6</a>)</li><li> Patients with Hepatic Impairment: Use caution. (<a href="#S2.1">2.1</a>, <a href="#S5.10">5.10</a>, <a href="#S8.7">8.7</a>, <a href="#S12.3">12.3</a>)</li></ul></div><div><div></div></div><div></div><div></div><div></div><div></div></div><div></div><div></div><div><div></div><div></div><div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div></div><div><div></div></div><div><div><div></div><div><div></div><div><div></div><div></div></div></div></div></div><div></div><div><div></div></div><div></div><div></div><div></div><div></div><p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p><p class="HighlightsRevision">Revised: 8/2012</p></div></td></tr></table></div></div><div id="nlmftoc"><span id="backtodmsections"><a title=" Back to Highlights and Tabs " href="javascript:nlmftoc('backtodmsections');">Back to Highlights and Tabs</a></span><div class="Index" id="Index"><table style="table-layout:fixed" width="100%" cellpadding="5" cellspacing="5"><tr><td valign="top" align="left" width="50%"><div><h1 class="Colspan"><a style="text-decoration:none;" name="dmsections">FULL PRESCRIBING INFORMATION: CONTENTS</a><a name="footnote-reference-content" href="#footnote-content">*</a></h1><h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING:  DIARRHEA AND MYELOSUPPRESSION</span></a></h1><h1><a href="#section-1" class="toc">1	INDICATIONS AND USAGE</a></h1><h1><a href="#section-2" class="toc">2     DOSAGE AND ADMINISTRATION</a></h1><h2><a href="#section-2.1" class="toc">2.1 Colorectal Cancer Combination Regimens 1 and 2</a></h2><h2><a href="#section-2.2" class="toc">2.2   Colorectal Single Agent Regimens 1 and 2</a></h2><h2><a href="#section-2.3" class="toc">2.3   Dosage in Patients with Reduced UGT1A1 Activity</a></h2><h2><a href="#section-2.4" class="toc">2.4  Premedication</a></h2><h2><a href="#section-2.5" class="toc">2.5   Preparation of Infusion Solution</a></h2><h2><a href="#section-2.6" class="toc">2.6  Safe Handling</a></h2><h2><a href="#section-2.7" class="toc">2.7  Extravasation</a></h2><h1><a href="#section-3" class="toc">3    DOSAGE FORMS AND STRENGTHS</a></h1><h1><a href="#section-4" class="toc">4	CONTRAINDICATIONS</a></h1><h1><a href="#section-5" class="toc">5    WARNINGS AND PRECAUTIONS</a></h1><h2><a href="#section-5.1" class="toc">5.1  Diarrhea and Cholinergic Reactions</a></h2><h2><a href="#section-5.2" class="toc">5.2   Myelosuppression</a></h2><h2><a href="#section-5.3" class="toc">5.3  Patients With Reduced UGT1A1 Activity</a></h2><h2><a href="#section-5.4" class="toc">5.4   Hypersensitivity</a></h2><h2><a href="#section-5.5" class="toc">5.5   Renal Impairment/Renal Failure</a></h2><h2><a href="#section-5.6" class="toc">5.6   Pulmonary Toxicity</a></h2><h2><a href="#section-5.7" class="toc">5.7  Toxicity of the 5 Day Regimen</a></h2><h2><a href="#section-5.8" class="toc">5.8  Increased Toxicity in Patients with Performance Status 2</a></h2><h2><a href="#section-5.9" class="toc">5.9   Pregnancy</a></h2><h2><a href="#section-5.10" class="toc">5.10  Patients with Hepatic Impairment</a></h2><h1><a href="#section-6" class="toc">6	ADVERSE REACTIONS</a></h1><h2><a href="#section-6.1" class="toc">6.1   Clinical Studies Experience</a></h2><h2><a href="#section-6.2" class="toc">6.2   Postmarketing Experience</a></h2><h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1><h2><a href="#section-7.1" class="toc">7.1   5-Fluorouracil (5-FU) and Leucovorin (LV)</a></h2><h2><a href="#section-7.2" class="toc">7.2   Strong CYP 3A4 Inducers</a></h2><h2><a href="#section-7.3" class="toc">7.3  Strong CYP 3A4 Inhibitors</a></h2><h2><a href="#section-7.4" class="toc">7.4   Atazanavir Sulfate</a></h2><h2><a href="#section-7.5" class="toc">7.5   Drug-Laboratory Test Interactions</a></h2><h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1><h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2><h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2><h2><a href="#section-8.3" class="toc">8.4   Pediatric Use</a></h2><h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2><h2><a href="#section-8.5" class="toc">8.6    Renal Impairment</a></h2><h2><a href="#section-8.6" class="toc">8.7    Hepatic Impairment</a></h2><h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1><h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1><h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1><h2><a href="#section-11.1" class="toc">12.1  Mechanism of Action</a></h2><h2><a href="#section-11.2" class="toc">12.2  Pharmacodynamics</a></h2><h2><a href="#section-11.3" class="toc">12.3  Pharmacokinetics</a></h2><h1><a href="#section-12" class="toc">13	NONCLINICAL TOXICOLOGY</a></h1><h2><a href="#section-12.1" class="toc">13.1   Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2><h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1><h2><a href="#section-13.1" class="toc">14.1  Metastatic Colorectal Cancer</a></h2><h1><a href="#section-14" class="toc">15	REFERENCES</a></h1><h1><a href="#section-15" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING</a></h1><h1><a href="#section-16" class="toc">17	PATIENT COUNSELING INFORMATION</a></h1><dl class="Footnote"><dt><a name="footnote-content" href="#footnote-reference-content">*</a></dt><dd>Sections or subsections omitted from the full prescribing information are not listed.</dd></dl></div></td></tr></table></div></div><div class="Contents"><h1>FULL PRESCRIBING INFORMATION</h1><div class="Section"><a name="nlm48780-1"></a><a name="DLDE"></a><a name="section-1"></a><p></p></div><a name="nlm34066-1"></a><div class="Warning"><a name="BOX"></a><a name="section-1"></a><p></p><h1><span class="Emphasis">WARNING:  DIARRHEA AND MYELOSUPPRESSION</span></h1><ul><li><span class="Bold">Early and late forms of diarrhea can occur. Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. Late diarrhea can be life threatening and should be treated promptly with loperamide. Monitor patients with diarrhea and give fluid and electrolytes as needed.  Institute antibiotic therapy if patients develop ileus, fever, or severe neutropenia.  Interrupt CAMPTOSAR and reduce subsequent doses if severe diarrhea occurs. </span></li><li><span class="Bold">Severe myelosuppression may occur.</span></li></ul></div><div class="Section"><a name="nlm34067-9"></a><a name="S1"></a><a name="section-1"></a><p></p><h1>1	INDICATIONS AND USAGE</h1><ul><li>CAMPTOSAR Injection is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic carcinoma of the colon or rectum.</li><li>CAMPTOSAR is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.</li></ul></div><div class="Section"><a name="nlm34068-7"></a><a name="S2"></a><a name="section-2"></a><p></p><h1>2     DOSAGE AND ADMINISTRATION</h1><div class="Section"><a name="nlm42229-5"></a><a name="S2.1"></a><a name="section-2.1"></a><p></p><h2>2.1 Colorectal Cancer Combination Regimens 1 and 2</h2><p class="First">Administer CAMPTOSAR as a 90-minute intravenous infusion followed by LV and 5-FU. The currently recommended regimens are shown in Table 1.</p><p>A reduction in the starting dose by one dose level of CAMPTOSAR may be considered for patients with any of the following conditions: prior pelvic/abdominal radiotherapy, performance status of 2, or increased bilirubin levels. Dosing for patients with bilirubin &gt;2 mg/dL cannot be recommended because there is insufficient information to recommend a dose in these patients.</p><a name="t1"></a><table width="100%"><caption><span>Table 1.  Combination-Agent Dosage Regimens and Dose Modifications<a class="Sup" href="#footnote-1" name="footnote-reference-1">*</a></span></caption><col align="center" valign="top" width="20%"><col align="center" valign="top" width="20%"><col align="center" valign="top" width="20%"><col align="center" valign="top" width="20%"><col align="center" valign="top" width="20%"><tfoot><tr><td align="left" colspan="5"><dl class="Footnote"><dt><a href="#footnote-reference-1" name="footnote-1">*</a></dt><dd>Dose reductions beyond Dose Level &ndash;2 by decrements of &asymp; 20% may be warranted for patients continuing to experience toxicity.  Provided intolerable toxicity does not develop, treatment with additional cycles may be continued indefinitely as long as patients continue to experience clinical benefit.</dd><dt><a href="#footnote-reference-2" name="footnote-2">&dagger;</a></dt><dd>Infusion follows bolus administration.</dd></dl></td></tr></tfoot><tbody class="Headless"><tr class="First"><td align="center" rowspan="3"><span class="Bold">Regimen 1</span><br>6-wk cycle with bolus 5-FU/LV<br>(next cycle begins on day 43)</td><td class="Botrule Lrule" align="center" rowspan="3" valign="middle">CAMPTOSAR<br>LV<br>5-FU</td><td class="Lrule" align="center" colspan="3">125 mg/m<span class="Sup">2 </span>intravenous infusion over 90 minutes, days 1,8,15,22<br>20 mg/m<span class="Sup">2</span> intravenous injection bolus, days 1,8,15,22<br>500 mg/m<span class="Sup">2</span> intravenous injection bolus, days 1,8,15,22</td></tr><tr><td class="Lrule Toprule" align="center" colspan="3"><span class="Bold">Starting Dose &amp; Modified Dose Levels (mg/m<span class="Sup">2</span>)</span></td></tr><tr><td class="Botrule Lrule Toprule" align="center">Starting Dose</td><td class="Botrule Toprule" align="center">Dose Level -1</td><td class="Botrule Toprule" align="center">Dose Level -2</td></tr><tr><td align="center"></td><td class="Lrule" align="center">CAMPTOSAR</td><td class="Lrule" align="center">125</td><td align="center">100</td><td align="center" colspan="2">75</td></tr><tr><td align="center"></td><td class="Lrule" align="center">LV</td><td class="Lrule" align="center">20</td><td align="center">20</td><td align="center" colspan="2">20</td></tr><tr><td align="center"></td><td class="Lrule" align="center">5-FU</td><td class="Lrule" align="center">500</td><td align="center">400</td><td align="center" colspan="2">300</td></tr><tr><td class="Toprule" align="center"><span class="Bold">Regimen 2</span></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center" colspan="3"></td></tr><tr><td align="center">6-wk cycle with infusional<br>5-FU/LV<br>(next cycle begins on day 43)</td><td class="Lrule" align="center">CAMPTOSAR<br>LV<br>5-FU       Bolus<br>5-FU       Infusion<a class="Sup" href="#footnote-2" name="footnote-reference-2">&dagger;</a></td><td class="Lrule" align="center" colspan="3">180 mg/m<span class="Sup">2</span> intravenous infusion over 90 minutes, days 1,15,29<br>200 mg/m<span class="Sup">2</span> intravenous infusion over 2 hours, days 1,2,15,16,29,30<br>400 mg/m<span class="Sup">2</span> intravenous injection bolus, days 1,2,15,16,29,30<br>600 mg/m<span class="Sup">2</span> intravenous infusion over 22 hours, days 1,2,15,16,29,30</td></tr><tr><td align="center"></td><td class="Lrule" align="center"></td><td class="Lrule Toprule" align="center" colspan="3"><span class="Bold">Starting Dose &amp; Modified Dose Levels (mg/m<span class="Sup">2</span>)</span></td><td></td></tr><tr><td align="center"></td><td class="Botrule Lrule" align="center"></td><td class="Lrule Toprule" align="center">Starting Dose</td><td class="Toprule" align="center">Dose Level -1</td><td class="Toprule" align="center">Dose Level -2</td><td></td></tr><tr><td align="center"></td><td class="Lrule" align="center">CAMPTOSAR</td><td class="Lrule Toprule" align="center">180</td><td class="Toprule" align="center">150</td><td class="Toprule" align="center">120</td></tr><tr><td align="center"></td><td class="Lrule" align="center">LV</td><td class="Lrule" align="center">200</td><td align="center">200</td><td align="center">200</td></tr><tr><td align="center"></td><td class="Lrule" align="center">5-FU       Bolus</td><td class="Lrule" align="center">400</td><td align="center">320</td><td align="center">240</td></tr><tr class="Last"><td align="center"></td><td class="Lrule" align="center">5-FU       Infusion<a class="Sup" href="#footnote-2">&dagger;</a></td><td class="Lrule" align="center">600</td><td align="center">480</td><td align="center">360</td></tr></tbody></table><p>Dosing for patients with bilirubin &gt;2 mg/dL cannot be recommended because there is insufficient information to recommend a dose in these patients [<span class="Italics">see <a href="#S5.10">Warnings and Precautions (5.10)</a>, <a href="#S8.7">Use in Specific Populations (8.7)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p><div class="Section"><a name="nlm42229-5"></a><a name="section-2.1.1"></a><p></p><p class="First"><span class="Underline">Dose Modifications</span></p><p>Based on recommended dose levels described in Table 1, Combination Regimens of CAMPTOSAR and Dose Modifications, subsequent doses should be adjusted as suggested in Table 2, Recommended Dose Modifications for Combination Regimens.  All dose modifications should be based on the worst preceding toxicity.</p><table width="100%"><caption><span>Table 2.  Recommended Dose Modifications for CAMPTOSAR/5-Fluorouracil (5-FU)/Leucovorin (LV) Combination Schedules</span></caption><col align="left" valign="top" width="30%"><col align="left" valign="top" width="40%"><col align="left" valign="top" width="30%"><thead><tr class="Botrule First"><th align="left" colspan="3">Patients should return to pre-treatment bowel function without requiring antidiarrhea medications for at least 24 hours before the next chemotherapy administration. A new cycle of therapy should not begin until the granulocyte count has recovered to &ge;1500/mm<span class="Sup">3</span>, and the platelet count has recovered to &ge;100,000/mm<span class="Sup">3</span>, and treatment-related diarrhea is fully resolved.  Treatment should be delayed 1 to 2 weeks to allow for recovery from treatment-related toxicities.  If the patient has not recovered after a 2-week delay, consideration should be given to discontinuing therapy.</th></tr><tr class="Last"><th align="center">Toxicity<br>NCI CTC Grade<a class="Sup" href="#footnote-3" name="footnote-reference-3">*</a> (Value)</th><th class="Lrule" align="center">During a Cycle of Therapy</th><th class="Lrule" align="center">At the Start of Subsequent Cycles of Therapy<a class="Sup" href="#footnote-4" name="footnote-reference-4">&dagger;</a></th></tr></thead><tfoot><tr><td align="left" colspan="3"><dl class="Footnote"><dt><a href="#footnote-reference-3" name="footnote-3">*</a></dt><dd>National Cancer Institute Common Toxicity Criteria (version 1.0)</dd><dt><a href="#footnote-reference-4" name="footnote-4">&dagger;</a></dt><dd>Relative to the starting dose used in the previous cycle</dd><dt><a href="#footnote-reference-5" name="footnote-5">&Dagger;</a></dt><dd>Pretreatment</dd><dt><a href="#footnote-reference-6" name="footnote-6">&sect;</a></dt><dd>Excludes alopecia, anorexia, asthenia</dd></dl></td></tr></tfoot><tbody><tr class="Botrule First"><td align="left">No toxicity</td><td class="Lrule" align="left">Maintain dose level</td><td class="Lrule" align="left">Maintain dose level</td></tr><tr class="Botrule"><td align="left"><span class="Bold">Neutropenia</span><br>1  (1500 to 1999/mm<span class="Sup">3</span>)<br>2  (1000 to 1499/mm<span class="Sup">3</span>)<br>3  (500 to 999/mm<span class="Sup">3</span>)<br>4  (&lt;500/mm<span class="Sup">3</span>)</td><td class="Lrule" align="left"><br>Maintain dose level<br>&darr; 1 dose level<br>Omit dose until resolved to &le; grade 2, then &darr; 1 dose level<br>Omit dose until resolved to &le; grade 2, then &darr; 2 dose levels</td><td class="Lrule" align="left"><br>Maintain dose level<br>Maintain dose level<br>&darr; 1 dose level<br>&darr; 2 dose levels</td></tr><tr><td align="left"><span class="Bold">Neutropenic fever</span></td><td class="Lrule" align="left" colspan="2">Omit dose until resolved, then &darr; 2 dose levels</td></tr><tr><td class="Toprule" align="left"><span class="Bold">Other hematologic toxicities</span></td><td class="Lrule Toprule" align="left" colspan="2">Dose modifications for leukopenia or thrombocytopenia during a cycle of therapy and at the start of subsequent cycles of therapy are also based on NCI toxicity criteria and are the same as recommended for neutropenia above.</td></tr><tr><td class="Toprule" align="left"><span class="Bold">Diarrhea</span><br>1  (2&ndash;3 stools/day &gt; pretx<a class="Sup" href="#footnote-5" name="footnote-reference-5">&Dagger;</a>)<br>2  (4&ndash;6 stools/day &gt; pretx)<br>3  (7&ndash;9 stools/day &gt; pretx)<br>4  (&ge;10 stools/day &gt; pretx)</td><td class="Lrule Toprule" align="left"><br>Delay dose until resolved to baseline, then give same dose<br>Omit dose until resolved to baseline, then &darr; 1 dose level<br>Omit dose until resolved to baseline, then &darr; 1 dose level<br>Omit dose until resolved to baseline, then &darr; 2 dose levels</td><td class="Lrule Toprule" align="left"><br>Maintain dose level<br>Maintain dose level<br>&darr; 1 dose level<br>&darr; 2 dose levels</td></tr><tr class="Last"><td class="Toprule" align="left"><span class="Bold">Other nonhematologic toxicities<a class="Sup" href="#footnote-6" name="footnote-reference-6">&sect;</a></span><br>1<br>2<br>3<br>4</td><td class="Lrule Toprule" align="left"><br>Maintain dose level<br>Omit dose until resolved to &le; grade 1, then &darr; 1 dose level<br>Omit dose until resolved to &le; grade 2, then &darr; 1 dose level<br>Omit dose until resolved to &le; grade 2, then &darr; 2 dose levels<br><br><span class="Italics">For mucositis/stomatitis decrease only 5-FU, not CAMPTOSAR</span></td><td class="Lrule Toprule" align="left"><br>Maintain dose level<br>Maintain dose level<br>&darr; 1 dose level<br>&darr; 2 dose levels<br><br><span class="Italics">For mucositis/stomatitis decrease only 5-FU, not CAMPTOSAR.</span></td></tr></tbody></table></div></div><div class="Section"><a name="nlm42229-5"></a><a name="S2.2"></a><a name="section-2.2"></a><p></p><h2>2.2   Colorectal Single Agent Regimens 1 and 2</h2><p class="First">Administer CAMPTOSAR as a 90-minute intravenous infusion. The currently recommended regimens are shown in Table 3.</p><p>A reduction in the starting dose by one dose level of CAMPTOSAR may be considered for patients with any of the following conditions: prior pelvic/abdominal radiotherapy, performance status of 2, or increased bilirubin levels. Dosing for patients with bilirubin &gt;2 mg/dL cannot be recommended because there is insufficient information to recommend a dose in these patients.</p><table width="100%"><caption><span>Table 3. Single-Agent Regimens of CAMPTOSAR and Dose Modifications</span></caption><col align="left" valign="top" width="25%"><col align="center" valign="top" width="35%"><col align="center" valign="top" width="20%"><col align="center" valign="top" width="20%"><tfoot><tr><td align="left" colspan="4"><dl class="Footnote"><dt><a href="#footnote-reference-7" name="footnote-7">*</a></dt><dd>Subsequent doses may be adjusted as high as 150 mg/m<span class="Sup">2</span> or to as low as 50 mg/m<span class="Sup">2</span> in 25 to 50 mg/m<span class="Sup">2</span> decrements depending upon individual patient tolerance.</dd><dt><a href="#footnote-reference-8" name="footnote-8">&dagger;</a></dt><dd>Provided intolerable toxicity does not develop, treatment with additional cycles may be continued indefinitely as long as patients continue to experience clinical benefit.</dd><dt><a href="#footnote-reference-9" name="footnote-9">&Dagger;</a></dt><dd>Subsequent doses may be adjusted as low as 200 mg/m<span class="Sup">2</span> in 50 mg/m<span class="Sup">2</span> decrements depending upon individual patient tolerance.</dd></dl></td></tr></tfoot><tbody class="Headless"><tr class="First"><td align="left"><span class="Bold">Regimen 1 (weekly)<a class="Sup" href="#footnote-7" name="footnote-reference-7">*</a></span></td><td class="Lrule" align="left" colspan="3">125 mg/m<span class="Sup">2 </span>intravenous infusion over 90 minutes, days 1,8,15,22 then 2-week rest</td></tr><tr><td align="left"></td><td class="Lrule Toprule" align="left" colspan="3">&nbsp;&nbsp;<span class="Bold">Starting Dose and Modified Dose Levels<a class="Sup" href="#footnote-8" name="footnote-reference-8">&dagger;</a> (mg/m<span class="Sup">2</span>)</span></td></tr><tr><td align="left"></td><td class="Botrule Lrule Toprule" align="center">Starting Dose</td><td class="Botrule Toprule" align="center">Dose Level -1</td><td class="Botrule Toprule" align="center">Dose Level -2</td></tr><tr><td align="left"></td><td class="Lrule" align="center">125</td><td align="center">100</td><td align="center">75</td></tr><tr><td class="Toprule" align="left" valign="middle"><span class="Bold">Regimen 2 (every 3 weeks)<a class="Sup" href="#footnote-9" name="footnote-reference-9">&Dagger;</a></span></td><td class="Lrule Toprule" align="left" colspan="3" valign="middle">350 mg/m<span class="Sup">2 </span>intravenous infusion over 90 minutes, once every 3 weeks<a class="Sup" href="#footnote-8">&dagger;</a></td></tr><tr><td align="left"></td><td class="Lrule Toprule" align="left" colspan="3">&nbsp;&nbsp;<span class="Bold">Starting Dose and Modified Dose Levels (mg/m<span class="Sup">2</span>)</span></td></tr><tr><td align="left"></td><td class="Botrule Lrule Toprule" align="center">Starting Dose</td><td class="Botrule Toprule" align="center">Dose Level -1</td><td class="Botrule Toprule" align="center">Dose Level -2</td></tr><tr class="Last"><td class="Rrule" align="left"></td><td align="center">350</td><td align="center">300</td><td align="center">250</td></tr></tbody></table><div class="Section"><a name="nlm42229-5"></a><a name="section-2.2.1"></a><p></p><p class="First"><span class="Underline">Dose Modifications</span></p><p>Based on recommended dose-levels described in Table 3, Single-Agent Regimens of CAMPTOSAR and Dose Modifications, subsequent doses should be adjusted as suggested in Table 4, Recommended Dose Modifications for Single-Agent Schedules. All dose modifications should be based on the worst preceding toxicity.</p><a name="t4"></a><table width="100%"><caption><span>Table 4:  Recommended Dose Modifications For Single-Agent Schedules<a class="Sup" href="#footnote-10" name="footnote-reference-10">*</a></span></caption><col align="left" valign="top" width="20%"><col align="left" valign="top" width="35%"><col align="left" valign="top" width="20%"><col align="left" valign="top" width="25%"><thead><tr class="Botrule First"><th align="left" colspan="4">A new cycle of therapy should not begin until the granulocyte count has recovered to &ge;1500/mm<span class="Sup">3</span>, and the platelet count has recovered to &ge;100,000/mm<span class="Sup">3</span>, and treatment-related diarrhea is fully resolved.  Treatment should be delayed 1 to 2 weeks to allow for recovery from treatment-related toxicities.  If the patient has not recovered after a 2-week delay, consideration should be given to discontinuing CAMPTOSAR.</th></tr><tr><th align="center" valign="bottom">Worst Toxicity<br>NCI Grade<a class="Sup" href="#footnote-11" name="footnote-reference-11">&dagger;</a> (Value)</th><th class="Botrule Lrule" align="center" valign="middle">During a Cycle of Therapy</th><th class="Botrule Lrule" align="center" colspan="2" valign="middle">At the Start of the Next Cycles of Therapy (After Adequate Recovery), Compared with the Starting Dose in the Previous Cycle<a class="Sup" href="#footnote-10">*</a></th></tr><tr class="Last"><th align="left"></th><th class="Lrule" align="center">Weekly</th><th class="Lrule" align="center">Weekly</th><th class="Lrule" align="center">Once Every 3 Weeks</th></tr></thead><tfoot><tr><td align="left" colspan="4"><dl class="Footnote"><dt><a href="#footnote-reference-10" name="footnote-10">*</a></dt><dd>All dose modifications should be based on the worst preceding toxicity</dd><dt><a href="#footnote-reference-11" name="footnote-11">&dagger;</a></dt><dd>National Cancer Institute Common Toxicity Criteria (version 1.0)</dd><dt><a href="#footnote-reference-12" name="footnote-12">&Dagger;</a></dt><dd>Pretreatment</dd><dt><a href="#footnote-reference-13" name="footnote-13">&sect;</a></dt><dd>Excludes alopecia, anorexia, asthenia</dd></dl></td></tr></tfoot><tbody><tr class="Botrule First"><td align="left">No toxicity</td><td class="Lrule" align="left">Maintain dose level</td><td class="Lrule" align="left">&uarr; 25 mg/m<span class="Sup">2</span> up to a maximum dose of 150 mg/m<span class="Sup">2</span></td><td class="Lrule" align="left">Maintain dose level</td></tr><tr><td align="left"><span class="Bold">Neutropenia</span></td><td class="Lrule" align="left"></td><td class="Lrule" align="left"></td><td class="Lrule" align="left"></td></tr><tr class="Botrule"><td align="left">1  (1500 to 1999/mm<span class="Sup">3</span>)<br>2  (1000 to 1499/mm<span class="Sup">3</span>)<br>3  (500 to 999/mm<span class="Sup">3</span>)<br>4  (&lt;500/mm<span class="Sup">3</span>)</td><td class="Lrule" align="left">Maintain dose level<br>&darr; 25 mg/m<span class="Sup">2</span><br>Omit dose until resolved to &le; grade 2, then &darr; 25 mg/m<span class="Sup">2 </span><br>Omit dose until resolved to &le; grade 2, then &darr; 50 mg/m<span class="Sup">2 </span></td><td class="Lrule" align="left">Maintain dose level<br>Maintain dose level<br>&darr; 25 mg/m<span class="Sup">2</span><br>&darr; 50 mg/m<span class="Sup">2</span></td><td class="Lrule" align="left">Maintain dose level<br>Maintain dose level<br>&darr; 50 mg/m<span class="Sup">2</span><br>&darr; 50 mg/m<span class="Sup">2</span></td></tr><tr class="Botrule"><td align="left"><span class="Bold">Neutropenic fever</span></td><td class="Lrule" align="left">Omit dose until resolved, then &darr; 50 mg/m<span class="Sup">2 </span>when resolved</td><td class="Lrule" align="left">&darr; 50 mg/m<span class="Sup">2</span></td><td class="Lrule" align="left">&darr; 50 mg/m<span class="Sup">2</span></td></tr><tr class="Botrule"><td align="left"><span class="Bold">Other hematologic toxicities</span></td><td class="Lrule" align="left" colspan="3">Dose modifications for leukopenia, thrombocytopenia, and anemia during a cycle of therapy and at the start of subsequent cycles of therapy are also based on NCI toxicity criteria and are the same as recommended for neutropenia above.</td></tr><tr><td align="left"><span class="Bold">Diarrhea</span></td><td class="Lrule" align="left"></td><td class="Lrule" align="left"></td><td class="Lrule" align="left"></td></tr><tr class="Botrule"><td align="left">1  (2&ndash;3 stools/day &gt; pretx<a class="Sup" href="#footnote-12" name="footnote-reference-12">&Dagger;</a>)<br>2  (4&ndash;6 stools/day &gt; pretx)<br>3  (7&ndash;9 stools/day &gt; pretx)<br>4  (&ge;10 stools/day &gt; pretx)</td><td class="Lrule" align="left">Maintain dose level<br>&darr; 25 mg/m<span class="Sup">2</span><br>Omit dose until resolved to &le; grade 2, then &darr; 25 mg/m<span class="Sup">2 </span><br>Omit dose until resolved to &le; grade 2  then &darr; 50 mg/m<span class="Sup">2 </span></td><td class="Lrule" align="left">Maintain dose level<br>Maintain dose level<br>&darr; 25 mg/m<span class="Sup">2</span><br>&darr; 50 mg/m<span class="Sup">2</span></td><td class="Lrule" align="left">Maintain dose level<br>Maintain dose level<br>&darr; 50 mg/m<span class="Sup">2</span><br>&darr; 50 mg/m<span class="Sup">2</span></td></tr><tr class="Last"><td align="left"><span class="Bold">Other nonhematologic<a class="Sup" href="#footnote-13" name="footnote-reference-13">&sect;</a> toxicities</span><br>1<br>2<br>3<br>4</td><td class="Lrule" align="left"><br><br>Maintain dose level<br>&darr; 25 mg/m<span class="Sup">2</span><br>Omit dose until resolved to &le; grade 2, then &darr; 25 mg/m<span class="Sup">2 </span><br>Omit dose until resolved to &le; grade 2, then &darr; 50 mg/m<span class="Sup">2 </span></td><td class="Lrule" align="left"><br><br>Maintain dose level<br>&darr; 25 mg/m<span class="Sup">2</span><br>&darr; 25 mg/m<span class="Sup">2</span><br>&darr; 50 mg/m<span class="Sup">2</span></td><td class="Lrule" align="left"><br><br>Maintain dose level<br>&darr; 50 mg/m<span class="Sup">2</span><br>&darr; 50 mg/m<span class="Sup">2</span><br>&darr; 50 mg/m<span class="Sup">2</span></td></tr></tbody></table></div></div><div class="Section"><a name="nlm42229-5"></a><a name="S2.3"></a><a name="section-2.3"></a><p></p><h2>2.3   Dosage in Patients with Reduced UGT1A1 Activity</h2><p class="First">When administered in combination with other agents, or as a single-agent, a reduction in the starting dose by at least one level of CAMPTOSAR should be considered for patients known to be homozygous for the UGT1A1*28 allele [<span class="Italics">see <a href="#S2.1">Dosage and Administration (2.1</a> and <a href="#s2.2">2.2)</a> and <a href="#S5.3">Warnings and Precautions (5.3)</a></span>].  However, the precise dose reduction in this patient population is not known, and subsequent dose modifications should be considered based on individual patient tolerance to treatment (see Tables 1&ndash;4).</p></div><div class="Section"><a name="nlm42229-5"></a><a name="S2.4"></a><a name="section-2.4"></a><p></p><h2>2.4  Premedication</h2><p class="First">It is recommended that patients receive premedication with antiemetic agents. In clinical studies of the weekly dosage schedule, the majority of patients received 10 mg of dexamethasone given in conjunction with another type of antiemetic agent, such as a 5-HT<span class="Sup">3</span> blocker (e.g., ondansetron or granisetron). Antiemetic agents should be given on the day of treatment, starting at least 30 minutes before administration of CAMPTOSAR. Physicians should also consider providing patients with an antiemetic regimen (e.g., prochlorperazine) for subsequent use as needed. A similar antiemetic regimen should be used with Camptosar in combination therapy.</p><p>Prophylactic or therapeutic administration of atropine should be considered in patients experiencing cholinergic symptoms.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="S2.5"></a><a name="section-2.5"></a><p></p><h2>2.5   Preparation of Infusion Solution</h2><p class="First">Inspect vial contents for particulate matter and discoloration and repeat inspection when drug product is withdrawn from vial into syringe.</p><p>CAMPTOSAR Injection 20 mg/mL is intended for single use only and any unused portion should be discarded.</p><p>CAMPTOSAR Injection must be diluted prior to infusion. CAMPTOSAR should be diluted in 5% Dextrose Injection, USP, (preferred) or 0.9% Sodium Chloride Injection, USP, to a final concentration range of 0.12 mg/mL to 2.8 mg/mL. Other drugs should not be added to the infusion solution.</p><p>The solution is physically and chemically stable for up to 24 hours at room temperature and in ambient fluorescent lighting. Solutions diluted in 5% Dextrose Injection, USP, and stored at refrigerated temperatures (approximately 2&deg; to 8&deg;C, 36&deg; to 46&deg;F), and protected from light are physically and chemically stable for 48 hours. Refrigeration of admixtures using 0.9% Sodium Chloride Injection, USP, is not recommended due to a low and sporadic incidence of visible particulates. Freezing CAMPTOSAR and admixtures of CAMPTOSAR may result in precipitation of the drug and should be avoided.</p><p>The CAMPTOSAR Injection solution should be used immediately after reconstitution as it contains no antibacterial preservative. Because of possible microbial contamination during dilution, it is advisable to use the admixture prepared with 5% Dextrose Injection, USP, within 24 hours if refrigerated (2&deg; to 8&deg;C, 36&deg; to 46&deg;F). In the case of admixtures prepared with 5% Dextrose Injection, USP, or Sodium Chloride Injection, USP, the solutions should be used within 4 hours if kept at room temperature. If reconstitution and dilution are performed under strict aseptic conditions (e.g. on Laminar Air Flow bench), CAMPTOSAR Injection solution should be used (infusion completed) within 12 hours at room temperature or 24 hours if refrigerated (2&deg; to 8&deg;C, 36&deg; to 46&deg;F).</p></div><div class="Section"><a name="nlm42229-5"></a><a name="S2.6"></a><a name="section-2.6"></a><p></p><h2>2.6  Safe Handling</h2><p class="First">Care should be exercised in the handling and preparation of infusion solutions prepared from CAMPTOSAR Injection. The use of gloves is recommended. If a solution of CAMPTOSAR contacts the skin, wash the skin immediately and thoroughly with soap and water. If CAMPTOSAR contacts the mucous membranes, flush thoroughly with water.  Several published guidelines for handling and disposal of anticancer agents are available.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="S2.7"></a><a name="section-2.7"></a><p></p><h2>2.7  Extravasation</h2><p class="First">Care should be taken to avoid extravasation, and the infusion site should be monitored for signs of inflammation. Should extravasation occur, flushing the site with sterile water and applications of ice are recommended.</p></div></div><div class="Section"><a name="nlm43678-2"></a><a name="S3"></a><a name="section-3"></a><p></p><h1>3    DOSAGE FORMS AND STRENGTHS</h1><p class="First">CAMPTOSAR Injection is available in three single-dose sizes:</p><ul><li>2 mL-fill vial containing 40 mg irinotecan hydrochloride</li><li>5 mL-fill vial containing 100 mg irinotecan hydrochloride</li><li>15 mL-fill vial containing 300 mg irinotecan hydrochloride</li></ul></div><div class="Section"><a name="nlm34070-3"></a><a name="S4"></a><a name="section-4"></a><p></p><h1>4	CONTRAINDICATIONS</h1><ul><li>CAMPTOSAR Injection is contraindicated in patients with a known hypersensitivity to the drug or its excipients.</li></ul></div><div class="Section"><a name="nlm43685-7"></a><a name="S5"></a><a name="section-5"></a><p></p><h1>5    WARNINGS AND PRECAUTIONS</h1><div class="Section"><a name="nlm42229-5"></a><a name="S5.1"></a><a name="section-5.1"></a><p></p><h2>5.1  Diarrhea and Cholinergic Reactions</h2><p class="First">Early diarrhea (occurring during or shortly after infusion of CAMPTOSAR) is usually transient and infrequently severe. It may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Bradycardia may also occur. Early diarrhea and other cholinergic symptoms may be prevented or treated. Consider prophylactic or therapeutic administration of 0.25 mg to 1 mg of intravenous or subcutaneous atropine (unless clinically contraindicated).  These symptoms are expected to occur more frequently with higher irinotecan doses.</p><p>Late diarrhea (generally occurring more than 24 hours after administration of CAMPTOSAR) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Grade 3&ndash;4 late diarrhea occurred in 23&ndash;31% of patients receiving weekly dosing. In the clinical studies, the median time to the onset of late diarrhea was 5 days with 3-week dosing and 11 days with weekly dosing. Late diarrhea can be complicated by colitis, ulceration, bleeding, ileus, obstruction, and infection. Cases of megacolon and intestinal perforation have been reported.  Patients should have loperamide readily available to begin treatment for late diarrhea.  Begin loperamide at the first episode of poorly formed or loose stools or the earliest onset of bowel movements more frequent than normal. One dosage regimen for loperamide is 4 mg at the first onset of late diarrhea and then 2 mg every 2 hours until the patient is diarrhea-free for at least 12 hours. Loperamide is not recommended to be used for more than 48 consecutive hours at these doses, because of the risk of paralytic ileus.  During the night, the patient may take 4 mg of loperamide every 4 hours. Monitor and replace fluid and electrolytes.  Use antibiotic support for ileus, fever, or severe neutropenia.  Subsequent weekly chemotherapy treatments should be delayed in patients until return of pretreatment bowel function for at least 24 hours without anti-diarrhea medication. Patients must not be treated with irinotecan until resolution of the bowel obstruction. If grade 2, 3, or 4 late diarrhea recurs, subsequent doses of CAMPTOSAR should be decreased [<span class="Italics">see <a href="#S2">Dosage and Administration (2)</a></span>].</p><p>Avoid diuretics or laxatives in patients with diarrhea.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="S5.2"></a><a name="section-5.2"></a><p></p><h2>5.2   Myelosuppression</h2><p class="First">Deaths due to sepsis following severe neutropenia have been reported in patients treated with CAMPTOSAR. In the clinical studies evaluating the weekly dosage schedule, neutropenic fever (concurrent NCI grade 4 neutropenia and fever of grade 2 or greater) occurred in 3% of the patients; 6% of patients received G-CSF for the treatment of neutropenia. Manage febrile neutropenia promptly with antibiotic support [<span class="Italics">see <a href="#S5.2">Warnings and Precautions (5.2)</a></span>]. Hold CAMPTOSAR if neutropenic fever occurs or if the absolute neutrophil count drops &lt;1000/mm<span class="Sup">3</span>. After recovery to an absolute neutrophil count &ge;1000/mm<span class="Sup">3</span>, subsequent doses of CAMPTOSAR should be reduced [<span class="Italics">see <a href="#S2">Dosage and Administration (2)</a></span>].</p><p>When evaluated in the trials of weekly administration, the frequency of grade 3 and 4 neutropenia was higher in patients who received previous pelvic/abdominal irradiation than in those who had not received such irradiation (48% [13/27] versus 24% [67/277]; p=0.04). Patients who have previously received pelvic/abdominal irradiation are at increased risk of severe myelosuppression following the administration of CAMPTOSAR. Based on sparse available data, the concurrent administration of CAMPTOSAR with irradiation is not recommended. </p><p>Patients with baseline serum total bilirubin levels of 1.0 mg/dL or more also had a greater likelihood of experiencing first-cycle grade 3 or 4 neutropenia than those with bilirubin levels that were less than 1.0 mg/dL (50% [19/38] versus 18% [47/266]; p&lt;0.001). Patients with deficient glucuronidation of bilirubin, such as those with Gilbert's syndrome, may be at greater risk of myelosuppression when receiving therapy with CAMPTOSAR.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="S5.3"></a><a name="section-5.3"></a><p></p><h2>5.3  Patients With Reduced UGT1A1 Activity</h2><p class="First">Individuals who are homozygous for the UGT1A1*28 allele (UGT1A1 7/7 genotype) are at increased risk for neutropenia following initiation of CAMPTOSAR treatment.</p><p>In a study of 66 patients who received single-agent CAMPTOSAR (350 mg/m<span class="Sup">2</span> once-every-3-weeks), the incidence of grade 4 neutropenia in patients homozygous for the UGT1A1*28 allele was 50%, and in patients heterozygous for this allele (UGT1A1 6/7 genotype) the incidence was 12.5%.  No grade 4 neutropenia was observed in patients homozygous for the wild-type allele (UGT1A1 6/6 genotype).</p><p>In a prospective study (n=250) to investigate the role of UGT1A1*28 polymorphism in the development of toxicity in patients treated with CAMPTOSAR (180 mg/m<span class="Sup">2</span>) in combination with infusional 5-FU/LV, the incidence of grade 4 neutropenia in patients homozygous for the UGT1A1*28 allele was 4.5%, and in patients heterozygous for this allele the incidence was 5.3%.  Grade 4 neutropenia was observed in 1.8% of patients homozygous for the wild-type allele.</p><p>In another study in which 109 patients were treated with CAMPTOSAR (100&ndash;125 mg/m<span class="Sup">2</span>) in combination with bolus 5-FU/LV, the incidence of grade 4 neutropenia in patients homozygous for the UGT1A1*28 allele was 18.2%, and in patients heterozygous for this allele the incidence was 11.1%.  Grade 4 neutropenia was observed in 6.8% of patients homozygous for the wild-type allele.</p><p>When administered in combination with other agents or as a single-agent, a reduction in the starting dose by at least one level of CAMPTOSAR should be considered for patients known to be homozygous for the UGT1A1*28 allele. However, the precise dose reduction in this patient population is not known and subsequent dose modifications should be considered based on individual patient tolerance to treatment [<span class="Italics">see <a href="#S2">Dosage and Administration (2)</a></span>].</p><div class="Section"><a name="nlm42229-5"></a><a name="section-5.3.1"></a><p></p><p class="First"><span class="Underline">UGT1A1 Testing</span></p><p>A laboratory test is available to determine the UGT1A1 status of patients.  Testing can detect the UGT1A1 6/6, 6/7 and 7/7 genotypes.</p></div></div><div class="Section"><a name="nlm42229-5"></a><a name="S5.4"></a><a name="section-5.4"></a><p></p><h2>5.4   Hypersensitivity</h2><p class="First">Hypersensitivity reactions including severe anaphylactic or anaphylactoid reactions have been observed.  Discontinue CAMPTOSAR if anaphylactic reaction occurs.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="S5.5"></a><a name="section-5.5"></a><p></p><h2>5.5   Renal Impairment/Renal Failure</h2><p class="First">Renal impairment and acute renal failure have been identified, usually in patients who became volume depleted from severe vomiting and/or diarrhea.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="S5.6"></a><a name="section-5.6"></a><p></p><h2>5.6   Pulmonary Toxicity</h2><p class="First">Interstitial Pulmonary Disease (IPD)-like events, including fatalities, have occurred in patients receiving irinotecan (in combination and as monotherapy). Risk factors include pre-existing lung disease, use of pneumotoxic drugs, radiation therapy, and colony stimulating factors.  Patients with risk factors should be closely monitored for respiratory symptoms before and during irinotecan therapy. In Japanese studies, a reticulonodular pattern on chest x-ray was observed in a small percentage of patients. New or progressive, dyspnea, cough, and fever should prompt interruption of chemotherapy, pending diagnostic evaluation. If IPD is diagnosed, irinotecan and other chemotherapy should be discontinued and appropriate treatment instituted as needed [<span class="Italics">see <a href="#S6.1">Adverse Reactions (6.1)</a></span>].</p></div><div class="Section"><a name="nlm42229-5"></a><a name="S5.7"></a><a name="section-5.7"></a><p></p><h2>5.7  Toxicity of the 5 Day Regimen</h2><p class="First">Outside of a well-designed clinical study, CAMPTOSAR Injection should not be used in combination with a regimen of 5-FU/LV administered for 4&ndash;5 consecutive days every 4 weeks because of reports of increased toxicity, including toxic deaths. CAMPTOSAR should be used as recommended in Table 2 [<span class="Italics">see <a href="#S2">Dosage and Administration (2)</a></span>].</p></div><div class="Section"><a name="nlm42229-5"></a><a name="S5.8"></a><a name="section-5.8"></a><p></p><h2>5.8  Increased Toxicity in Patients with Performance Status 2</h2><p class="First">In patients receiving either irinotecan/5-FU/LV or 5-FU/LV in the clinical trials, higher rates of hospitalization, neutropenic fever, thromboembolism, first-cycle treatment discontinuation, and early deaths were observed in patients with a baseline performance status of 2 than in patients with a baseline performance status of 0 or 1.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="S5.9"></a><a name="section-5.9"></a><p></p><h2>5.9   Pregnancy</h2><p class="First">CAMPTOSAR can cause fetal harm when administered to a pregnant woman. Irinotecan was embryotoxic in rats and rabbits at doses significantly lower than those administered to humans on a mg/m<span class="Sup">2</span> basis.  In rats, at exposures approximately 0.2 times those achieved in humans at the 125 mg/m<span class="Sup">2</span> dose, irinotecan was embryotoxic and resulted in decreased learning ability and female fetal body weight in surviving pups; the drug was teratogenic at lower exposures (approximately 0.025 times the AUC in humans at the 125 mg/m<span class="Sup">2</span> dose). There are no adequate and well-controlled studies of irinotecan in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with CAMPTOSAR.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="S5.10"></a><a name="section-5.10"></a><p></p><h2>5.10  Patients with Hepatic Impairment</h2><p class="First">The use of CAMPTOSAR in patients with significant hepatic impairment has not been established. In clinical trials of either dosing schedule, irinotecan was not administered to patients with serum bilirubin &gt;2.0 mg/dL, or transaminase &gt;3 times the upper limit of normal if no liver metastasis, or transaminase &gt;5 times the upper limit of normal with liver metastasis. In clinical trials of the weekly dosage schedule, patients with modestly elevated baseline serum total bilirubin levels (1.0 to 2.0 mg/dL) had a significantly greater likelihood of experiencing first-cycle, grade 3 or 4 neutropenia than those with bilirubin levels that were less than 1.0 mg/dL (50% [19/38] versus 18% [47/226]; p&lt;0.001) [<span class="Italics">see <a href="#S2.1">Dosage and Administration (2.1)</a>, <a href="#S8.7">Use in Specific Populations (8.7)</a></span><span class="Italics"> and <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p></div></div><div class="Section"><a name="nlm34084-4"></a><a name="S6"></a><a name="section-6"></a><p></p><h1>6	ADVERSE REACTIONS</h1><div class="Section"><a name="nlm42229-5"></a><a name="S6.1"></a><a name="section-6.1"></a><p></p><h2>6.1   Clinical Studies Experience</h2><p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p><p>Common adverse reactions (&ge;30%) observed in combination therapy clinical studies are: nausea, vomiting, abdominal pain, diarrhea, constipation, anorexia, mucositis, neutropenia, leukopenia (including lymphocytopenia), anemia, thrombocytopenia, asthenia, pain, fever, infection, abnormal bilirubin, and alopecia.</p><p>Common adverse reactions (&ge;30%) observed in single agent therapy clinical studies are: nausea, vomiting, abdominal pain, diarrhea, constipation, anorexia, neutropenia, leukopenia (including lymphocytopenia), anemia, asthenia, fever, body weight decreasing, and alopecia.</p><p>Serious opportunistic infections have not been observed, and no complications have specifically been attributed to lymphocytopenia.</p><div class="Section"><a name="nlm42229-5"></a><a name="section-6.1.1"></a><p></p><p class="First"><span class="Underline">First-Line Combination Therapy</span></p><p>A total of 955 patients with metastatic colorectal cancer received the recommended regimens of irinotecan in combination with 5-FU/LV, 5-FU/LV alone, or irinotecan alone. In the two phase 3 studies, 370 patients received irinotecan in combination with 5-FU/LV, 362 patients received 5-FU/LV alone, and 223 patients received irinotecan alone [<span class="Italics">see <a href="#S2">Dosage and Administration (2)</a></span>].</p><p>In Study 1, 49 (7.3%) patients died within 30 days of last study treatment: 21 (9.3%) received irinotecan in combination with 5-FU/LV, 15 (6.8%) received 5-FU/LV alone, and 13 (5.8%) received irinotecan alone. Deaths potentially related to treatment occurred in 2 (0.9%) patients who received irinotecan in combination with 5-FU/LV (2 neutropenic fever/sepsis), 3 (1.4%) patients who received 5-FU/LV alone (1 neutropenic fever/sepsis, 1 CNS bleeding during thrombocytopenia, 1 unknown) and 2 (0.9%) patients who received irinotecan alone (2 neutropenic fever). Deaths from any cause within 60 days of first study treatment were reported for 15 (6.7%) patients who received irinotecan in combination with 5-FU/LV, 16 (7.3%) patients who received 5-FU/LV alone, and 15 (6.7%) patients who received irinotecan alone. Discontinuations due to adverse events were reported for 17 (7.6%) patients who received irinotecan in combination with 5FU/LV, 14 (6.4%) patients who received 5-FU/LV alone, and 26 (11.7%) patients who received irinotecan alone.</p><p>In Study 2, 10 (3.5%) patients died within 30 days of last study treatment: 6 (4.1%) received irinotecan in combination with 5-FU/LV and 4 (2.8%) received 5-FU/LV alone. There was one potentially treatment-related death, which occurred in a patient who received irinotecan in combination with 5-FU/LV (0.7%, neutropenic sepsis). Deaths from any cause within 60 days of first study treatment were reported for 3 (2.1%) patients who received irinotecan in combination with 5-FU/LV and 2 (1.4%) patients who received 5-FU/LV alone. Discontinuations due to adverse events were reported for 9 (6.2%) patients who received irinotecan in combination with 5FU/LV and 1 (0.7%) patient who received 5-FU/LV alone.</p><p>The most clinically significant adverse events for patients receiving irinotecan-based therapy were diarrhea, nausea, vomiting, neutropenia, and alopecia. The most clinically significant adverse events for patients receiving 5-FU/LV therapy were diarrhea, neutropenia, neutropenic fever, and mucositis. In Study 1, grade 4 neutropenia, neutropenic fever (defined as grade 2 fever and grade 4 neutropenia), and mucositis were observed less often with weekly irinotecan/5-FU/LV than with monthly administration of 5-FU/LV.</p><p>Tables 5 and 6 list the clinically relevant adverse events reported in Studies 1 and 2, respectively.</p><a name="t5"></a><table width="100%"><caption><span>Table 5.  Study 1:  Percent (%) of Patients Experiencing Clinically Relevant Adverse Events in Combination Therapies<a class="Sup" href="#footnote-14" name="footnote-reference-14">*</a></span></caption><col align="left" valign="top" width="30%"><col align="center" valign="top" width="12%"><col align="center" valign="top" width="11%"><col align="center" valign="top" width="12%"><col align="center" valign="top" width="12%"><col align="center" valign="top" width="12%"><col align="center" valign="top" width="11%"><thead><tr class="First"><th align="left" rowspan="3" valign="middle">Adverse Event</th><th class="Botrule Lrule" align="center" colspan="6">Study 1</th></tr><tr valign="bottom"><th class="Lrule" align="center" colspan="2">Irinotecan + Bolus 5-FU/LV weekly &times; 4 every 6 weeks<br>N=225</th><th class="Lrule" align="center" colspan="2">Bolus 5-FU/LV daily &times; 5 every 4 weeks<br>N=219</th><th class="Lrule" align="center" colspan="2">Irinotecan weekly &times; 4 every 6 weeks<br>N=223</th></tr><tr class="Last"><th class="Lrule Toprule" align="center">Grade 1&ndash;4</th><th class="Lrule Toprule" align="center">Grade 3&amp;4</th><th class="Lrule Toprule" align="center">Grade 1&ndash;4</th><th class="Lrule Toprule" align="center">Grade 3&amp;4</th><th class="Lrule Toprule" align="center">Grade 1&ndash;4</th><th class="Lrule Toprule" align="center">Grade 3&amp;4</th></tr></thead><tfoot><tr><td align="left" colspan="7"><dl class="Footnote"><dt><a href="#footnote-reference-14" name="footnote-14">*</a></dt><dd>Severity of adverse events based on NCI CTC (version 1.0)</dd><dt><a href="#footnote-reference-15" name="footnote-15">&dagger;</a></dt><dd>Complete hair loss = Grade 2</dd><dt><a href="#footnote-reference-16" name="footnote-16">&Dagger;</a></dt><dd>Includes angina pectoris, arterial thrombosis, cerebral infarct, cerebrovascular accident, deep thrombophlebitis, embolus lower extremity, heart arrest, myocardial infarct, myocardial ischemia, peripheral vascular disorder, pulmonary embolus, sudden death, thrombophlebitis, thrombosis, vascular disorder.</dd></dl></td></tr></tfoot><tbody><tr class="Botrule First"><td align="left">TOTAL Adverse Events</td><td class="Lrule Toprule" align="center">100</td><td class="Lrule Toprule" align="center">53.3</td><td class="Lrule Toprule" align="center">100</td><td class="Lrule Toprule" align="center">45.7</td><td class="Lrule Toprule" align="center">99.6</td><td class="Lrule Toprule" align="center">45.7</td></tr><tr><td align="left"><span class="Bold">GASTROINTESTINAL</span></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;Diarrhea</td><td class="Lrule" align="center">84.9</td><td class="Lrule" align="center">22.7</td><td class="Lrule" align="center">69.4</td><td class="Lrule" align="center">13.2</td><td class="Lrule" align="center">83.0</td><td class="Lrule" align="center">31.0</td></tr><tr><td align="left">&nbsp;&nbsp;&nbsp;&nbsp;late</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">15.1</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">5.9</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">18.4</td></tr><tr><td align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;grade 3</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">7.6</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">7.3</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">12.6</td></tr><tr><td align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;grade 4<br>&nbsp;&nbsp;&nbsp;&nbsp;early</td><td class="Lrule" align="center">45.8</td><td class="Lrule" align="center">4.9</td><td class="Lrule" align="center">31.5</td><td class="Lrule" align="center">1.4</td><td class="Lrule" align="center">43.0</td><td class="Lrule" align="center">6.7</td></tr><tr><td align="left">&nbsp;&nbsp;Nausea</td><td class="Lrule" align="center">79.1</td><td class="Lrule" align="center">15.6</td><td class="Lrule" align="center">67.6</td><td class="Lrule" align="center">8.2</td><td class="Lrule" align="center">81.6</td><td class="Lrule" align="center">16.1</td></tr><tr><td align="left">&nbsp;&nbsp;Abdominal pain</td><td class="Lrule" align="center">63.1</td><td class="Lrule" align="center">14.6</td><td class="Lrule" align="center">50.2</td><td class="Lrule" align="center">11.5</td><td class="Lrule" align="center">67.7</td><td class="Lrule" align="center">13.0</td></tr><tr><td align="left">&nbsp;&nbsp;Vomiting</td><td class="Lrule" align="center">60.4</td><td class="Lrule" align="center">9.7</td><td class="Lrule" align="center">46.1</td><td class="Lrule" align="center">4.1</td><td class="Lrule" align="center">62.8</td><td class="Lrule" align="center">12.1</td></tr><tr><td align="left">&nbsp;&nbsp;Anorexia</td><td class="Lrule" align="center">34.2</td><td class="Lrule" align="center">5.8</td><td class="Lrule" align="center">42.0</td><td class="Lrule" align="center">3.7</td><td class="Lrule" align="center">43.9</td><td class="Lrule" align="center">7.2</td></tr><tr><td align="left">&nbsp;&nbsp;Constipation</td><td class="Lrule" align="center">41.3</td><td class="Lrule" align="center">3.1</td><td class="Lrule" align="center">31.5</td><td class="Lrule" align="center">1.8</td><td class="Lrule" align="center">32.3</td><td class="Lrule" align="center">0.4</td></tr><tr><td align="left">&nbsp;&nbsp;Mucositis</td><td class="Lrule" align="center">32.4</td><td class="Lrule" align="center">2.2</td><td class="Lrule" align="center">76.3</td><td class="Lrule" align="center">16.9</td><td class="Lrule" align="center">29.6</td><td class="Lrule" align="center">2.2</td></tr><tr><td class="Toprule" align="left"><span class="Bold">HEMATOLOGIC</span></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;Neutropenia</td><td class="Lrule" align="center">96.9</td><td class="Lrule" align="center">53.8</td><td class="Lrule" align="center">98.6</td><td class="Lrule" align="center">66.7</td><td class="Lrule" align="center">96.4</td><td class="Lrule" align="center">31.4</td></tr><tr><td align="left">&nbsp;&nbsp;&nbsp;&nbsp;grade 3</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">29.8</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">23.7</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">19.3</td></tr><tr><td align="left">&nbsp;&nbsp;&nbsp;&nbsp;grade 4</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">24.0</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">42.5</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">12.1</td></tr><tr><td align="left">&nbsp;&nbsp;Leukopenia</td><td class="Lrule" align="center">96.9</td><td class="Lrule" align="center">37.8</td><td class="Lrule" align="center">98.6</td><td class="Lrule" align="center">23.3</td><td class="Lrule" align="center">96.4</td><td class="Lrule" align="center">21.5</td></tr><tr><td align="left">&nbsp;&nbsp;Anemia</td><td class="Lrule" align="center">96.9</td><td class="Lrule" align="center">8.4</td><td class="Lrule" align="center">98.6</td><td class="Lrule" align="center">5.5</td><td class="Lrule" align="center">96.9</td><td class="Lrule" align="center">4.5</td></tr><tr><td align="left">&nbsp;&nbsp;Neutropenic fever</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">7.1</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">14.6</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">5.8</td></tr><tr><td align="left">&nbsp;&nbsp;Thrombocytopenia</td><td class="Lrule" align="center">96.0</td><td class="Lrule" align="center">2.6</td><td class="Lrule" align="center">98.6</td><td class="Lrule" align="center">2.7</td><td class="Lrule" align="center">96.0</td><td class="Lrule" align="center">1.7</td></tr><tr><td align="left">&nbsp;&nbsp;Neutropenic infection</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">1.8</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">2.2</td></tr><tr><td class="Toprule" align="left"><span class="Bold">BODY AS A WHOLE</span></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;Asthenia</td><td class="Lrule" align="center">70.2</td><td class="Lrule" align="center">19.5</td><td class="Lrule" align="center">64.4</td><td class="Lrule" align="center">11.9</td><td class="Lrule" align="center">69.1</td><td class="Lrule" align="center">13.9</td></tr><tr><td align="left">&nbsp;&nbsp;Pain</td><td class="Lrule" align="center">30.7</td><td class="Lrule" align="center">3.1</td><td class="Lrule" align="center">26.9</td><td class="Lrule" align="center">3.6</td><td class="Lrule" align="center">22.9</td><td class="Lrule" align="center">2.2</td></tr><tr><td align="left">&nbsp;&nbsp;Fever</td><td class="Lrule" align="center">42.2</td><td class="Lrule" align="center">1.7</td><td class="Lrule" align="center">32.4</td><td class="Lrule" align="center">3.6</td><td class="Lrule" align="center">43.5</td><td class="Lrule" align="center">0.4</td></tr><tr><td align="left">&nbsp;&nbsp;Infection</td><td class="Lrule" align="center">22.2</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">16.0</td><td class="Lrule" align="center">1.4</td><td class="Lrule" align="center">13.9</td><td class="Lrule" align="center">0.4</td></tr><tr><td class="Toprule" align="left"><span class="Bold">METABOLIC &amp; NUTRITIONAL</span></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td></tr><tr class="Botrule"><td align="left">&nbsp;&nbsp;Bilirubin</td><td class="Lrule" align="center">87.6</td><td class="Lrule" align="center">7.1</td><td class="Lrule" align="center">92.2</td><td class="Lrule" align="center">8.2</td><td class="Lrule" align="center">83.9</td><td class="Lrule" align="center">7.2</td></tr><tr><td align="left"><span class="Bold">DERMATOLOGIC</span></td><td class="Lrule" align="center">0.9</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">3.2</td><td class="Lrule" align="center">0.5</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">0</td></tr><tr><td align="left">&nbsp;&nbsp;Exfoliative dermatitis</td><td class="Lrule" align="center">19.1</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">26.5</td><td class="Lrule" align="center">0.9</td><td class="Lrule" align="center">14.3</td><td class="Lrule" align="center">0.4</td></tr><tr class="Botrule"><td align="left">&nbsp;&nbsp;Rash<br>   &nbsp;&nbsp;Alopecia<a class="Sup" href="#footnote-15" name="footnote-reference-15">&dagger;</a></td><td class="Lrule" align="center">43.1</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">26.5</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">46.1</td><td class="Lrule" align="center">--</td></tr><tr><td align="left"><span class="Bold">RESPIRATORY</span></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;Dyspnea</td><td class="Lrule" align="center">27.6</td><td class="Lrule" align="center">6.3</td><td class="Lrule" align="center">16.0</td><td class="Lrule" align="center">0.5</td><td class="Lrule" align="center">22.0</td><td class="Lrule" align="center">2.2</td></tr><tr><td align="left">&nbsp;&nbsp;Cough</td><td class="Lrule" align="center">26.7</td><td class="Lrule" align="center">1.3</td><td class="Lrule" align="center">18.3</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">20.2</td><td class="Lrule" align="center">0.4</td></tr><tr class="Botrule"><td align="left">&nbsp;&nbsp;Pneumonia</td><td class="Lrule" align="center">6.2</td><td class="Lrule" align="center">2.7</td><td class="Lrule" align="center">1.4</td><td class="Lrule" align="center">1.0</td><td class="Lrule" align="center">3.6</td><td class="Lrule" align="center">1.3</td></tr><tr><td align="left"><span class="Bold">NEUROLOGIC</span></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;Dizziness</td><td class="Lrule" align="center">23.1</td><td class="Lrule" align="center">1.3</td><td class="Lrule" align="center">16.4</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">21.1</td><td class="Lrule" align="center">1.8</td></tr><tr><td align="left">&nbsp;&nbsp;Somnolence</td><td class="Lrule" align="center">12.4</td><td class="Lrule" align="center">1.8</td><td class="Lrule" align="center">4.6</td><td class="Lrule" align="center">1.8</td><td class="Lrule" align="center">9.4</td><td class="Lrule" align="center">1.3</td></tr><tr class="Botrule"><td align="left">&nbsp;&nbsp;Confusion</td><td class="Lrule" align="center">7.1</td><td class="Lrule" align="center">1.8</td><td class="Lrule" align="center">4.1</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">2.7</td><td class="Lrule" align="center">0</td></tr><tr><td align="left"><span class="Bold">CARDIOVASCULAR</span></td><td class="Lrule Toprule" align="center">9.3</td><td class="Lrule Toprule" align="center">0.9</td><td class="Lrule Toprule" align="center">5.0</td><td class="Lrule Toprule" align="center">0</td><td class="Lrule Toprule" align="center">9.0</td><td class="Lrule Toprule" align="center">0</td></tr><tr><td align="left">&nbsp;&nbsp;Vasodilatation</td><td class="Lrule" align="center">5.8</td><td class="Lrule" align="center">1.3</td><td class="Lrule" align="center">2.3</td><td class="Lrule" align="center">0.5</td><td class="Lrule" align="center">5.8</td><td class="Lrule" align="center">1.7</td></tr><tr class="Last"><td align="left">&nbsp;&nbsp;Hypotension<br>   &nbsp;&nbsp;Thromboembolic events<a class="Sup" href="#footnote-16" name="footnote-reference-16">&Dagger;</a></td><td class="Lrule" align="center">9.3</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">11.4</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">5.4</td><td class="Lrule" align="center">--</td></tr></tbody></table><table width="90%"><caption><span>Table 6.  Study 2:  Percent (%) of Patients Experiencing Clinically Relevant Adverse Events in Combination Therapies<a class="Sup" href="#footnote-17" name="footnote-reference-17">*</a></span></caption><col align="left" valign="top" width="40%"><col align="center" valign="top" width="15%"><col align="center" valign="top" width="15%"><col align="center" valign="top" width="15%"><col align="center" valign="top" width="15%"><thead><tr class="First"><th align="left" rowspan="2" valign="bottom">Adverse Event</th><th class="Lrule" align="center" colspan="4" valign="bottom">Study 2</th></tr><tr valign="bottom"><th class="Botrule Lrule Toprule" align="center" colspan="2">Irinotecan + 5-FU/LV infusional days 1&amp;2 every 2 weeks<br>N= 145</th><th class="Botrule Lrule Toprule" align="center" colspan="2">5-FU/LV infusional days 1&amp;2 every 2 weeks<br>N=143</th></tr><tr class="Last"><th align="left"></th><th class="Lrule" align="center">Grades 1&ndash;4</th><th class="Lrule" align="center">Grades 3&amp;4</th><th class="Lrule" align="center">Grades 1&ndash;4</th><th class="Lrule" align="center">Grades 3&amp;4</th></tr></thead><tfoot><tr><td align="left" colspan="5"><dl class="Footnote"><dt><a href="#footnote-reference-17" name="footnote-17">*</a></dt><dd>Severity of adverse events based on NCI CTC (version 1.0)</dd><dt><a href="#footnote-reference-18" name="footnote-18">&dagger;</a></dt><dd>Includes rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, abdominal cramping or diarrhea (occurring during or shortly after infusion of irinotecan)</dd><dt><a href="#footnote-reference-19" name="footnote-19">&Dagger;</a></dt><dd>Complete hair loss = Grade 2</dd><dt><a href="#footnote-reference-20" name="footnote-20">&sect;</a></dt><dd>Includes angina pectoris, arterial thrombosis, cerebral infarct, cerebrovascular accident, deep thrombophlebitis, embolus lower extremity, heart arrest, myocardial infarct, myocardial ischemia, peripheral vascular disorder, pulmonary embolus, sudden death, thrombophlebitis, thrombosis, vascular disorder.</dd></dl></td></tr></tfoot><tbody><tr class="Botrule First"><td align="left">TOTAL Adverse Events</td><td class="Lrule" align="center">100</td><td class="Lrule" align="center">72.4</td><td class="Lrule" align="center">100</td><td class="Lrule" align="center">39.2</td></tr><tr><td align="left"><span class="Bold">GASTROINTESTINAL</span></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;Diarrhea</td><td class="Lrule" align="center">72.4</td><td class="Lrule" align="center">14.4</td><td class="Lrule" align="center">44.8</td><td class="Lrule" align="center">6.3</td></tr><tr><td align="left">&nbsp;&nbsp;&nbsp;&nbsp;late</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">10.3</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">4.2</td></tr><tr><td align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;grade 3</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">4.1</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">2.1</td></tr><tr><td align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;grade 4<br>&nbsp;&nbsp;Cholinergic syndrome<a class="Sup" href="#footnote-18" name="footnote-reference-18">&dagger;</a></td><td class="Lrule" align="center">28.3</td><td class="Lrule" align="center">1.4</td><td class="Lrule" align="center">0.7</td><td class="Lrule" align="center">0</td></tr><tr><td align="left">&nbsp;&nbsp;Nausea</td><td class="Lrule" align="center">66.9</td><td class="Lrule" align="center">2.1</td><td class="Lrule" align="center">55.2</td><td class="Lrule" align="center">3.5</td></tr><tr><td align="left">&nbsp;&nbsp;Abdominal pain</td><td class="Lrule" align="center">17.2</td><td class="Lrule" align="center">2.1</td><td class="Lrule" align="center">16.8</td><td class="Lrule" align="center">0.7</td></tr><tr><td align="left">&nbsp;&nbsp;Vomiting</td><td class="Lrule" align="center">44.8</td><td class="Lrule" align="center">3.5</td><td class="Lrule" align="center">32.2</td><td class="Lrule" align="center">2.8</td></tr><tr><td align="left">&nbsp;&nbsp;Anorexia</td><td class="Lrule" align="center">35.2</td><td class="Lrule" align="center">2.1</td><td class="Lrule" align="center">18.9</td><td class="Lrule" align="center">0.7</td></tr><tr><td align="left">&nbsp;&nbsp;Constipation</td><td class="Lrule" align="center">30.3</td><td class="Lrule" align="center">0.7</td><td class="Lrule" align="center">25.2</td><td class="Lrule" align="center">1.4</td></tr><tr><td align="left">&nbsp;&nbsp;Mucositis</td><td class="Lrule" align="center">40.0</td><td class="Lrule" align="center">4.1</td><td class="Lrule" align="center">28.7</td><td class="Lrule" align="center">2.8</td></tr><tr><td class="Toprule" align="left"><span class="Bold">HEMATOLOGIC</span></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;Neutropenia</td><td class="Lrule" align="center">82.5</td><td class="Lrule" align="center">46.2</td><td class="Lrule" align="center">47.9</td><td class="Lrule" align="center">13.4</td></tr><tr><td align="left">&nbsp;&nbsp;&nbsp;&nbsp;grade 3</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">36.4</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">12.7</td></tr><tr><td align="left">&nbsp;&nbsp;&nbsp;&nbsp;grade 4</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">9.8</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">0.7</td></tr><tr><td align="left">&nbsp;&nbsp;Leukopenia</td><td class="Lrule" align="center">81.3</td><td class="Lrule" align="center">17.4</td><td class="Lrule" align="center">42.0</td><td class="Lrule" align="center">3.5</td></tr><tr><td align="left">&nbsp;&nbsp;Anemia</td><td class="Lrule" align="center">97.2</td><td class="Lrule" align="center">2.1</td><td class="Lrule" align="center">90.9</td><td class="Lrule" align="center">2.1</td></tr><tr><td align="left">&nbsp;&nbsp;Neutropenic fever</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">3.4</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">0.7</td></tr><tr><td align="left">&nbsp;&nbsp;Thrombocytopenia</td><td class="Lrule" align="center">32.6</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">32.2</td><td class="Lrule" align="center">0</td></tr><tr><td align="left">&nbsp;&nbsp;Neutropenic infection</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">2.1</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">0</td></tr><tr><td class="Toprule" align="left"><span class="Bold">BODY AS A WHOLE</span></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;Asthenia</td><td class="Lrule" align="center">57.9</td><td class="Lrule" align="center">9.0</td><td class="Lrule" align="center">48.3</td><td class="Lrule" align="center">4.2</td></tr><tr><td align="left">&nbsp;&nbsp;Pain</td><td class="Lrule" align="center">64.1</td><td class="Lrule" align="center">9.7</td><td class="Lrule" align="center">61.5</td><td class="Lrule" align="center">8.4</td></tr><tr><td align="left">&nbsp;&nbsp;Fever</td><td class="Lrule" align="center">22.1</td><td class="Lrule" align="center">0.7</td><td class="Lrule" align="center">25.9</td><td class="Lrule" align="center">0.7</td></tr><tr class="Botrule"><td align="left">&nbsp;&nbsp;Infection</td><td class="Lrule" align="center">35.9</td><td class="Lrule" align="center">7.6</td><td class="Lrule" align="center">33.6</td><td class="Lrule" align="center">3.5</td></tr><tr><td align="left"><span class="Bold">METABOLIC AND NUTRITIONAL</span></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td></tr><tr class="Botrule"><td align="left">&nbsp;&nbsp;Bilirubin</td><td class="Lrule" align="center">19.1</td><td class="Lrule" align="center">3.5</td><td class="Lrule" align="center">35.9</td><td class="Lrule" align="center">10.6</td></tr><tr><td align="left"><span class="Bold">DERMATOLOGIC</span></td><td class="Lrule" align="center">10.3</td><td class="Lrule" align="center">0.7</td><td class="Lrule" align="center">12.6</td><td class="Lrule" align="center">0.7</td></tr><tr><td align="left">&nbsp;&nbsp;Hand and foot syndrome</td><td class="Lrule" align="center">17.2</td><td class="Lrule" align="center">0.7</td><td class="Lrule" align="center">20.3</td><td class="Lrule" align="center">0</td></tr><tr class="Botrule"><td align="left">&nbsp;&nbsp;Cutaneous signs<br>   &nbsp;&nbsp;Alopecia<a class="Sup" href="#footnote-19" name="footnote-reference-19">&Dagger;</a></td><td class="Lrule" align="center">56.6</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">16.8</td><td class="Lrule" align="center">--</td></tr><tr><td align="left"><span class="Bold">RESPIRATORY</span></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td></tr><tr class="Botrule"><td align="left">&nbsp;&nbsp;Dyspnea</td><td class="Lrule" align="center">9.7</td><td class="Lrule" align="center">1.4</td><td class="Lrule" align="center">4.9</td><td class="Lrule" align="center">0</td></tr><tr><td align="left"><span class="Bold">CARDIOVASCULAR</span></td><td class="Lrule" align="center">3.4</td><td class="Lrule" align="center">1.4</td><td class="Lrule" align="center">0.7</td><td class="Lrule" align="center">0</td></tr><tr class="Last"><td align="left">&nbsp;&nbsp;Hypotension<br>   &nbsp;&nbsp;Thromboembolic events<a class="Sup" href="#footnote-20" name="footnote-reference-20">&sect;</a></td><td class="Lrule" align="center">11.7</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">5.6</td><td class="Lrule" align="center">--</td></tr></tbody></table></div><div class="Section"><a name="nlm42229-5"></a><a name="section-6.1.2"></a><p></p><p class="First"><span class="Underline">Second-Line Single-Agent Therapy </span></p></div><div class="Section"><a name="nlm42229-5"></a><a name="section-6.1.3"></a><p></p><p class="First"><span class="Bold Italics">Weekly Dosage Schedule</span></p><p>In three clinical studies evaluating the weekly dosage schedule, 304 patients with metastatic carcinoma of the colon or rectum that had recurred or progressed following 5-FU-based therapy were treated with CAMPTOSAR. Seventeen of the patients died within 30 days of the administration of CAMPTOSAR; in five cases (1.6%, 5/304), the deaths were potentially drug-related. One of the patients died of neutropenic sepsis without fever. Neutropenic fever occurred in nine (3.0%) other patients; these patients recovered with supportive care.</p><p>One hundred nineteen (39.1%) of the 304 patients were hospitalized because of adverse events; 81 (26.6%) patients were hospitalized for events judged to be related to administration of CAMPTOSAR. The primary reasons for drug-related hospitalization were diarrhea, with or without nausea and/or vomiting (18.4%); neutropenia/leukopenia, with or without diarrhea and/or fever (8.2%); and nausea and/or vomiting (4.9%).</p><p>The first dose of at least one cycle of CAMPTOSAR was reduced for 67% of patients who began the studies at the 125-mg/m<span class="Sup">2</span> starting dose. Within-cycle dose reductions were required for 32% of the cycles initiated at the 125-mg/m<span class="Sup">2</span> dose level. The most common reasons for dose reduction were late diarrhea, neutropenia, and leukopenia. Thirteen (4.3%) patients discontinued treatment with CAMPTOSAR because of adverse events. The adverse events in Table 7 are based on the experience of the 304 patients enrolled in the three studies described in <span class="Italics">CLINICAL STUDIES</span> (<span class="Italics">14.1</span>).</p><table width="80%"><caption><span>Table 7. Adverse Events Occurring in &gt;10% of 304  Previously Treated Patients with Metastatic Carcinoma of the Colon or Rectum<a class="Sup" href="#footnote-21" name="footnote-reference-21">*</a></span></caption><col align="left" valign="top" width="40%"><col align="center" valign="top" width="30%"><col align="center" valign="top" width="30%"><thead><tr class="First"><th align="left"></th><th class="Lrule" align="center" colspan="2">% of  Patients Reporting</th></tr><tr class="Last"><th align="left">Body System &amp; Event</th><th class="Lrule Toprule" align="center">NCI Grades 1&ndash;4</th><th class="Lrule Toprule" align="center">NCI Grades 3 &amp; 4</th></tr></thead><tfoot><tr><td align="left" colspan="3"><dl class="Footnote"><dt><a href="#footnote-reference-21" name="footnote-21">*</a></dt><dd>Severity of adverse events based on NCI CTC (version 1.0)</dd><dt><a href="#footnote-reference-22" name="footnote-22">&dagger;</a></dt><dd>Occurring &gt; 24 hours after administration of CAMPTOSAR</dd><dt><a href="#footnote-reference-23" name="footnote-23">&Dagger;</a></dt><dd>Occurring &le;24 hours after administration of CAMPTOSAR</dd><dt><a href="#footnote-reference-24" name="footnote-24">&sect;</a></dt><dd>Primarily upper respiratory infections</dd><dt><a href="#footnote-reference-25" name="footnote-25">&para;</a></dt><dd>Not applicable; complete hair loss = NCI grade 2</dd></dl></td></tr></tfoot><tbody><tr class="First"><td align="left"><span class="Bold">GASTROINTESTINAL</span></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;Diarrhea (late)<a class="Sup" href="#footnote-22" name="footnote-reference-22">&dagger;</a></td><td class="Lrule" align="center">88</td><td class="Lrule" align="center">31</td></tr><tr><td align="left">&nbsp;&nbsp;&nbsp;&nbsp;7&ndash;9 stools/day (grade 3)</td><td class="Lrule" align="center">&mdash;</td><td class="Lrule" align="center">(16)</td></tr><tr><td align="left">&nbsp;&nbsp;&nbsp;&nbsp;&ge;10 stools/day (grade 4)</td><td class="Lrule" align="center">&mdash;</td><td class="Lrule" align="center">(14)</td></tr><tr><td align="left">&nbsp;&nbsp;Nausea</td><td class="Lrule" align="center">86</td><td class="Lrule" align="center">17</td></tr><tr><td align="left">&nbsp;&nbsp;Vomiting</td><td class="Lrule" align="center">67</td><td class="Lrule" align="center">12</td></tr><tr><td align="left">&nbsp;&nbsp;Anorexia</td><td class="Lrule" align="center">55</td><td class="Lrule" align="center">6</td></tr><tr><td align="left">&nbsp;&nbsp;Diarrhea (early)<a class="Sup" href="#footnote-23" name="footnote-reference-23">&Dagger;</a></td><td class="Lrule" align="center">51</td><td class="Lrule" align="center">8</td></tr><tr><td align="left">&nbsp;&nbsp;Constipation</td><td class="Lrule" align="center">30</td><td class="Lrule" align="center">2</td></tr><tr><td align="left">&nbsp;&nbsp;Flatulence</td><td class="Lrule" align="center">12</td><td class="Lrule" align="center">0</td></tr><tr><td align="left">&nbsp;&nbsp;Stomatitis</td><td class="Lrule" align="center">12</td><td class="Lrule" align="center">1</td></tr><tr><td align="left">&nbsp;&nbsp;Dyspepsia</td><td class="Lrule" align="center">10</td><td class="Lrule" align="center">0</td></tr><tr><td class="Toprule" align="left"><span class="Bold">HEMATOLOGIC</span></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;Leukopenia</td><td class="Lrule" align="center">63</td><td class="Lrule" align="center">28</td></tr><tr><td align="left">&nbsp;&nbsp;Anemia</td><td class="Lrule" align="center">60</td><td class="Lrule" align="center">7</td></tr><tr><td align="left">&nbsp;&nbsp;Neutropenia</td><td class="Lrule" align="center">54</td><td class="Lrule" align="center">26</td></tr><tr><td align="left">&nbsp;&nbsp;&nbsp;&nbsp;500 to &lt;1000/mm<span class="Sup">3</span> (grade 3)</td><td class="Lrule" align="center">&mdash;</td><td class="Lrule" align="center">(15)</td></tr><tr><td align="left">&nbsp;&nbsp;&nbsp;&nbsp;&lt;500/mm<span class="Sup">3</span> (grade 4)</td><td class="Lrule" align="center">&mdash;</td><td class="Lrule" align="center">(12)</td></tr><tr><td class="Toprule" align="left"><span class="Bold">BODY AS A WHOLE</span></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;Asthenia</td><td class="Lrule" align="center">76</td><td class="Lrule" align="center">12</td></tr><tr><td align="left">&nbsp;&nbsp;Abdominal cramping/pain</td><td class="Lrule" align="center">57</td><td class="Lrule" align="center">16</td></tr><tr><td align="left">&nbsp;&nbsp;Fever</td><td class="Lrule" align="center">45</td><td class="Lrule" align="center">1</td></tr><tr><td align="left">&nbsp;&nbsp;Pain</td><td class="Lrule" align="center">24</td><td class="Lrule" align="center">2</td></tr><tr><td align="left">&nbsp;&nbsp;Headache</td><td class="Lrule" align="center">17</td><td class="Lrule" align="center">1</td></tr><tr><td align="left">&nbsp;&nbsp;Back pain</td><td class="Lrule" align="center">14</td><td class="Lrule" align="center">2</td></tr><tr><td align="left">&nbsp;&nbsp;Chills</td><td class="Lrule" align="center">14</td><td class="Lrule" align="center">0</td></tr><tr><td align="left">&nbsp;&nbsp;Minor infection<a class="Sup" href="#footnote-24" name="footnote-reference-24">&sect;</a></td><td class="Lrule" align="center">14</td><td class="Lrule" align="center">0</td></tr><tr><td align="left">&nbsp;&nbsp;Edema</td><td class="Lrule" align="center">10</td><td class="Lrule" align="center">1</td></tr><tr><td align="left">&nbsp;&nbsp;Abdominal enlargement</td><td class="Lrule" align="center">10</td><td class="Lrule" align="center">0</td></tr><tr><td class="Toprule" align="left"><span class="Bold">METABOLIC AND NUTRITIONAL</span></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;&darr; Body weight</td><td class="Lrule" align="center">30</td><td class="Lrule" align="center">1</td></tr><tr><td align="left">&nbsp;&nbsp;Dehydration</td><td class="Lrule" align="center">15</td><td class="Lrule" align="center">4</td></tr><tr><td align="left">&nbsp;&nbsp;&uarr; Alkaline phosphatase</td><td class="Lrule" align="center">13</td><td class="Lrule" align="center">4</td></tr><tr><td align="left">&nbsp;&nbsp;&uarr; SGOT</td><td class="Lrule" align="center">10</td><td class="Lrule" align="center">1</td></tr><tr><td class="Toprule" align="left"><span class="Bold">DERMATOLOGIC</span></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;Alopecia</td><td class="Lrule" align="center">60</td><td class="Lrule" align="center">NA<a class="Sup" href="#footnote-25" name="footnote-reference-25">&para;</a></td></tr><tr><td align="left">&nbsp;&nbsp;Sweating</td><td class="Lrule" align="center">16</td><td class="Lrule" align="center">0</td></tr><tr><td align="left">&nbsp;&nbsp;Rash</td><td class="Lrule" align="center">13</td><td class="Lrule" align="center">1</td></tr><tr><td class="Toprule" align="left"><span class="Bold">RESPIRATORY</span></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;Dyspnea</td><td class="Lrule" align="center">22</td><td class="Lrule" align="center">4</td></tr><tr><td align="left">&nbsp;&nbsp;&uarr; Coughing</td><td class="Lrule" align="center">17</td><td class="Lrule" align="center">0</td></tr><tr><td align="left">&nbsp;&nbsp;Rhinitis</td><td class="Lrule" align="center">16</td><td class="Lrule" align="center">0</td></tr><tr><td class="Toprule" align="left"><span class="Bold">NEUROLOGIC</span></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;Insomnia</td><td class="Lrule" align="center">19</td><td class="Lrule" align="center">0</td></tr><tr><td align="left">&nbsp;&nbsp;Dizziness</td><td class="Lrule" align="center">15</td><td class="Lrule" align="center">0</td></tr><tr><td class="Toprule" align="left"><span class="Bold">CARDIOVASCULAR</span></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td></tr><tr class="Last"><td align="left">&nbsp;&nbsp;Vasodilation (flushing)</td><td class="Lrule" align="center">11</td><td class="Lrule" align="center">0</td></tr></tbody></table></div><div class="Section"><a name="nlm42229-5"></a><a name="section-6.1.4"></a><p></p><p class="First"><span class="Bold Italics">Once-Every-3-Week Dosage Schedule</span></p><p>A total of 535 patients with metastatic colorectal cancer whose disease had recurred or progressed following prior 5-FU therapy participated in the two phase 3 studies: 316 received irinotecan, 129 received 5-FU, and 90 received best supportive care. Eleven (3.5%) patients treated with irinotecan died within 30 days of treatment. In three cases (1%, 3/316), the deaths were potentially related to irinotecan treatment and were attributed to neutropenic infection, grade 4 diarrhea, and asthenia, respectively. One (0.8%, 1/129) patient treated with 5-FU died within 30 days of treatment; this death was attributed to grade 4 diarrhea.</p><p>Hospitalizations due to serious adverse events occurred at least once in 60% (188/316) of patients who received irinotecan, 63% (57/90) who received best supportive care, and 39% (50/129) who received 5-FU-based therapy. Eight percent of patients treated with irinotecan and 7% treated with 5-FU-based therapy discontinued treatment due to adverse events.</p><p>Of the 316 patients treated with irinotecan, the most clinically significant adverse events (all grades, 1&ndash;4) were diarrhea (84%), alopecia (72%), nausea (70%), vomiting (62%), cholinergic symptoms (47%), and neutropenia (30%). Table 8 lists the grade 3 and 4 adverse events reported in the patients enrolled to all treatment arms of the two studies described in <span class="Italics"><a href="#S14.1">CLINICAL STUDIES (14.1)</a></span>.</p><table width="90%"><caption><span>Table 8:  Percent Of Patients Experiencing Grade 3 &amp; 4 Adverse Events In Comparative Studies Of Once-Every-3-Week Irinotecan Therapy<a class="Sup" href="#footnote-26" name="footnote-reference-26">*</a></span></caption><col align="left" valign="top" width="28%"><col align="center" valign="top" width="18%"><col align="center" valign="top" width="18%"><col align="center" valign="top" width="18%"><col align="center" valign="top" width="18%"><thead><tr class="First"><th align="left"></th><th class="Lrule" align="center" colspan="2">Study 1</th><th class="Lrule" align="center" colspan="2">Study 2</th></tr><tr class="Last" valign="bottom"><th align="left">Adverse Event</th><th class="Lrule Toprule" align="center">Irinotecan<br>N=189</th><th class="Lrule Toprule" align="center">BSC <a class="Sup" href="#footnote-27" name="footnote-reference-27">&dagger;</a><br>N=90</th><th class="Lrule Toprule" align="center">Irinotecan<br>N=127</th><th class="Lrule Toprule" align="center">5-FU<br>N=129</th></tr></thead><tfoot><tr><td align="left" colspan="5"><dl class="Footnote"><dt><a href="#footnote-reference-26" name="footnote-26">*</a></dt><dd>Severity of adverse events based on NCI CTC (version 1.0)</dd><dt><a href="#footnote-reference-27" name="footnote-27">&dagger;</a></dt><dd>BSC = best supportive care</dd><dt><a href="#footnote-reference-28" name="footnote-28">&Dagger;</a></dt><dd>Hepatic includes events such as ascites and jaundice</dd><dt><a href="#footnote-reference-29" name="footnote-29">&sect;</a></dt><dd>Cutaneous signs include events such as rash</dd><dt><a href="#footnote-reference-30" name="footnote-30">&para;</a></dt><dd>Respiratory includes events such as dyspnea and cough</dd><dt><a href="#footnote-reference-31" name="footnote-31">#</a></dt><dd>Neurologic includes events such as somnolence</dd><dt><a href="#footnote-reference-32" name="footnote-32">&THORN;</a></dt><dd>Cardiovascular includes events such as dysrhythmias, ischemia, and mechanical cardiac dysfunction</dd><dt><a href="#footnote-reference-33" name="footnote-33">&szlig;</a></dt><dd>Other includes events such as accidental injury, hepatomegaly, syncope, vertigo, and weight loss</dd></dl></td></tr></tfoot><tbody><tr class="First" valign="bottom"><td class="Toprule" align="left">TOTAL Grade 3/4<br>Adverse Events</td><td class="Lrule Toprule" align="center">79</td><td class="Lrule Toprule" align="center">67</td><td class="Lrule Toprule" align="center">69</td><td class="Lrule Toprule" align="center">54</td></tr><tr><td class="Toprule" align="left"><span class="Bold">GASTROINTESTINAL</span></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;Diarrhea</td><td class="Lrule" align="center">22</td><td class="Lrule" align="center">6</td><td class="Lrule" align="center">22</td><td class="Lrule" align="center">11</td></tr><tr><td align="left">&nbsp;&nbsp;Vomiting</td><td class="Lrule" align="center">14</td><td class="Lrule" align="center">8</td><td class="Lrule" align="center">14</td><td class="Lrule" align="center">5</td></tr><tr><td align="left">&nbsp;&nbsp;Nausea</td><td class="Lrule" align="center">14</td><td class="Lrule" align="center">3</td><td class="Lrule" align="center">11</td><td class="Lrule" align="center">4</td></tr><tr><td align="left">&nbsp;&nbsp;Abdominal pain</td><td class="Lrule" align="center">14</td><td class="Lrule" align="center">16</td><td class="Lrule" align="center">9</td><td class="Lrule" align="center">8</td></tr><tr><td align="left">&nbsp;&nbsp;Constipation</td><td class="Lrule" align="center">10</td><td class="Lrule" align="center">8</td><td class="Lrule" align="center">8</td><td class="Lrule" align="center">6</td></tr><tr><td align="left">&nbsp;&nbsp;Anorexia</td><td class="Lrule" align="center">5</td><td class="Lrule" align="center">7</td><td class="Lrule" align="center">6</td><td class="Lrule" align="center">4</td></tr><tr><td align="left">&nbsp;&nbsp;Mucositis</td><td class="Lrule" align="center">2</td><td class="Lrule" align="center">1</td><td class="Lrule" align="center">2</td><td class="Lrule" align="center">5</td></tr><tr><td class="Toprule" align="left"><span class="Bold">HEMATOLOGIC</span></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;Leukopenia/Neutropenia</td><td class="Lrule" align="center">22</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">14</td><td class="Lrule" align="center">2</td></tr><tr><td align="left">&nbsp;&nbsp;Anemia</td><td class="Lrule" align="center">7</td><td class="Lrule" align="center">6</td><td class="Lrule" align="center">6</td><td class="Lrule" align="center">3</td></tr><tr><td align="left">&nbsp;&nbsp;Hemorrhage</td><td class="Lrule" align="center">5</td><td class="Lrule" align="center">3</td><td class="Lrule" align="center">1</td><td class="Lrule" align="center">3</td></tr><tr><td align="left">&nbsp;&nbsp;Thrombocytopenia</td><td class="Lrule" align="center">1</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">4</td><td class="Lrule" align="center">2</td></tr><tr><td align="left"><span class="Bold">Infection</span></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;without grade 3/4 neutropenia</td><td class="Lrule" align="center">8</td><td class="Lrule" align="center">3</td><td class="Lrule" align="center">1</td><td class="Lrule" align="center">4</td></tr><tr><td align="left">&nbsp;&nbsp;with grade 3/4 neutropenia</td><td class="Lrule" align="center">1</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">2</td><td class="Lrule" align="center">0</td></tr><tr><td align="left"><span class="Bold">Fever </span></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;without grade 3/4 neutropenia</td><td class="Lrule" align="center">2</td><td class="Lrule" align="center">1</td><td class="Lrule" align="center">2</td><td class="Lrule" align="center">0</td></tr><tr><td align="left">&nbsp;&nbsp;with grade 3/4 neutropenia</td><td class="Lrule" align="center">2</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">4</td><td class="Lrule" align="center">2</td></tr><tr><td class="Rrule Toprule" align="left"><span class="Bold">BODY AS A WHOLE</span></td><td class="Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;Pain</td><td class="Lrule" align="center">19</td><td class="Lrule" align="center">22</td><td class="Lrule" align="center">17</td><td class="Lrule" align="center">13</td></tr><tr><td align="left">&nbsp;&nbsp;Asthenia</td><td class="Botrule Lrule" align="center">15</td><td class="Botrule Lrule" align="center">19</td><td class="Botrule Lrule" align="center">13</td><td class="Botrule Lrule" align="center">12</td></tr><tr><td class="Toprule" align="left"><span class="Bold">METABOLIC AND NUTRITIONAL</span></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td></tr><tr><td align="left">Hepatic <a class="Sup" href="#footnote-28" name="footnote-reference-28">&Dagger;</a></td><td class="Lrule" align="center">9</td><td class="Lrule" align="center">7</td><td class="Lrule" align="center">9</td><td class="Lrule" align="center">6</td></tr><tr><td class="Rrule Toprule" align="left"><span class="Bold">DERMATOLOGIC</span></td><td class="Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;Hand and foot syndrome</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">5</td></tr><tr><td align="left">&nbsp;&nbsp;Cutaneous signs <a class="Sup" href="#footnote-29" name="footnote-reference-29">&sect;</a></td><td class="Lrule" align="center">2</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">1</td><td class="Lrule" align="center">3</td></tr><tr><td class="Rrule Toprule" align="left"><span class="Bold">RESPIRATORY</span><a class="Sup" href="#footnote-30" name="footnote-reference-30">&para;</a></td><td class="Toprule" align="center">10</td><td class="Lrule Toprule" align="center">8</td><td class="Lrule Toprule" align="center">5</td><td class="Lrule Toprule" align="center">7</td></tr><tr><td class="Rrule Toprule" align="left"><span class="Bold">NEUROLOGIC</span><a class="Sup" href="#footnote-31" name="footnote-reference-31">#</a></td><td class="Toprule" align="center">12</td><td class="Lrule Toprule" align="center">13</td><td class="Lrule Toprule" align="center">9</td><td class="Lrule Toprule" align="center">4</td></tr><tr><td class="Toprule" align="left"><span class="Bold">CARDIOVASCULAR</span><a class="Sup" href="#footnote-32" name="footnote-reference-32">&THORN;</a></td><td class="Lrule Toprule" align="center">9</td><td class="Lrule Toprule" align="center">3</td><td class="Lrule Toprule" align="center">4</td><td class="Lrule Toprule" align="center">2</td></tr><tr class="Last"><td class="Toprule" align="left"><span class="Bold">OTHER</span><a class="Sup" href="#footnote-33" name="footnote-reference-33">&szlig;</a></td><td class="Lrule Toprule" align="center">32</td><td class="Lrule Toprule" align="center">28</td><td class="Lrule Toprule" align="center">12</td><td class="Lrule Toprule" align="center">14</td></tr></tbody></table><p>The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients). The 8.5% incidence of akathisia, however, is within the range reported for use of prochlorperazine when given as a premedication for other chemotherapies.</p></div></div><div class="Section"><a name="nlm42229-5"></a><a name="S6.2"></a><a name="section-6.2"></a><p></p><h2>6.2   Postmarketing Experience</h2><p class="First">The following adverse reactions have been identified during post approval use of CAMPTOSAR.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p>Myocardial ischemic events have been observed following irinotecan therapy. Thromboembolic events have been observed in patients receiving CAMPTOSAR.</p><p>Symptomatic pancreatitis, asymptomatic pancreatic enzyme elevation have been reported. Increases in serum levels of transaminases (i.e., AST and ALT) in the absence of progressive liver metastasis have been observed.</p><p>Hyponatremia, mostly with diarrhea and vomiting, has been reported. </p><p>Transient dysarthria has been reported in patients treated with CAMPTOSAR; in some cases, the event was attributed to the cholinergic syndrome observed during or shortly after infusion of irinotecan. </p><p>Interaction between irinotecan and neuromuscular blocking agents cannot be ruled out. Irinotecan has anticholinesterase activity, which may prolong the neuromuscular blocking effects of suxamethonium and the neuromuscular blockade of non-depolarizing drugs may be antagonized.</p></div></div><div class="Section"><a name="nlm34073-7"></a><a name="S7"></a><a name="section-7"></a><p></p><h1>7 DRUG INTERACTIONS</h1><div class="Section"><a name="nlm42229-5"></a><a name="S7.1"></a><a name="section-7.1"></a><p></p><h2>7.1   5-Fluorouracil (5-FU) and Leucovorin (LV)</h2><p class="First">In a phase 1 clinical study involving irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) in 26 patients with solid tumors, the disposition of irinotecan was not substantially altered when the drugs were co-administered. Although the C<span class="Sub">max </span>and AUC<span class="Sub">0&ndash;24 </span>of SN-38, the active metabolite, were reduced (by 14% and 8%, respectively) when irinotecan was followed by 5-FU and LV administration compared with when irinotecan was given alone, this sequence of administration was used in the combination trials and is recommended [<span class="Italics">see <a href="#S2">Dosage and Administration (2)</a></span>]. Formal <span class="Italics">in vivo</span> or <span class="Italics">in vitro</span> drug interaction studies to evaluate the influence of irinotecan on the disposition of 5-FU and LV have not been conducted.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="S7.2"></a><a name="section-7.2"></a><p></p><h2>7.2   Strong CYP 3A4 Inducers</h2><div class="Section"><a name="nlm42229-5"></a><a name="section-7.2.1"></a><p></p><p class="First"><span class="Underline">Anticonvulsants and other strong inducers</span><span class="Underline">:</span> Exposure to irinotecan and its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital or carbamazepine. The appropriate starting dose for patients taking these anticonvulsants or other strong inducers such as rifampin and rifabutin has not been defined. Consideration should be given to substituting non-enzyme inducing therapies at least 2 weeks prior to initiation of irinotecan therapy.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="section-7.2.2"></a><p></p><p class="First"><span class="Underline">St. John's</span><span class="Underline"> wort</span><span class="Underline">:</span>  Exposure to the active metabolite SN-38 is reduced in patients receiving concomitant St. John's wort. St. John's wort should be discontinued at least 2 weeks prior to the first cycle of irinotecan, and St. John's wort is contraindicated during irinotecan therapy.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="section-7.2.3"></a><p></p><p class="First"><span class="Underline">Dexamethasone</span>, a moderate CYP3A4 inducer, does not appear to alter the pharmacokinetics of irinotecan.</p></div></div><div class="Section"><a name="nlm42229-5"></a><a name="S7.3"></a><a name="section-7.3"></a><p></p><h2>7.3  Strong CYP 3A4 Inhibitors</h2><p class="First">Ketoconazole is a strong inhibitor of CYP3A4 enzymes. Patients receiving concomitant ketoconazole have increased exposure to irinotecan and its active metabolite SN-38. Patients should discontinue ketoconazole at least 1 week prior to starting irinotecan therapy and ketoconazole is contraindicated during irinotecan therapy.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="S7.4"></a><a name="section-7.4"></a><p></p><h2>7.4   Atazanavir Sulfate</h2><p class="First">Coadministration of atazanavir sulfate, a CYP3A4 and UGT1A1 inhibitor has the potential to increase systemic exposure to SN-38, the active metabolite of irinotecan.  Physicians should take this into consideration when co-administering these drugs.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="S7.5"></a><a name="section-7.5"></a><p></p><h2>7.5   Drug-Laboratory Test Interactions</h2><p class="First">There are no known interactions between CAMPTOSAR and laboratory tests.</p></div></div><div class="Section"><a name="nlm43684-0"></a><a name="S8"></a><a name="section-8"></a><p></p><h1>8 USE IN SPECIFIC POPULATIONS</h1><div class="Section"><a name="nlm42228-7"></a><a name="S8.1"></a><a name="section-8.1"></a><p></p><h2>8.1 Pregnancy</h2><div class="Section"><a name="nlm42229-5"></a><a name="section-8.1.1"></a><p></p><p class="First">Pregnancy Category D [<span class="Italics">see <a href="#S5.9">Warnings and Precautions (5.9)</a></span>]</p><p>CAMPTOSAR can cause fetal harm when administered to a pregnant woman. Radioactivity related to <span class="Sup">14</span>C-irinotecan crosses the placenta of rats following intravenous administration of 10 mg/kg (which in separate studies produced an irinotecan C<span class="Sub">max </span>and AUC about 3 and 0.5 times, respectively, the corresponding values in patients administered 125 mg/m<span class="Sup">2</span>). Intravenous administration of irinotecan 6 mg/kg/day to rats and rabbits during the period of organogenesis resulted in increased post-implantation loss and decreased numbers of live fetuses. In separate studies in rats, this dose produced an irinotecan C<span class="Sub">max </span>and AUC of about 2 and 0.2 times, respectively, the corresponding values in patients administered 125 mg/m<span class="Sup">2</span>.  In rabbits, the embryotoxic dose was about one-half the recommended human weekly starting dose on a mg/m<span class="Sup">2</span> basis. Irinotecan was teratogenic in rats at doses greater than 1.2 mg/kg/day and in rabbits at 6.0 mg/kg/day. In separate studies in rats, this dose produced an irinotecan C<span class="Sub">max </span>and AUC about 2/3 and 1/40th, respectively, of the corresponding values in patients administered 125 mg/m<span class="Sup">2</span>.  In rabbits, the teratogenic dose was about one-half the recommended human weekly starting dose on a mg/m<span class="Sup">2</span> basis. Teratogenic effects included a variety of external, visceral, and skeletal abnormalities. Irinotecan administered to rat dams for the period following organogenesis through weaning at doses of 6 mg/kg/day caused decreased learning ability and decreased female body weights in the offspring. There are no adequate and well-controlled studies of irinotecan in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with CAMPTOSAR.</p></div></div><div class="Section"><a name="nlm34080-2"></a><a name="S8.3"></a><a name="section-8.2"></a><p></p><h2>8.3 Nursing Mothers</h2><p class="First">Radioactivity appeared in rat milk within 5 minutes of intravenous administration of radiolabeled irinotecan and was concentrated up to 65-fold at 4 hours after administration relative to plasma concentrations.  It is not known whether this drug is excreted in human milk.  Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from CAMPTOSAR, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. </p></div><div class="Section"><a name="nlm34081-0"></a><a name="S8.4"></a><a name="section-8.3"></a><p></p><h2>8.4   Pediatric Use</h2><p class="First">The effectiveness of irinotecan in pediatric patients has not been established.  Results from two open-label, single arm studies were evaluated.  One hundred and seventy children with refractory solid tumors were enrolled in one phase 2 trial in which 50 mg/ m<span class="Sup">2 </span>of irinotecan was infused for 5 consecutive days every 3 weeks.  Grade 3&ndash;4 neutropenia was experienced by 54 (31.8%) patients.  Neutropenia was complicated by fever in 15 (8.8%) patients.  Grade 3&ndash;4 diarrhea was observed in 35 (20.6%) patients.  This adverse event profile was comparable to that observed in adults.  In the second phase 2 trial of 21 children with previously untreated rhabdomyosarcoma, 20 mg/m<span class="Sup">2 </span>of irinotecan was infused for 5 consecutive days on weeks 0, 1, 3 and 4.  This single agent therapy was followed by multimodal therapy.  Accrual to the single agent irinotecan phase was halted due to the high rate (28.6%) of progressive disease and the early deaths (14%).  The adverse event profile was different in this study from that observed in adults; the most significant grade 3 or 4 adverse events were dehydration experienced by 6 patients (28.6%) associated with severe hypokalemia in 5 patients (23.8%) and hyponatremia in 3 patients (14.3%); in addition Grade 3&ndash;4 infection was reported in 5 patients (23.8%) (across all courses of therapy and irrespective of causal relationship).</p><p>Pharmacokinetic parameters for irinotecan and SN-38 were determined in 2 pediatric solid-tumor trials at dose levels of 50 mg/m<span class="Sup">2 </span>(60-min infusion, n=48) and 125 mg/m<span class="Sup">2 </span>(90-min infusion, n=6).  Irinotecan clearance (mean &plusmn; S.D.) was 17.3 &plusmn; 6.7 L/h/m<span class="Sup">2</span> for the 50mg/m<span class="Sup">2</span> dose and 16.2 &plusmn; 4.6 L/h/m<span class="Sup">2 </span>for the 125 mg/m<span class="Sup">2 </span>dose, which is comparable to that in adults.  Dose-normalized SN-38 AUC values were comparable between adults and children.  Minimal accumulation of irinotecan and SN-38 was observed in children on daily dosing regimens [daily &times; 5 every 3 weeks or (daily &times; 5) &times; 2 weeks every 3 weeks].</p></div><div class="Section"><a name="nlm34082-8"></a><a name="S8.5"></a><a name="section-8.4"></a><p></p><h2>8.5 Geriatric Use</h2><p class="First">Patients greater than 65 years of age should be closely monitored because of a greater risk of early and late diarrhea in this population [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span> and <span class="Italics"><a href="#S6.1">Adverse Reactions (6.1)</a>]</span>. The starting dose of CAMPTOSAR in patients 70 years and older for the once-every-3-week-dosage schedule should be 300 mg/m<span class="Sup">2</span> [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a> and <a href="#S2">Dosage and Administration (2)</a></span>].</p><p>The frequency of grade 3 and 4 late diarrhea by age was significantly greater in patients &ge;65 years than in patients &lt;65 years (40% [53/133] versus 23% [40/171]; p=0.002). In another study of 183 patients treated on the weekly schedule, the frequency of grade 3 or 4 late diarrhea in patients &ge;65 years of age was 28.6% [26/91]  and  in patients &lt;65 years of age was 23.9% [22/92].</p></div><div class="Section"><a name="nlm42229-5"></a><a name="S8.6"></a><a name="section-8.5"></a><p></p><h2>8.6    Renal Impairment</h2><p class="First">The influence of renal impairment on the pharmacokinetics of irinotecan has not been evaluated. Therefore, use caution in patients with impaired renal function.  Irinotecan is not recommended for use in patients on dialysis.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="S8.7"></a><a name="section-8.6"></a><p></p><h2>8.7    Hepatic Impairment</h2><p class="First">Irinotecan clearance is diminished in patients with hepatic impairment while exposure to the active metabolite SN-38 is increased relative to that in patients with normal hepatic function. The magnitude of these effects is proportional to the degree of liver impairment as measured by elevations in total bilirubin and transaminase concentrations. Therefore, use caution in patients with hepatic impairment. The tolerability of irinotecan in patients with hepatic dysfunction (bilirubin greater than 2 mg/dl) has not been assessed sufficiently, and no recommendations for dosing can be made [<span class="Italics">see </span><span class="Italics"><a href="#S2.1">Dosage and Administration (2.1)</a>, <a href="#S5.10">Warnings and Precautions (5.10)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p></div></div><div class="Section"><a name="nlm34088-5"></a><a name="S10"></a><a name="section-9"></a><p></p><h1>10 OVERDOSAGE</h1><p class="First">In U.S. phase 1 trials, single doses of up to 345 mg/m<span class="Sup">2</span> of irinotecan were administered to patients with various cancers. Single doses of up to 750 mg/m<span class="Sup">2</span> of irinotecan have been given in non-U.S. trials. The adverse events in these patients were similar to those reported with the recommended dosage and regimen. There have been reports of overdosage at doses up to approximately twice the recommended therapeutic dose, which may be fatal.  The most significant adverse reactions reported were severe neutropenia and severe diarrhea. There is no known antidote for overdosage of CAMPTOSAR. Maximum supportive care should be instituted to prevent dehydration due to diarrhea and to treat any infectious complications.</p></div><div class="Section"><a name="nlm34089-3"></a><a name="S11"></a><a name="section-10"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">CAMPTOSAR Injection (irinotecan hydrochloride injection) is an antineoplastic agent of the topoisomerase I inhibitor class.</p><p>CAMPTOSAR is supplied as a sterile, pale yellow, clear, aqueous solution.   Each milliliter of solution contains 20 mg of irinotecan hydrochloride (on the basis of the trihydrate salt), 45 mg of sorbitol, NF, and 0.9 mg of lactic acid, USP. The pH of the solution has been adjusted to 3.5 (range, 3.0 to 3.8) with sodium hydroxide or hydrochloric acid. CAMPTOSAR is intended for dilution with 5% Dextrose Injection, USP (D5W), or 0.9% Sodium Chloride Injection, USP, prior to intravenous infusion. The preferred diluent is 5% Dextrose Injection, USP.</p><p>Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extract from plants such as <span class="Italics">Camptotheca acuminata </span>or is chemically synthesized<span class="Italics">.</span></p><p>The chemical name is <span class="Italics">(<span class="Bold">S</span>)</span>-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo1<span class="Bold Italics">H</span>-pyrano[3',4':6,7]-indolizino[1,2-b]quinolin-9-yl-[1,4'bipiperidine]-1'-carboxylate, monohydrochloride, trihydrate. Its empirical formula is C<span class="Sub">33</span>H<span class="Sub">38</span>N<span class="Sub">4</span>O<span class="Sub">6</span>&bull;HCl&bull;3H<span class="Sub">2</span>O and molecular weight is 677.19. It is slightly soluble in water and organic solvents.  Its structural formula is as follows:</p><div class="Figure"><img src="image.cfm?id=95945&type=img&name=camptosar%2D01.jpg" alt="Chemical Structure"></div></div><div class="Section"><a name="nlm34090-1"></a><a name="S12"></a><a name="section-11"></a><p></p><h1>12 CLINICAL PHARMACOLOGY</h1><div class="Section"><a name="nlm43679-0"></a><a name="S12.1"></a><a name="section-11.1"></a><p></p><h2>12.1  Mechanism of Action</h2><p class="First">Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I, which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.</p></div><div class="Section"><a name="nlm43681-6"></a><a name="S12.2"></a><a name="section-11.2"></a><p></p><h2>12.2  Pharmacodynamics</h2><p class="First">Irinotecan serves as a water-soluble precursor of the lipophilic metabolite SN-38. SN-38 is formed from irinotecan by carboxylesterase-mediated cleavage of the carbamate bond between the camptothecin moiety and the dipiperidino side chain. SN-38 is approximately 1000 times as potent as irinotecan as an inhibitor of topoisomerase I purified from human and rodent tumor cell lines. <span class="Italics">In vitro </span>cytotoxicity assays show that the potency of SN-38 relative to irinotecan varies from 2- to 2000-fold; however, the plasma area under the concentration versus time curve (AUC) values for SN-38 are 2% to 8% of irinotecan and SN-38 is 95% bound to plasma proteins compared to approximately 50% bound to plasma proteins for irinotecan [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>]. The precise contribution of SN-38 to the activity of CAMPTOSAR is thus unknown. Both irinotecan and SN-38 exist in an active lactone form and an inactive hydroxy acid anion form. A pH-dependent equilibrium exists between the two forms such that an acid pH promotes the formation of the lactone, while a more basic pH favors the hydroxy acid anion form.</p><p>Administration of irinotecan has resulted in antitumor activity in mice bearing cancers of rodent origin and in human carcinoma xenografts of various histological types.</p></div><div class="Section"><a name="nlm43682-4"></a><a name="S12.3"></a><a name="section-11.3"></a><p></p><h2>12.3  Pharmacokinetics</h2><p class="First">After intravenous infusion of irinotecan in humans, irinotecan plasma concentrations decline in a multiexponential manner, with a mean terminal elimination half-life of about 6 to 12 hours. The mean terminal elimination half-life of the active metabolite SN-38 is about 10 to 20 hours. The half-lives of the lactone (active) forms of irinotecan and SN-38 are similar to those of total irinotecan and SN-38, as the lactone and hydroxy acid forms are in equilibrium.</p><p>Over the recommended dose range of 50 to 350 mg/m<span class="Sup">2</span>, the AUC of irinotecan increases linearly with dose; the AUC of SN-38 increases less than proportionally with dose. Maximum concentrations of the active metabolite SN-38 are generally seen within 1 hour following the end of a 90-minute infusion of irinotecan. Pharmacokinetic parameters for irinotecan and SN-38 following a 90-minute infusion of irinotecan at dose levels of 125 and 340 mg/m<span class="Sup">2</span> determined in two clinical studies in patients with solid tumors are summarized in Table 9:</p><table width="100%"><caption><span>Table 9. Summary of Mean (&plusmn;Standard Deviation) Irinotecan and SN-38 Pharmacokinetic Parameters in Patients with Solid Tumors</span></caption><col align="center" valign="middle" width="11%"><col align="center" valign="middle" width="11%"><col align="center" valign="middle" width="12%"><col align="center" valign="middle" width="10%"><col align="center" valign="middle" width="10%"><col align="center" valign="middle" width="12%"><col align="center" valign="middle" width="11%"><col align="center" valign="middle" width="12%"><col align="center" valign="middle" width="11%"><thead><tr class="Botrule First"><th class="Rrule" align="center" rowspan="2">Dose<br>(mg/m<span class="Sup">2</span>)</th><th class="Rrule" align="center" colspan="5">Irinotecan</th><th align="center" colspan="3">SN-38</th></tr><tr class="Last"><th class="Rrule" align="center">C<span class="Sub">max</span><br>(ng/mL)</th><th class="Rrule" align="center">AUC<span class="Sub">0&ndash;24</span><br>(ng∙h/mL)</th><th class="Rrule" align="center">t<span class="Sub">1/2</span><br>(h)</th><th class="Rrule" align="center">V<span class="Sub">z</span><br>(L/m<span class="Sup">2</span>)</th><th class="Rrule" align="center">CL<br>(L/h/m<span class="Sup">2</span>)</th><th class="Rrule" align="center">C<span class="Sub">max</span><br>(ng/mL)</th><th class="Rrule" align="center">AUC<span class="Sub">0&ndash;24</span><br>(ng∙h/mL)</th><th align="center">t<span class="Sub">1/2</span><br>(h)</th></tr></thead><tfoot><tr class="First"><td align="left" colspan="9">C<span class="Sub">max </span>- Maximum plasma concentration</td></tr><tr><td align="left" colspan="9">AUC<span class="Sub">0&ndash;24 </span>- Area under the plasma concentration-time curve from time</td></tr><tr><td align="left" colspan="9">0 to 24 hours after the end of the 90-minute infusion</td></tr><tr><td align="left" colspan="9">t<span class="Sub">1/2 </span>- Terminal elimination half-life</td></tr><tr><td align="left" colspan="9">V<span class="Sub">z</span> - Volume of distribution of terminal elimination phase</td></tr><tr class="Last"><td align="left" colspan="9">CL - Total systemic clearance</td></tr><tr><td align="left" colspan="9"><dl class="Footnote"><dt><a href="#footnote-reference-34" name="footnote-34">*</a></dt><dd>Plasma specimens collected for 24 hours following the end of the 90-minute infusion.</dd><dt><a href="#footnote-reference-35" name="footnote-35">&dagger;</a></dt><dd>Plasma specimens collected for 48 hours following the end of the 90-minute infusion. Because of the longer collection period, these values provide a more accurate reflection of the terminal elimination half-lives of irinotecan and SN-38.</dd></dl></td></tr></tfoot><tbody><tr class="Botrule First"><td class="Rrule" align="center">125<br>(N=64)</td><td class="Rrule" align="center">1,660<br>&plusmn;797</td><td class="Rrule" align="center">10,200<br>&plusmn;3,270</td><td class="Rrule" align="center">5.8<a class="Sup" href="#footnote-34" name="footnote-reference-34">*</a><br>&plusmn;0.7</td><td class="Rrule" align="center">110<br>&plusmn;48.5</td><td class="Rrule" align="center">13.3<br>&plusmn;6.01</td><td class="Rrule" align="center">26.3<br>&plusmn;11.9</td><td class="Rrule" align="center">229<br>&plusmn;108</td><td align="center">10.4<a class="Sup" href="#footnote-34">*</a><br>&plusmn;3.1</td></tr><tr class="Last"><td class="Rrule" align="center">340<br>(N=6)</td><td class="Rrule" align="center">3,392<br>&plusmn;874</td><td class="Rrule" align="center">20,604<br>&plusmn;6,027</td><td class="Rrule" align="center">11.7<a class="Sup" href="#footnote-35" name="footnote-reference-35">&dagger;</a><br>&plusmn;1.0</td><td class="Rrule" align="center">234<br>&plusmn;69.6</td><td class="Rrule" align="center">13.9<br>&plusmn;4.0</td><td class="Rrule" align="center">56.0<br>&plusmn;28.2</td><td class="Rrule" align="center">474<br>&plusmn;245</td><td align="center">21.0<a class="Sup" href="#footnote-35">&dagger;</a><br>&plusmn;4.3</td></tr></tbody></table><div class="Section"><a name="nlm42229-5"></a><a name="section-11.3.1"></a><p></p><p class="First"><span class="Bold Italics">Distribution</span></p><p>Irinotecan exhibits moderate plasma protein binding (30% to 68% bound). SN-38 is highly bound to human plasma proteins (approximately 95% bound). The plasma protein to which irinotecan and SN-38 predominantly binds is albumin.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="section-11.3.2"></a><p></p><p class="First"><span class="Bold Italics">Metabolism</span></p><p>The metabolic conversion of irinotecan to the active metabolite SN-38 is mediated by carboxylesterase enzymes and primarily occurs in the liver<span class="Italics">. In vitro</span> studies indicate that irinotecan, SN-38 and another metabolite aminopentane carboxylic acid (APC), do not inhibit cytochrome P-450 isozymes. SN-38 is subsequently conjugated predominantly by the enzyme UDP-glucuronosyl transferase 1A1 (UGT1A1) to form a glucuronide metabolite. UGT1A1 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity such as the UGT1A1*28 polymorphism.  Approximately 10% of the North American population is homozygous for the UGT1A1*28 allele (also referred to as UGT1A1 7/7 genotype).  In a prospective study, in which irinotecan was administered as a single-agent (350 mg/m<span class="Sup">2</span>) on a once-every-3-week schedule, patients with the UGT1A1 7/7 genotype had a higher exposure to SN-38 than patients with the wild-type UGT1A1 allele (UGT1A1 6/6 genotype) [<span class="Italics">see <a href="#S5.3">Warnings and Precautions (5.3)</a> and <a href="#S2">Dosage and Administration (2)</a></span>]. SN-38 glucuronide had 1/50 to 1/100 the activity of SN-38 in cytotoxicity assays using two cell lines <span class="Italics">in vitro</span>.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="section-11.3.3"></a><p></p><p class="First"><span class="Bold Italics">Excretion</span></p><p>The disposition of irinotecan has not been fully elucidated in humans. The urinary excretion of irinotecan is 11% to 20%; SN-38, &lt;1%; and SN-38 glucuronide, 3%. The cumulative biliary and urinary excretion of irinotecan and its metabolites (SN-38 and SN-38 glucuronide) over a period of 48 hours following administration of irinotecan in two patients ranged from approximately 25% (100 mg/m<span class="Sup">2</span>) to 50% (300 mg/m<span class="Sup">2</span>).</p></div><div class="Section"><a name="nlm42229-5"></a><a name="section-11.3.4"></a><p></p><p class="First"><span class="Bold Italics">Effect of Age</span></p><p>The pharmacokinetics of irinotecan administered using the weekly schedule was evaluated in a study of 183 patients that was prospectively designed to investigate the effect of age on irinotecan toxicity. Results from this trial indicate that there are no differences in the pharmacokinetics of irinotecan, SN-38, and SN-38 glucuronide in patients &lt;65 years of age compared with patients &ge;65 years of age. In a study of 162 patients that was not prospectively designed to investigate the effect of age, small (less than 18%) but statistically significant differences in dose-normalized irinotecan pharmacokinetic parameters in patients &lt;65 years of age compared to patients &ge;65 years of age were observed. Although dose-normalized AUC<span class="Sub">0&ndash;24</span> for SN-38 in patients &ge;65 years of age was 11% higher than in patients &lt;65 years of age, this difference was not statistically significant.  No change in the starting dose is recommended for geriatric patients receiving the weekly dosage schedule of irinotecan [<span class="Italics">see <a href="#S2">Dosage and Administration (2)</a></span>].</p></div><div class="Section"><a name="nlm42229-5"></a><a name="section-11.3.5"></a><p></p><p class="First"><span class="Bold Italics">Effect of Gender</span></p><p>The pharmacokinetics of irinotecan do not appear to be influenced by gender.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="section-11.3.6"></a><p></p><p class="First"><span class="Bold Italics">Effect of Race</span></p><p>The influence of race on the pharmacokinetics of irinotecan has not been evaluated.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="section-11.3.7"></a><p></p><p class="First"><span class="Bold Italics">Effect of Hepatic Impairment</span></p><p>Irinotecan clearance is diminished in patients with hepatic impairment while exposure to the active metabolite SN-38 is increased relative to that in patients with normal hepatic function. The magnitude of these effects is proportional to the degree of liver impairment as measured by elevations in total bilirubin and transaminase concentrations. However, the tolerability of irinotecan in patients with hepatic dysfunction (bilirubin greater than 2 mg/dl) has not been assessed sufficiently, and no recommendations for dosing can be made [<span class="Italics">see </span><span class="Italics"><a href="#S2.1">Dosage and Administration (2.1)</a></span>, <span class="Italics"><a href="#S5.10">Warnings and Precautions (5.10)</a> and <a href="#S8.7">Use in Specific Populations (8.7)</a></span>].</p></div><div class="Section"><a name="nlm42229-5"></a><a name="section-11.3.8"></a><p></p><p class="First"><span class="Bold Italics">Effect of Renal Impairment</span></p><p>The influence of renal impairment on the pharmacokinetics of irinotecan has not been evaluated. Therefore, caution should be undertaken in patients with impaired renal function. Irinotecan is not recommended for use in patients on dialysis [<span class="Italics">see </span><span class="Italics"><a href="#S8.6">Use in Specific Populations (8.6)</a></span>].</p></div></div></div><div class="Section"><a name="nlm43680-8"></a><a name="S13"></a><a name="section-12"></a><p></p><h1>13	NONCLINICAL TOXICOLOGY</h1><div class="Section"><a name="nlm34083-6"></a><a name="S13.1"></a><a name="section-12.1"></a><p></p><h2>13.1   Carcinogenesis, Mutagenesis, Impairment of Fertility</h2><p class="First">Long-term carcinogenicity studies with irinotecan were not conducted. Rats were, however, administered intravenous doses of 2 mg/kg or 25 mg/kg irinotecan once per week for 13 weeks (in separate studies, the 25 mg/kg dose produced an irinotecan C<span class="Sub">max </span>and AUC that were about 7.0 times and 1.3 times the respective values in patients administered 125 mg/m<span class="Sup">2</span> weekly) and were then allowed to recover for 91 weeks. Under these conditions, there was a significant linear trend with dose for the incidence of combined uterine horn endometrial stromal polyps and endometrial stromal sarcomas.  Irinotecan was clastogenic both <span class="Italics">in vitro</span> (chromosome aberrations in Chinese hamster ovary cells) and <span class="Italics">in vivo</span> (micronucleus test in mice). Neither irinotecan nor its active metabolite SN-38 was mutagenic in the <span class="Italics">in vitro</span> Ames assay.</p><p>No significant adverse effects on fertility and general reproductive performance were observed after intravenous administration of irinotecan in doses of up to 6 mg/kg/day to rats and rabbits; however, atrophy of male reproductive organs was observed after multiple daily irinotecan doses both in rodents at 20 mg/kg and in dogs at 0.4 mg/kg.  In separate studies in rodents, this dose produced an irinotecan C<span class="Sub">max </span>and AUC about 5 and 1 times, respectively, of the corresponding values in patients administered 125 mg/m<span class="Sup">2</span> weekly.  In dogs this dose produced an irinotecan C<span class="Sub">max</span> and AUC about one-half and 1/15th, respectively, of the corresponding values in patients administered 125 mg/m<span class="Sup">2</span> weekly.</p></div></div><div class="Section"><a name="nlm34092-7"></a><a name="S14"></a><a name="section-13"></a><p></p><h1>14 CLINICAL STUDIES</h1><p class="First">Irinotecan has been studied in clinical trials in combination with 5-fluorouracil (5-FU) and leucovorin (LV) and as a single agent [<span class="Italics">see <a href="#S2">Dosage and Administration (2)</a></span>]. When given as a component of combination-agent treatment, irinotecan was either given with a weekly schedule of bolus 5-FU/LV or with an every-2-week schedule of infusional 5-FU/LV. Weekly and once-every-3-week dosage schedules were used for the single-agent irinotecan studies. Clinical studies of combination and single-agent use are described below.</p><div class="Section"><a name="nlm42229-5"></a><a name="S14.1"></a><a name="section-13.1"></a><p></p><h2>14.1  Metastatic Colorectal Cancer</h2><div class="Section"><a name="nlm42229-5"></a><a name="section-13.1.1"></a><p></p><p class="First"><span class="Italics">First </span><span class="Italics">Line Therapy in Combination </span><span class="Italics">w</span><span class="Italics">ith 5-FU/LV</span><span class="Italics">: Studies 1 and 2</span></p><p>Two phase 3, randomized, controlled, multinational clinical trials support the use of CAMPTOSAR Injection as first-line treatment of patients with metastatic carcinoma of the colon or rectum. In each study, combinations of irinotecan with 5-FU and LV were compared with 5-FU and LV alone. Study 1 compared combination irinotecan/bolus 5-FU/LV therapy given weekly with a standard bolus regimen of 5-FU/LV alone given daily for 5 days every 4 weeks; an irinotecan-alone treatment arm given on a weekly schedule was also included. Study 2 evaluated two different methods of administering infusional 5-FU/LV, with or without irinotecan. In both studies, concomitant medications such as antiemetics, atropine, and loperamide were given to patients for prophylaxis and/or management of symptoms from treatment. In Study 2, a 7-day course of fluoroquinolone antibiotic prophylaxis was given in patients whose diarrhea persisted for greater than 24 hours despite loperamide or if they developed a fever in addition to diarrhea. Treatment with oral fluoroquinolone was also initiated in patients who developed an absolute neutrophil count (ANC) &lt;500/mm<span class="Sup">3</span>, even in the absence of fever or diarrhea. Patients in both studies also received treatment with intravenous antibiotics if they had persistent diarrhea or fever or if ileus developed.</p><p>In both studies, the combination of irinotecan/5-FU/LV therapy resulted in significant improvements in objective tumor response rates, time to tumor progression, and survival when compared with 5-FU/LV alone. These differences in survival were observed in spite of second-line therapy in a majority of patients on both arms, including crossover to irinotecan-containing regimens in the control arm. Patient characteristics and major efficacy results are shown in Table 10.</p><table width="100%"><caption><span>Table 10. Combination Dosage Schedule: Study Results</span></caption><col align="left" valign="middle" width="25%"><col align="center" valign="middle" width="16%"><col align="center" valign="middle" width="16%"><col align="center" valign="middle" width="15%"><col align="center" valign="middle" width="14%"><col align="center" valign="middle" width="14%"><thead><tr class="First"><th class="Rrule" align="left"></th><th class="Botrule Rrule" align="center" colspan="3">Study 1</th><th class="Botrule" align="center" colspan="2">Study 2</th></tr><tr class="Last" valign="bottom"><th class="Rrule" align="left"></th><th align="center">Irinotecan + Bolus 5-FU/LV weekly &times; 4 every 6 weeks</th><th class="Rrule" align="center">Bolus 5-FU/LV daily &times; 5 every 4 weeks</th><th class="Rrule" align="center">Irinotecan weekly &times; 4 every 6 weeks</th><th align="center">Irinotecan + Infusional 5-FU/LV</th><th align="center">Infusional 5-FU/LV</th></tr></thead><tfoot><tr><td align="left" colspan="6"><dl class="Footnote"><dt><a href="#footnote-reference-36" name="footnote-36">*</a></dt><dd>Study 1: N=225 (irinotecan/5-FU/LV),N=219 (5-FU/LV),N=223 (irinotecan)<br>Study 2: N=199 (irinotecan/5-FU/LV),N=186 (5-FU/LV)</dd><dt><a href="#footnote-reference-37" name="footnote-37">&dagger;</a></dt><dd>Confirmed &ge; 4 to 6 weeks after first evidence of objective response</dd><dt><a href="#footnote-reference-38" name="footnote-38">&Dagger;</a></dt><dd>Chi-square test</dd><dt><a href="#footnote-reference-39" name="footnote-39">&sect;</a></dt><dd>Log-rank test</dd></dl></td></tr></tfoot><tbody><tr class="Botrule First"><td class="Rrule" align="left">Number of patients</td><td align="center">231</td><td class="Rrule" align="center">226</td><td align="center">226</td><td align="center">198</td><td align="center">187</td></tr><tr class="Botrule"><td align="left" colspan="6"><span class="Bold">Demographics and treatment administration</span></td></tr><tr class="Botrule"><td class="Rrule" align="left">Female/Male (%)</td><td align="center">34/65</td><td class="Rrule" align="center">45/54</td><td class="Rrule" align="center">35/64</td><td align="center">33/67</td><td align="center">47/53</td></tr><tr class="Botrule" valign="top"><td class="Rrule" align="left">Median age in years (range)</td><td align="center">62 (25&ndash;85)</td><td class="Rrule" align="center">61 (19&ndash;85)</td><td class="Rrule" align="center">61 (30&ndash;87)</td><td align="center">62 (27&ndash;75)</td><td align="center">59 (24&ndash;75)</td></tr><tr><td class="Rrule" align="left">Performance status (%)</td><td align="center"></td><td class="Rrule" align="center"></td><td class="Rrule" align="center"></td><td align="center"></td><td align="center"></td></tr><tr><td class="Rrule" align="left">0</td><td align="center">39</td><td class="Rrule" align="center">41</td><td class="Rrule" align="center">46</td><td align="center">51</td><td align="center">51</td></tr><tr><td class="Rrule" align="left">1</td><td align="center">46</td><td class="Rrule" align="center">45</td><td class="Rrule" align="center">46</td><td align="center">42</td><td align="center">41</td></tr><tr class="Botrule"><td class="Rrule" align="left">2</td><td align="center">15</td><td class="Rrule" align="center">13</td><td class="Rrule" align="center">8</td><td align="center">7</td><td align="center">8</td></tr><tr><td class="Rrule" align="left">Primary tumor (%)</td><td align="center"></td><td class="Rrule" align="center"></td><td class="Rrule" align="center"></td><td align="center"></td><td align="center"></td></tr><tr><td class="Rrule" align="left">Colon</td><td align="center">81</td><td class="Rrule" align="center">85</td><td class="Rrule" align="center">84</td><td align="center">55</td><td align="center">65</td></tr><tr class="Botrule"><td class="Rrule" align="left">Rectum</td><td align="center">17</td><td class="Rrule" align="center">14</td><td class="Rrule" align="center">15</td><td align="center">45</td><td align="center">35</td></tr><tr class="Botrule"><td class="Botrule Rrule" align="left">Median time from diagnosis to randomization (months, range)</td><td align="center">1.9<br>(0&ndash;161)</td><td class="Rrule" align="center">1.7<br>(0&ndash;203)</td><td class="Rrule" align="center">1.8<br>(0.1&ndash;185)</td><td align="center">4.5<br>(0&ndash;88)</td><td align="center">2.7<br>(0&ndash;104)</td></tr><tr class="Botrule"><td class="Rrule" align="left">Prior adjuvant 5-FU therapy (%)<br>No<br>Yes</td><td align="center">89<br>11</td><td class="Rrule" align="center">92<br>8</td><td class="Rrule" align="center">90<br>10</td><td align="center">74<br>26</td><td align="center">76<br>24</td></tr><tr class="Botrule"><td class="Rrule" align="left">Median duration of study treatment<a class="Sup" href="#footnote-36" name="footnote-reference-36">*</a> (months)</td><td align="center">5.5</td><td class="Rrule" align="center">4.1</td><td class="Rrule" align="center">3.9</td><td align="center">5.6</td><td align="center">4.5</td></tr><tr class="Botrule"><td class="Rrule" align="left">Median Relative Dose Intensity (%)<a class="Sup" href="#footnote-36">*</a><br>Irinotecan<br>5-FU</td><td align="center">72<br>71</td><td class="Rrule" align="center">&mdash;<br>86</td><td class="Rrule" align="center">75<br>&mdash;</td><td align="center">87<br>86</td><td align="center">&mdash;<br>93</td></tr><tr class="Botrule"><td align="left" colspan="6"><span class="Bold">Efficacy Results</span></td></tr><tr valign="top"><td class="Botrule Rrule" align="left" rowspan="2">Confirmed objective tumor response rate<a class="Sup" href="#footnote-37" name="footnote-reference-37">&dagger;</a> (%)</td><td align="center">39</td><td class="Rrule" align="center">21</td><td class="Rrule" align="center">18</td><td align="center">35</td><td align="center">22</td></tr><tr class="Botrule" valign="top"><td class="Rrule" align="center" colspan="2">(p&lt;0.0001)<a class="Sup" href="#footnote-38" name="footnote-reference-38">&Dagger;</a></td><td class="Rrule" align="center"></td><td align="center" colspan="2">(p&lt;0.005)<a class="Sup" href="#footnote-38">&Dagger;</a></td></tr><tr valign="top"><td class="Botrule Rrule" align="left" rowspan="2">Median time to tumor progression<a class="Sup" href="#footnote-39" name="footnote-reference-39">&sect;</a><br>(months)</td><td align="center">7.0</td><td class="Rrule" align="center">4.3</td><td class="Rrule" align="center">4.2</td><td align="center">6.7</td><td align="center">4.4</td></tr><tr class="Botrule" valign="top"><td class="Rrule" align="center" colspan="2">(p=0.004)<a class="Sup" href="#footnote-39">&sect;</a></td><td class="Rrule" align="center"></td><td align="center" colspan="2">(p&lt;0.001)<a class="Sup" href="#footnote-39">&sect;</a></td></tr><tr valign="top"><td class="Botrule Rrule" align="left" rowspan="2">Median survival<br>(months)</td><td align="center">14.8</td><td class="Rrule" align="center">12.6</td><td class="Rrule" align="center">12.0</td><td align="center">17.4</td><td align="center">14.1</td></tr><tr class="Last"><td class="Rrule" align="center" colspan="2">(p&lt;0.05)<a class="Sup" href="#footnote-39">&sect;</a></td><td class="Rrule" align="center"></td><td align="center" colspan="2">(p&lt;0.05)<a class="Sup" href="#footnote-39">&sect;</a></td></tr></tbody></table><p>Improvement was noted with irinotecan-based combination therapy relative to 5-FU/LV when response rates and time to tumor progression were examined across the following demographic and disease-related subgroups (age, gender, ethnic origin, performance status, extent of organ involvement with cancer, time from diagnosis of cancer, prior adjuvant therapy, and baseline laboratory abnormalities). Figures 1 and 2 illustrate the Kaplan-Meier survival curves for the comparison of irinotecan/5-FU/LV versus 5-FU/LV in Studies 1 and 2, respectively.</p><div class="Figure"><img src="image.cfm?id=95945&type=img&name=camptosar%2D02.jpg" alt="Figure 1"></div><div class="Figure"><img src="image.cfm?id=95945&type=img&name=camptosar%2D03.jpg" alt="Figure 2"></div></div><div class="Section"><a name="nlm42229-5"></a><a name="section-13.1.2"></a><p></p><p class="First"><span class="Italics"><span class="Underline">Second-Line </span></span><span class="Italics"><span class="Underline">Therapy</span></span><span class="Italics"><span class="Underline"> After 5-FU-Based Treatment</span></span></p><div class="Section"><a name="nlm42229-5"></a><a name="section-13.1.2.1"></a><p></p><p class="First"><span class="Italics">4 Weekly Doses on a 6-Week Cycle: Studies 3, 4, and 5</span></p><p>Data from three open-label, single-agent, clinical studies, involving a total of 304 patients in 59 centers, support the use of CAMPTOSAR in the treatment of patients with metastatic cancer of the colon or rectum that has recurred or progressed following treatment with 5-FU-based therapy. These studies were designed to evaluate tumor response rate and do not provide information on effects on survival and disease-related symptoms. In each study, CAMPTOSAR was administered in repeated 6-week cycles consisting of a 90-minute intravenous infusion once weekly for 4 weeks, followed by a 2-week rest period. Starting doses of CAMPTOSAR in these trials were 100, 125, or 150 mg/m<span class="Sup">2</span>, but the 150-mg/m<span class="Sup">2</span> dose was poorly tolerated (due to high rates of grade 4 late diarrhea and febrile neutropenia). Study 3 enrolled 48 patients and was conducted by a single investigator at several regional hospitals. Study 4 was a multicenter study conducted by the North Central Cancer Treatment Group. All 90 patients enrolled in Study 4 received a starting dose of 125 mg/m<span class="Sup">2</span>. Study 5 was a multicenter study that enrolled 166 patients from 30 institutions. The initial dose in Study 5 was 125 mg/m<span class="Sup">2</span> but was reduced to 100 mg/m<span class="Sup">2</span> because the toxicity seen at the 125-mg/m<span class="Sup">2</span> dose was perceived to be greater than that seen in previous studies. All patients in these studies had metastatic colorectal cancer, and the majority had disease that recurred or progressed following a 5-FU-based regimen administered for metastatic disease. The results of the individual studies are shown in Table 11.</p><table width="90%"><caption><span>Table 11.  Weekly Dosage Schedule: Study Results</span></caption><col align="left" valign="top" width="40%"><col align="center" valign="top" width="15%"><col align="center" valign="top" width="15%"><col align="center" valign="top" width="15%"><col align="center" valign="top" width="15%"><thead><tr class="First"><th align="left"></th><th class="Lrule" align="center" colspan="4">Study</th></tr><tr class="Last"><th align="left"></th><th class="Lrule Toprule" align="center">3</th><th class="Lrule Toprule" align="center">4</th><th class="Lrule Toprule" align="center" colspan="2">5</th></tr></thead><tfoot><tr><td align="left" colspan="5"><dl class="Footnote"><dt><a href="#footnote-reference-40" name="footnote-40">*</a></dt><dd>Nine patients received 150 mg/m<span class="Sup">2</span> as a starting dose; two (22.2%) responded to CAMPTOSAR.</dd><dt><a href="#footnote-reference-41" name="footnote-41">&dagger;</a></dt><dd>Relative dose intensity for CAMPTOSAR based on planned dose intensity of 100, 83.3, and 66.7 mg/m<span class="Sup">2</span>/wk corresponding with 150, 125, and 100 mg/m<span class="Sup">2</span> starting doses, respectively.</dd><dt><a href="#footnote-reference-42" name="footnote-42">&Dagger;</a></dt><dd>Confirmed &ge; 4 to 6 weeks after first evidence of objective response.</dd></dl></td></tr></tfoot><tbody><tr class="Botrule First"><td class="Toprule" align="left">Number of Patients</td><td class="Lrule Toprule" align="center">48</td><td class="Lrule Toprule" align="center">90</td><td class="Lrule Toprule" align="center">64</td><td class="Lrule Toprule" align="center">102</td></tr><tr><td align="left">Starting Dose (mg/m<span class="Sup">2</span>/week &times; 4)</td><td class="Lrule" align="center">125<a class="Sup" href="#footnote-40" name="footnote-reference-40">*</a></td><td class="Lrule" align="center">125</td><td class="Lrule" align="center">125</td><td class="Lrule" align="center">100</td></tr><tr class="Botrule"><td class="Toprule" align="center" colspan="5"><span class="Bold">Demographics and Treatment Administration</span></td></tr><tr class="Botrule"><td align="left">Female/Male (%)</td><td class="Lrule" align="center">46/54</td><td class="Lrule" align="center">36/64</td><td class="Lrule" align="center">50/50</td><td class="Lrule" align="center">51/49</td></tr><tr class="Botrule"><td align="left">Median Age in years (range)</td><td class="Lrule" align="center">63 (29&ndash;78)</td><td class="Lrule" align="center">63 (32&ndash;81)</td><td class="Lrule" align="center">61 (42&ndash;84)</td><td class="Lrule" align="center">64 (25&ndash;84)</td></tr><tr><td align="left">Ethnic Origin (%)</td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;White</td><td class="Lrule" align="center">79</td><td class="Lrule" align="center">96</td><td class="Lrule" align="center">81</td><td class="Lrule" align="center">91</td></tr><tr><td align="left">&nbsp;&nbsp;African American</td><td class="Lrule" align="center">12</td><td class="Lrule" align="center">4</td><td class="Lrule" align="center">11</td><td class="Lrule" align="center">5</td></tr><tr><td align="left">&nbsp;&nbsp;Hispanic</td><td class="Lrule" align="center">8</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">8</td><td class="Lrule" align="center">2</td></tr><tr><td align="left">&nbsp;&nbsp;Oriental/Asian</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">2</td></tr><tr><td class="Toprule" align="left">Performance Status (%)</td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;0</td><td class="Lrule" align="center">60</td><td class="Lrule" align="center">38</td><td class="Lrule" align="center">59</td><td class="Lrule" align="center">44</td></tr><tr><td align="left">&nbsp;&nbsp;1</td><td class="Lrule" align="center">38</td><td class="Lrule" align="center">48</td><td class="Lrule" align="center">33</td><td class="Lrule" align="center">51</td></tr><tr class="Botrule"><td align="left">&nbsp;&nbsp;2</td><td class="Lrule" align="center">2</td><td class="Lrule" align="center">14</td><td class="Lrule" align="center">8</td><td class="Lrule" align="center">5</td></tr><tr><td align="left">Primary Tumor (%)</td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;Colon</td><td class="Lrule" align="center">100</td><td class="Lrule" align="center">71</td><td class="Lrule" align="center">89</td><td class="Lrule" align="center">87</td></tr><tr><td align="left">&nbsp;&nbsp;Rectum</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">29</td><td class="Lrule" align="center">11</td><td class="Lrule" align="center">8</td></tr><tr class="Botrule"><td align="left">&nbsp;&nbsp;Unknown</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">5</td></tr><tr><td align="left">Prior 5-FU Therapy (%)</td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;For Metastatic Disease</td><td class="Lrule" align="center">81</td><td class="Lrule" align="center">66</td><td class="Lrule" align="center">73</td><td class="Lrule" align="center">68</td></tr><tr><td align="left">&nbsp;&nbsp;&le; 6 months after Adjuvant</td><td class="Lrule" align="center">15</td><td class="Lrule" align="center">7</td><td class="Lrule" align="center">27</td><td class="Lrule" align="center">28</td></tr><tr><td align="left">&nbsp;&nbsp;&gt; 6 months after Adjuvant</td><td class="Lrule" align="center">2</td><td class="Lrule" align="center">16</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">2</td></tr><tr class="Botrule"><td align="left">&nbsp;&nbsp;Classification Unknown</td><td class="Lrule" align="center">2</td><td class="Lrule" align="center">12</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">3</td></tr><tr><td align="left">Prior Pelvic/Abdominal Irradiation (%)</td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;Yes</td><td class="Lrule" align="center">3</td><td class="Lrule" align="center">29</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">0</td></tr><tr><td align="left">&nbsp;&nbsp;Other</td><td class="Lrule" align="center">0</td><td class="Lrule" align="center">9</td><td class="Lrule" align="center">2</td><td class="Lrule" align="center">4</td></tr><tr class="Botrule"><td align="left">&nbsp;&nbsp;None</td><td class="Lrule" align="center">97</td><td class="Lrule" align="center">62</td><td class="Lrule" align="center">98</td><td class="Lrule" align="center">96</td></tr><tr class="Botrule" valign="bottom"><td align="left">Duration of Treatment with CAMPTOSAR (median, months)</td><td class="Lrule" align="center"><br>5</td><td class="Lrule" align="center"><br>4</td><td class="Lrule" align="center"><br>4</td><td class="Lrule" align="center"><br>3</td></tr><tr><td align="left">Relative Dose Intensity<a class="Sup" href="#footnote-41" name="footnote-reference-41">&dagger;</a> (median %)</td><td class="Lrule" align="center">74</td><td class="Lrule" align="center">67</td><td class="Lrule" align="center">73</td><td class="Lrule" align="center">81</td></tr><tr class="Botrule"><td class="Toprule" align="center" colspan="5"><span class="Bold">Efficacy</span></td></tr><tr class="Botrule"><td align="left">Confirmed Objective Response Rate (%)<a class="Sup" href="#footnote-42" name="footnote-reference-42">&Dagger;</a><br>(95% CI)</td><td class="Lrule" align="center">21<br>(9.3 &ndash; 32.3)</td><td class="Lrule" align="center">13<br>(6.3 &ndash; 20.4)</td><td class="Lrule" align="center">14<br>(5.5 &ndash; 22.6)</td><td class="Lrule" align="center">9<br>(3.3 &ndash; 14.3)</td></tr><tr class="Botrule"><td align="left">Time to Response (median, months)</td><td class="Lrule" align="center">2.6</td><td class="Lrule" align="center">1.5</td><td class="Lrule" align="center">2.8</td><td class="Lrule" align="center">2.8</td></tr><tr class="Botrule"><td align="left">Response Duration (median, months)</td><td class="Lrule" align="center">6.4</td><td class="Lrule" align="center">5.9</td><td class="Lrule" align="center">5.6</td><td class="Lrule" align="center">6.4</td></tr><tr class="Botrule"><td align="left">Survival (median, months)</td><td class="Lrule" align="center">10.4</td><td class="Lrule" align="center">8.1</td><td class="Lrule" align="center">10.7</td><td class="Lrule" align="center">9.3</td></tr><tr class="Last"><td align="left">1-Year Survival (%)</td><td class="Lrule" align="center">46</td><td class="Lrule" align="center">31</td><td class="Lrule" align="center">45</td><td class="Lrule" align="center">43</td></tr></tbody></table><p>In the intent-to-treat analysis of the pooled data across all three studies, 193 of the 304 patients began therapy at the recommended starting dose of 125 mg/m<span class="Sup">2</span>. Among these 193 patients, 2 complete and 27 partial responses were observed, for an overall response rate of 15.0% (95% Confidence Interval [CI], 10.0% to 20.1%) at this starting dose. A considerably lower response rate was seen with a starting dose of 100 mg/m<span class="Sup">2</span>. The majority of responses were observed within the first two cycles of therapy, but responses did occur in later cycles of treatment (one response was observed after the eighth cycle). The median response duration for patients beginning therapy at 125 mg/m<span class="Sup">2</span> was 5.8 months (range, 2.6 to 15.1 months). Of the 304 patients treated in the three studies, response rates to CAMPTOSAR were similar in males and females and among patients older and younger than 65 years. Rates were also similar in patients with cancer of the colon or cancer of the rectum and in patients with single and multiple metastatic sites. The response rate was 18.5% in patients with a performance status of 0 and 8.2% in patients with a performance status of 1 or 2. Patients with a performance status of 3 or 4 have not been studied. Over half of the patients responding to CAMPTOSAR had not responded to prior 5-FU. Patients who had received previous irradiation to the pelvis responded to CAMPTOSAR at approximately the same rate as those who had not previously received irradiation.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="section-13.1.2.2"></a><p></p><p class="First"><span class="Italics">Once-Every-3-Week Dosage Schedule</span></p><div class="Section"><a name="nlm42229-5"></a><a name="section-13.1.2.2.1"></a><p></p><p class="First"><span class="Italics">Single Arm Study: Study 6</span></p><p>Data from an open-label, single-agent, single-arm, multicenter, clinical study involving a total of 132 patients support a once every-3-week dosage schedule of irinotecan in the treatment of patients with metastatic cancer of the colon or rectum that recurred or progressed following treatment with 5-FU. Patients received a starting dose of 350 mg/m<span class="Sup">2</span> given by 30-minute intravenous infusion once every 3 weeks. Among the 132 previously treated patients in this trial, the intent-to-treat response rate was 12.1% (95% CI, 7.0% to 18.1%).</p></div><div class="Section"><a name="nlm42229-5"></a><a name="section-13.1.2.2.2"></a><p></p><p class="First"><span class="Italics">Randomized Studies: Studies 7 and 8</span></p><p>Two multicenter, randomized, clinical studies further support the use of irinotecan given by the once-every-3-week dosage schedule in patients with metastatic colorectal cancer whose disease has recurred or progressed following prior 5-FU therapy. In Study 7, second-line irinotecan therapy plus best supportive care was compared with best supportive care alone. In Study 8, second-line irinotecan therapy was compared with infusional 5-FU-based therapy. In both studies, irinotecan was administered intravenously at a starting dose of 350 mg/m<span class="Sup">2</span> over 90 minutes once every 3 weeks. The starting dose was 300 mg/m<span class="Sup">2</span> for patients who were 70 years and older or who had a performance status of 2. The highest total dose permitted was 700 mg. Dose reductions and/or administration delays were permitted in the event of severe hematologic and/or nonhematologic toxicities while on treatment. Best supportive care was provided to patients in both arms of Study 7 and included antibiotics, analgesics, corticosteroids, transfusions, psychotherapy, or any other symptomatic therapy as clinically indicated. In both studies, concomitant medications such as antiemetics, atropine, and loperamide were given to patients for prophylaxis and/or management of symptoms from treatment. If late diarrhea persisted for greater than 24 hours despite loperamide, a 7-day course of fluoroquinolone antibiotic prophylaxis was given. Patients in the control arm of the Study 8 received one of the following 5-FU regimens: (1) LV, 200 mg/m<span class="Sup">2</span> IV over 2 hours; followed by 5-FU, 400 mg/m<span class="Sup">2</span> IV bolus; followed by 5-FU, 600 mg/m<span class="Sup">2</span> continuous IV infusion over 22 hours on days 1 and 2 every 2 weeks; (2) 5-FU, 250 to 300 mg/m<span class="Sup">2</span>/day protracted continuous IV infusion until toxicity; (3) 5-FU, 2.6 to 3 g/m<span class="Sup">2</span> IV over 24 hours every week for 6 weeks with or without LV, 20 to 500 mg/m<span class="Sup">2</span>/day every week IV for 6 weeks with 2-week rest between cycles. Patients were to be followed every 3 to 6 weeks for 1 year.</p><p>A total of 535 patients were randomized in the two studies at 94 centers. The primary endpoint in both studies was survival. The studies demonstrated a significant overall survival advantage for irinotecan compared with best supportive care (p=0.0001) and infusional 5-FU-based therapy (p=0.035) as shown in Figures 3 and 4. In Study 7, median survival for patients treated with irinotecan was 9.2 months compared with 6.5 months for patients receiving best supportive care. In Study 8, median survival for patients treated with irinotecan was 10.8 months compared with 8.5 months for patients receiving infusional 5-FU-based therapy. Multiple regression analyses determined that patients' baseline characteristics also had a significant effect on survival. When adjusted for performance status and other baseline prognostic factors, survival among patients treated with irinotecan remained significantly longer than in the control populations (p=0.001 for Study 7 and p=0.017 for Study 8). Measurements of pain, performance status, and weight loss were collected prospectively in the two studies; however, the plan for the analysis of these data was defined retrospectively. When comparing irinotecan with best supportive care in Study 7, this analysis showed a statistically significant advantage for irinotecan, with longer time to development of pain (6.9 months versus 2.0 months), time to performance status deterioration (5.7 months versus 3.3 months), and time to &gt; 5% weight loss (6.4 months versus 4.2 months). Additionally, 33.3% (33/99) of patients with a baseline performance status of 1 or 2 showed an improvement in performance status when treated with irinotecan versus 11.3% (7/62) of patients receiving best supportive care (p=0.002). Because of the inclusion of patients with non-measurable disease, intent-to-treat response rates could not be assessed.</p><table class="Noautorules" width="100%"><col align="center" valign="top" width="100%"><tbody class="Headless"><tr><td align="center">Figure 3. Survival<br> Second-Line Irinotecan vs Best Supportive Care (BSC)<br>Study 7</td></tr><tr><td align="center"><img src="image.cfm?id=95945&type=img&name=camptosar%2D04.jpg" alt="Figure 3"></td></tr><tr><td align="center">Figure 4. Survival<br> Second-Line Irinotecan vs Infusion 5-FU<br>Study 8</td></tr><tr><td align="center"><img src="image.cfm?id=95945&type=img&name=camptosar%2D05.jpg" alt="Figure 4"></td></tr></tbody></table><table width="90%"><caption><span>Table 12.  Once-Every-3-Week Dosage Schedule:  Study Results</span></caption><col align="left" valign="top" width="40%"><col align="center" valign="top" width="15%"><col align="center" valign="top" width="15%"><col align="center" valign="top" width="15%"><col align="center" valign="top" width="15%"><thead><tr class="First"><th align="left"></th><th class="Botrule Lrule" align="center" colspan="2">Study 7</th><th class="Botrule Lrule" align="center" colspan="2">Study 8</th></tr><tr class="Last"><th align="left"></th><th class="Lrule" align="center">Irinotecan</th><th class="Lrule" align="center">BSC<a class="Sup" href="#footnote-43" name="footnote-reference-43">*</a></th><th class="Lrule" align="center">Irinotecan</th><th class="Lrule" align="center">5-FU</th></tr></thead><tfoot><tr><td align="left" colspan="5"><dl class="Footnote"><dt><a href="#footnote-reference-43" name="footnote-43">*</a></dt><dd>BSC = best supportive care</dd><dt><a href="#footnote-reference-44" name="footnote-44">&dagger;</a></dt><dd>Relative dose intensity for irinotecan based on planned dose intensity of 116.7 and 100 mg/m<span class="Sup">2</span>/wk corresponding with 350 and 300 mg/m<span class="Sup">2</span> starting doses, respectively.</dd></dl></td></tr></tfoot><tbody><tr class="Botrule First"><td align="left">Number of patients</td><td class="Lrule" align="center">189</td><td class="Lrule" align="center">90</td><td class="Lrule" align="center">127</td><td class="Lrule" align="center">129</td></tr><tr class="Botrule"><td align="left" colspan="5"><span class="Bold">Demographics and treatment administration</span></td></tr><tr class="Botrule"><td align="left">Female/Male (%)</td><td class="Lrule" align="center">32/68</td><td class="Lrule" align="center">42/58</td><td class="Lrule" align="center">43/57</td><td class="Lrule" align="center">35/65</td></tr><tr><td align="left">Median age in years (range)</td><td class="Lrule" align="center">59 (22&ndash;75)</td><td class="Lrule" align="center">62 (34&ndash;75)</td><td class="Lrule" align="center">58 (30&ndash;75)</td><td class="Lrule" align="center">58 (25&ndash;75)</td></tr><tr><td class="Toprule" align="left">Performance status (%)</td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td><td class="Lrule Toprule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;0</td><td class="Lrule" align="center">47</td><td class="Lrule" align="center">31</td><td class="Lrule" align="center">58</td><td class="Lrule" align="center">54</td></tr><tr><td align="left">&nbsp;&nbsp;1</td><td class="Lrule" align="center">39</td><td class="Lrule" align="center">46</td><td class="Lrule" align="center">35</td><td class="Lrule" align="center">43</td></tr><tr class="Botrule"><td align="left">&nbsp;&nbsp;2</td><td class="Lrule" align="center">14</td><td class="Lrule" align="center">23</td><td class="Lrule" align="center">8</td><td class="Lrule" align="center">3</td></tr><tr><td align="left">Primary tumor (%)</td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;Colon</td><td class="Lrule" align="center">55</td><td class="Lrule" align="center">52</td><td class="Lrule" align="center">57</td><td class="Lrule" align="center">62</td></tr><tr class="Botrule"><td align="left">&nbsp;&nbsp;Rectum</td><td class="Lrule" align="center">45</td><td class="Lrule" align="center">48</td><td class="Lrule" align="center">43</td><td class="Lrule" align="center">38</td></tr><tr><td align="left">Prior 5-FU therapy (%)</td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td><td class="Lrule" align="center"></td></tr><tr><td align="left">&nbsp;&nbsp;For metastatic disease</td><td class="Lrule" align="center">70</td><td class="Lrule" align="center">63</td><td class="Lrule" align="center">58</td><td class="Lrule" align="center">68</td></tr><tr class="Botrule"><td align="left">&nbsp;&nbsp;As adjuvant treatment</td><td class="Lrule" align="center">30</td><td class="Lrule" align="center">37</td><td class="Lrule" align="center">42</td><td class="Lrule" align="center">32</td></tr><tr class="Botrule"><td align="left">Prior irradiation (%)</td><td class="Lrule" align="center">26</td><td class="Lrule" align="center">27</td><td class="Lrule" align="center">18</td><td class="Lrule" align="center">20</td></tr><tr class="Botrule"><td align="left">Duration of study treatment (median, months)<br>(Log-rank test)</td><td class="Lrule" align="center">4.1</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">4.2<br>(p=0.02)</td><td class="Lrule" align="center">2.8</td></tr><tr class="Botrule"><td align="left">Relative dose intensity (median %)<a class="Sup" href="#footnote-44" name="footnote-reference-44">&dagger;</a></td><td class="Lrule" align="center">94</td><td class="Lrule" align="center">--</td><td class="Lrule" align="center">95</td><td class="Lrule" align="center">81&ndash;99</td></tr><tr class="Botrule"><td align="left" colspan="5">&nbsp;&nbsp;Survival</td></tr><tr class="Last"><td align="left">Survival (median, months)<br>(Log-rank test)</td><td class="Lrule" align="center">9.2<br>(p=0.0001)</td><td class="Lrule" align="center">6.5</td><td class="Lrule" align="center">10.8<br>(p=0.035)</td><td class="Lrule" align="center">8.5</td></tr></tbody></table><p>In the two randomized studies, the EORTC QLQ-C30 instrument was utilized. At the start of each cycle of therapy, patients completed a questionnaire consisting of 30 questions, such as "Did pain interfere with daily activities?" (1 = Not at All, to 4 = Very Much) and "Do you have any trouble taking a long walk?" (Yes or No). The answers from the 30 questions were converted into 15 subscales, that were scored from 0 to 100, and the global health status subscale that was derived from two questions about the patient's sense of general well being in the past week. The results as summarized in Table 13 are based on patients' worst post-baseline scores. In Study 7, a multivariate analysis and univariate analyses of the individual subscales were performed and corrected for multivariate testing. Patients receiving irinotecan reported significantly better results for the global health status, on two of five functional subscales, and on four of nine symptom subscales. As expected, patients receiving irinotecan noted significantly more diarrhea than those receiving best supportive care. In Study 8, the multivariate analysis on all 15 subscales did not indicate a statistically significant difference between irinotecan and infusional 5-FU.</p><table width="100%"><caption><span>Table 13.  EORTC QLQ-C30:  Mean Worst Post-Baseline Score<a class="Sup" href="#footnote-45" name="footnote-reference-45">*</a></span></caption><col align="left" valign="top" width="28%"><col align="center" valign="top" width="14%"><col align="center" valign="top" width="11%"><col align="center" valign="top" width="11%"><col align="center" valign="top" width="14%"><col align="center" valign="top" width="11%"><col align="center" valign="top" width="11%"><thead><tr class="First"><th align="center">QLQ-C30 Subscale</th><th class="Botrule Lrule" align="center" colspan="3">Study 7</th><th class="Botrule Lrule" align="center" colspan="3">Study 8</th></tr><tr class="Last"><th align="left"></th><th class="Lrule" align="center">Irinotecan</th><th class="Lrule" align="center">BSC</th><th class="Lrule" align="center">p-value</th><th class="Lrule" align="center">Irinotecan</th><th class="Lrule" align="center">5-FU</th><th class="Lrule" align="center">p-value</th></tr></thead><tfoot><tr><td align="left" colspan="7"><dl class="Footnote"><dt><a href="#footnote-reference-45" name="footnote-45">*</a></dt><dd>For the five functional subscales and global health status subscale, higher scores imply better functioning, whereas, on the nine symptom subscales, higher scores imply more severe symptoms.  The subscale scores of each patient were collected at each visit until the patient dropped out of the study.</dd></dl></td></tr></tfoot><tbody><tr class="First"><td align="left"><span class="Bold">Global health status</span></td><td class="Lrule" align="center">47</td><td class="Lrule" align="center">37</td><td class="Lrule" align="center">0.03</td><td class="Lrule" align="center">53</td><td class="Lrule" align="center">52</td><td class="Lrule" align="center">0.9</td></tr><tr class="Botrule"><td class="Toprule" align="left" colspan="7"><span class="Bold">Functional scales </span></td></tr><tr class="Botrule"><td align="left">Cognitive</td><td class="Lrule" align="center">77</td><td class="Lrule" align="center">68</td><td class="Lrule" align="center">0.07</td><td class="Lrule" align="center">79</td><td class="Lrule" align="center">83</td><td class="Lrule" align="center">0.9</td></tr><tr class="Botrule"><td align="left">Emotional</td><td class="Lrule" align="center">68</td><td class="Lrule" align="center">64</td><td class="Lrule" align="center">0.4</td><td class="Lrule" align="center">64</td><td class="Lrule" align="center">68</td><td class="Lrule" align="center">0.9</td></tr><tr class="Botrule"><td align="left">Social</td><td class="Lrule" align="center">58</td><td class="Lrule" align="center">47</td><td class="Lrule" align="center">0.06</td><td class="Lrule" align="center">65</td><td class="Lrule" align="center">67</td><td class="Lrule" align="center">0.9</td></tr><tr class="Botrule"><td align="left">Physical</td><td class="Lrule" align="center">60</td><td class="Lrule" align="center">40</td><td class="Lrule" align="center">0.0003</td><td class="Lrule" align="center">66</td><td class="Lrule" align="center">66</td><td class="Lrule" align="center">0.9</td></tr><tr class="Botrule"><td align="left">Role</td><td class="Lrule" align="center">53</td><td class="Lrule" align="center">35</td><td class="Lrule" align="center">0.02</td><td class="Lrule" align="center">54</td><td class="Lrule" align="center">57</td><td class="Lrule" align="center">0.9</td></tr><tr class="Botrule"><td align="center" colspan="7"><span class="Bold">Symptom Scales</span></td></tr><tr class="Botrule"><td align="left">Fatigue</td><td class="Lrule" align="center">51</td><td class="Lrule" align="center">63</td><td class="Lrule" align="center">0.03</td><td class="Lrule" align="center">47</td><td class="Lrule" align="center">46</td><td class="Lrule" align="center">0.9</td></tr><tr class="Botrule"><td align="left">Appetite loss</td><td class="Lrule" align="center">37</td><td class="Lrule" align="center">57</td><td class="Lrule" align="center">0.0007</td><td class="Lrule" align="center">35</td><td class="Lrule" align="center">38</td><td class="Lrule" align="center">0.9</td></tr><tr class="Botrule"><td align="left">Pain assessment</td><td class="Lrule" align="center">41</td><td class="Lrule" align="center">56</td><td class="Lrule" align="center">0.009</td><td class="Lrule" align="center">38</td><td class="Lrule" align="center">34</td><td class="Lrule" align="center">0.9</td></tr><tr class="Botrule"><td align="left">Insomnia</td><td class="Lrule" align="center">39</td><td class="Lrule" align="center">47</td><td class="Lrule" align="center">0.3</td><td class="Lrule" align="center">39</td><td class="Lrule" align="center">33</td><td class="Lrule" align="center">0.9</td></tr><tr class="Botrule"><td align="left">Constipation</td><td class="Lrule" align="center">28</td><td class="Lrule" align="center">41</td><td class="Lrule" align="center">0.03</td><td class="Lrule" align="center">25</td><td class="Lrule" align="center">19</td><td class="Lrule" align="center">0.9</td></tr><tr class="Botrule"><td align="left">Dyspnea</td><td class="Lrule" align="center">31</td><td class="Lrule" align="center">40</td><td class="Lrule" align="center">0.2</td><td class="Lrule" align="center">25</td><td class="Lrule" align="center">24</td><td class="Lrule" align="center">0.9</td></tr><tr class="Botrule"><td align="left">Nausea/Vomiting</td><td class="Lrule" align="center">27</td><td class="Lrule" align="center">29</td><td class="Lrule" align="center">0.5</td><td class="Lrule" align="center">25</td><td class="Lrule" align="center">16</td><td class="Lrule" align="center">0.09</td></tr><tr class="Botrule"><td align="left">Financial impact</td><td class="Lrule" align="center">22</td><td class="Lrule" align="center">26</td><td class="Lrule" align="center">0.5</td><td class="Lrule" align="center">24</td><td class="Lrule" align="center">15</td><td class="Lrule" align="center">0.3</td></tr><tr class="Last"><td align="left">Diarrhea</td><td class="Lrule" align="center">32</td><td class="Lrule" align="center">19</td><td class="Lrule" align="center">0.01</td><td class="Lrule" align="center">32</td><td class="Lrule" align="center">22</td><td class="Lrule" align="center">0.2</td></tr></tbody></table></div></div></div></div></div><div class="Section"><a name="nlm34093-5"></a><a name="S15"></a><a name="section-14"></a><p></p><h1>15	REFERENCES</h1><ul class="Disc"><li>NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165.</li><li>OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html</li><li>American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. <span class="Italics">Am J Health-Syst Pharm.</span> 2006; 63:1172&ndash;1193.</li><li>Polovich, M., White, J. M., &amp; Kelleher, L.O. (eds.) 2005. Chemotherapy and biotherapy guidelines and recommendations for practice (2nd. ed.) Pittsburgh, PA: Oncology Nursing Society.</li></ul></div><div class="Section"><a name="nlm34069-5"></a><a name="S16"></a><a name="section-15"></a><p></p><h1>16  HOW SUPPLIED/STORAGE AND HANDLING</h1><p class="First">CAMPTOSAR Injection is available in single-dose brown glass vials in the following package sizes: </p><table class="Noautorules" width="70%"><col align="left" valign="top" width="10%"><col align="left" valign="top" width="10%"><col align="left" valign="top" width="80%"><tbody class="Headless"><tr><td align="left"></td><td align="left">2 mL</td><td align="left">NDC 0009-7529-02</td></tr><tr><td align="left"></td><td align="left">5 mL</td><td align="left">NDC 0009-7529-01</td></tr></tbody></table><p>CAMPTOSAR Injection is available in single-dose amber colored polypropylene CYTOSAFE<span class="Sup">&reg;</span> vials in the following package sizes: </p><table class="Noautorules" width="70%"><col align="left" valign="top" width="10%"><col align="left" valign="top" width="10%"><col align="left" valign="top" width="80%"><tbody class="Headless"><tr><td align="left"></td><td align="left">2 mL</td><td align="left">NDC 0009-7529-04</td></tr><tr><td align="left"></td><td align="left">5 mL</td><td align="left">NDC 0009-7529-03</td></tr><tr><td align="left"></td><td align="left">15 mL</td><td align="left">NDC 0009-7529-05</td></tr></tbody></table><div class="Section"><a name="nlm44425-7"></a><a name="section-15.1"></a><p></p><p class="First">Store at controlled room temperature 15&deg; to 30&deg;C (59&deg; to 86&deg;F).  Protect from light.  Keep the vial in the carton until the time of use.</p><p>Inspect the vial for damage and visible signs of leaks before removing from the carton.  If damaged, incinerate the unopened package.</p></div></div><div class="Section"><a name="nlm34076-0"></a><a name="S17"></a><a name="section-16"></a><p></p><h1>17	PATIENT COUNSELING INFORMATION</h1><ul><li>Patients and caregivers should be informed of gastrointestinal complications, such as nausea, vomiting, abdominal cramping, and diarrhea. Patients should have loperamide readily available to begin treatment for late diarrhea (generally occurring more than 24 hours after administration of CAMPTOSAR).   Begin loperamide at the first episode of poorly formed or loose stools or the earliest onset of bowel movements more frequent than normal. One dosage regimen for loperamide is 4 mg at the first onset of late diarrhea and then 2 mg every 2 hours until the patient is diarrhea-free for at least 12 hours. Loperamide is not recommended to be used for more than 48 consecutive hours at these doses, because of the risk of paralytic ileus.  During the night, the patient may take 4 mg of loperamide every 4 hours. Patients should contact their physician if any of the following occur: diarrhea for the first time during treatment; black or bloody stools; symptoms of dehydration such as lightheadedness, dizziness, or faintness; inability to take fluids by mouth due to nausea or vomiting; or inability to get diarrhea under control within 24 hours.</li><li>Patients should be warned about the potential for dizziness or visual disturbances which may occur within 24 hours following the administration of CAMPTOSAR.</li><li>Explain the significance of routine blood cell counts. Instruct patients to monitor their temperature frequently and immediately report any occurrence of fever or infection. </li><li>CAMPTOSAR may cause fetal harm. Advise patients to avoid becoming pregnant while receiving this drug.</li><li>Patients should be alerted to the possibility of alopecia.</li><li>Contains sorbitol.</li></ul></div><div class="Section"><a name="nlm42229-5"></a><a name="section-17"></a><p></p><p class="First">This product's label may have been updated. For current full prescribing information, please visit www.pfizer.com.</p><p><img src="image.cfm?id=95945&type=img&name=camptosar%2D06.jpg" alt="Logo"></p><p>Licensed from Yakult Honsha Co., LTD, Japan, and Daiichi Pharmaceutical Co., LTD, Japan </p><p>LAB-0134-18.0</p></div><div class="Section"><a name="nlm51945-4"></a><a name="section-18"></a><p></p><p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 100 mg/5 mL Vial Label</span></p><p>NDC 0009-7529-03<br>Single Use: Discard unused portion</p><p><span class="Bold">Camptosar<span class="Sup">&reg;</span></span><br>irinotecan HCl injection</p><p><span class="Bold">100 mg/5 mL</span><br>(20 mg/mL)</p><p>For Intravenous Use Only<br>Cytosafe<span class="Sup">&reg;</span> Vial<br><span class="Bold">Caution: Cytotoxic Agent</span></p><div class="Figure"><img src="image.cfm?id=95945&type=img&name=camptosar%2D07.jpg" alt="PRINCIPAL DISPLAY PANEL - 100 mg/5 mL Vial Label"></div></div><div class="Section"><a name="nlm51945-4"></a><a name="section-19"></a><p></p><p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 100 mg/5 mL Vial Carton</span></p><p>NDC 0009-7529-03<br><span class="Bold">Rx only</span></p><p><span class="Bold">Single Use: Discard unused portion<br>Camptosar<span class="Sup">&reg;</span></span><br>irinotecan hydrochloride<br>injection</p><p><span class="Bold">100 mg/5 mL</span><br>(20 mg/mL)</p><p>For Intravenous Use Only</p><p><span class="Bold">Cytosafe<span class="Sup">&reg;</span> Vial<br>Caution: Cytotoxic Agent</span></p><p><span class="Bold Italics">Pfizer Injectables</span></p><div class="Figure"><img src="image.cfm?id=95945&type=img&name=camptosar%2D08.jpg" alt="PRINCIPAL DISPLAY PANEL - 100 mg/5 mL Vial Carton"></div></div></div><div class="DataElementsTables"><table width="100%" cellPadding="3" cellSpacing="0" class="contentTablePetite"><tbody><tr><td class="contentTableTitle"><strong>CAMPTOSAR&nbsp;							</strong><br><span class="contentTableReg">irinotecan hydrochloride injection, solution</span></td></tr><tr><td><table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%"><tr><td class="formHeadingTitle" colspan="4">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Product Type</td><td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td><td class="formLabel">Item Code (Source)</td><td class="formItem">NDC:0009-7529</td></tr><tr class="formTableRow"><td class="formLabel" width="30%">Route of Administration</td><td class="formItem">INTRAVENOUS</td><td class="formLabel" width="30%">DEA Schedule</td><td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;							</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td></tr><tr><th scope="col" class="formTitle">Ingredient Name</th><th scope="col" class="formTitle">Basis of Strength</th><th scope="col" class="formTitle">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>IRINOTECAN HYDROCHLORIDE</strong> (IRINOTECAN) </td><td class="formItem">IRINOTECAN HYDROCHLORIDE</td><td class="formItem">20&nbsp;mg &nbsp;in&nbsp;1&nbsp;mL</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingTitle" colspan="2">Inactive Ingredients</td></tr><tr><th scope="col" class="formTitle">Ingredient Name</th><th scope="col" class="formTitle">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>LACTIC ACID</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>SODIUM HYDROXIDE</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>HYDROCHLORIC ACID</strong></td><td class="formItem">&nbsp;</td></tr></table></td></tr><tr><td></td></tr><tr><td><table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingTitle" colspan="5">Packaging</td></tr><tr><th class="formTitle" width="1" scope="col">#</th><th class="formTitle" scope="col">Item Code</th><th class="formTitle" scope="col">Package Description</th><th class="formTitle" scope="col">Marketing Start Date</th><th class="formTitle" scope="col">Marketing End Date</th></tr><tr class="formTableRowAlt"><th class="formItem" scope="row">1</th><td class="formItem">NDC:0009-7529-02</td><td class="formItem">1  in 1 CARTON</td><td class="formItem"></td><td class="formItem"></td></tr><tr class="formTableRowAlt"><th class="formItem" scope="row">1</th><td class="formItem"></td><td class="formItem">2 mL in 1 VIAL, SINGLE-DOSE</td><td class="formItem"></td><td class="formItem"></td></tr><tr class="formTableRow"><th class="formItem" scope="row">2</th><td class="formItem">NDC:0009-7529-01</td><td class="formItem">1  in 1 CARTON</td><td class="formItem"></td><td class="formItem"></td></tr><tr class="formTableRow"><th class="formItem" scope="row">2</th><td class="formItem"></td><td class="formItem">5 mL in 1 VIAL, SINGLE-DOSE</td><td class="formItem"></td><td class="formItem"></td></tr><tr class="formTableRowAlt"><th class="formItem" scope="row">3</th><td class="formItem">NDC:0009-7529-04</td><td class="formItem">1  in 1 CARTON</td><td class="formItem"></td><td class="formItem"></td></tr><tr class="formTableRowAlt"><th class="formItem" scope="row">3</th><td class="formItem"></td><td class="formItem">2 mL in 1 VIAL, SINGLE-DOSE</td><td class="formItem"></td><td class="formItem"></td></tr><tr class="formTableRow"><th class="formItem" scope="row">4</th><td class="formItem">NDC:0009-7529-03</td><td class="formItem">1  in 1 CARTON</td><td class="formItem"></td><td class="formItem"></td></tr><tr class="formTableRow"><th class="formItem" scope="row">4</th><td class="formItem"></td><td class="formItem">5 mL in 1 VIAL, SINGLE-DOSE</td><td class="formItem"></td><td class="formItem"></td></tr><tr class="formTableRowAlt"><th class="formItem" scope="row">5</th><td class="formItem">NDC:0009-7529-05</td><td class="formItem">1  in 1 CARTON</td><td class="formItem"></td><td class="formItem"></td></tr><tr class="formTableRowAlt"><th class="formItem" scope="row">5</th><td class="formItem"></td><td class="formItem">15 mL in 1 VIAL, SINGLE-DOSE</td><td class="formItem"></td><td class="formItem"></td></tr></table></td></tr><tr><td></td></tr><tr><td class="normalizer"><table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td></tr><tr><th class="formTitle" scope="col">Marketing Category</th><th class="formTitle" scope="col">Application Number or Monograph Citation</th><th class="formTitle" scope="col">Marketing Start Date</th><th class="formTitle" scope="col">Marketing End Date</th></tr><tr class="formTableRowAlt"><td class="formItem">NDA</td><td class="formItem">NDA020571</td><td class="formItem">06/14/1996</td><td class="formItem"></td></tr></table></td></tr></tbody></table><table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Labeler -&nbsp;</span>Pharmacia and Upjohn Company							(829076566)						</td></tr></table><table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td></tr><tr><th class="formTitle" scope="col">Name</th><th class="formTitle" scope="col">Address</th><th class="formTitle" scope="col">ID/FEI</th><th class="formTitle" scope="col">Business Operations</th></tr><tr class="formTableRowAlt"><td class="formItem">Pfizer Ireland Pharmaceuticals</td><td class="formItem"></td><td class="formItem">989811526</td><td class="formItem">MANUFACTURE(0009-7529)</td></tr></table><table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td></tr><tr><th class="formTitle" scope="col">Name</th><th class="formTitle" scope="col">Address</th><th class="formTitle" scope="col">ID/FEI</th><th class="formTitle" scope="col">Business Operations</th></tr><tr class="formTableRowAlt"><td class="formItem">Pfizer Cork Limited</td><td class="formItem"></td><td class="formItem">988786778</td><td class="formItem">MANUFACTURE(0009-7529)</td></tr></table><table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td></tr><tr><th class="formTitle" scope="col">Name</th><th class="formTitle" scope="col">Address</th><th class="formTitle" scope="col">ID/FEI</th><th class="formTitle" scope="col">Business Operations</th></tr><tr class="formTableRowAlt"><td class="formItem">Fresenius Kabi Oncology Limited</td><td class="formItem"></td><td class="formItem">915786944</td><td class="formItem">API MANUFACTURE(0009-7529)</td></tr></table><table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td></tr><tr><th class="formTitle" scope="col">Name</th><th class="formTitle" scope="col">Address</th><th class="formTitle" scope="col">ID/FEI</th><th class="formTitle" scope="col">Business Operations</th></tr><tr class="formTableRowAlt"><td class="formItem">Yakult Honsha Co. Ltd.</td><td class="formItem"></td><td class="formItem">706252103</td><td class="formItem">API MANUFACTURE(0009-7529)</td></tr></table><table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td></tr><tr><th class="formTitle" scope="col">Name</th><th class="formTitle" scope="col">Address</th><th class="formTitle" scope="col">ID/FEI</th><th class="formTitle" scope="col">Business Operations</th></tr><tr class="formTableRowAlt"><td class="formItem">Pfizer (Perth) Pty Limited</td><td class="formItem"></td><td class="formItem">757868963</td><td class="formItem">API MANUFACTURE(0009-7529), MANUFACTURE(0009-7529)</td></tr></table><table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td></tr><tr><th class="formTitle" scope="col">Name</th><th class="formTitle" scope="col">Address</th><th class="formTitle" scope="col">ID/FEI</th><th class="formTitle" scope="col">Business Operations</th></tr><tr class="formTableRowAlt"><td class="formItem">Pharmacia and Upjohn Company</td><td class="formItem"></td><td class="formItem">829076566</td><td class="formItem">MANUFACTURE(0009-7529)</td></tr></table></div><p><div class="EffectiveDate">Revised: 7/2012<div class="DocumentMetadata"><div><a href="javascript:toggleMixin();">Document Id: </a>4968599f-322e-4ed5-9657-ba5adceb1837</div><div>Set id: e518dfc6-7e93-4fee-a66c-51e1ab71c056</div><div>Version: 18</div><div>Effective Time: 20120731</div></div></div>&nbsp;<div class="DistributorName">Pharmacia and Upjohn Company</div></p>			</div>			</div>			<div id="nlmfooter">	<a href="http://www.nlm.nih.gov">		<img  src="/dailymed/images/logo.gif"		alt="Visit The National Library of Medicine" />	</a>	<a href="http://www.nlm.nih.gov/copyright.html">Copyright</a>,	<a href="http://www.nlm.nih.gov/privacy.html">Privacy</a>,	<a href="http://www.nlm.nih.gov/accessibility.html">Accessibility</a><br />	<a href="http://www.nlm.nih.gov">U.S. National Library of Medicine</a>, 8600 Rockville Pike, Bethesda, MD 20894<br />	<a href="http://www.nih.gov/">National Institutes of Health</a>,	<a href="http://www.hhs.gov/">Health &amp; Human Services</a></div>		</body>	</html>